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Response of tumours to chemotherapy is limited by resistance, 
inherent or developing during treatment, causes of which include 
impaired drug delivery and changes in cellular drug transport. 
Although high-dose intravenous melphalan, with priming and 
autologous bone marrow rescue, increased response rates, 
gastrointestinal toxicity limits further dose escalation. The aims 
of this study were to increase uptake of melphalan by tumours, by 
manipulating either their blood flow or cellular melphalan 
transport, without increasing normal tissue toxicity, and to explore 
ways of reducing gastrointestinal toxicity. 
Blood flow, measured from the fractional distribution of 
86Rb-rubidium chloride, 14c-melphalan uptake and melphalan-induced 
growth delay, were determined in cba mice bearing subcutaneous 
fibrosarcomas or human melanoma HX46 xenografts. Four vasodilators, 
including verapamil, and 3 vasoconstrictors failed to increa~e blood 
flow in fibrosarcomas. Only the hypertensive agent, angiotensin II, 
1.2ug/kg/min by iv infusion, and the melphalan acid alcohol solvent 
increased relative blood flow to the fibrosarcomas, but not to HX46 
xenografts. Angi otensi n II increased 14c-me l pha l an uptake at 30 
minutes, the effect becoming lost by 60 minutes, and had no effect 
on growth delay of fibrosarcomas. The acid alcohol solvent affected 
neither 14c-me l pha l an uptake nor growth delay. It was concluded 
that enhancement of tumour blood flow was unpredictable and depended 
on the particular tumour, site and host. Furthermore blood flow did 
not limit melphalan delivery to the tumours, and the vascular system 
differed in the fibrosarcomas and HX46 xenografts. 
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Verapamil increased blood 1 evel s of 14c-mel phal an administered 
iv or ip, increased 14c-melphalan uptake by the fibrosarcomas, and 
potentiated growth delay by melphalan in the fibrosarcomas and HX46 
xenografts. Changes in cytotoxicity correlated with pharmacokinetic 
effects rather than with 'blood flow. However, verapamil also 
increased the gastroi ntest i na 1 (jejunum mi crocol ony assay) and bone 
marrow (spleen colony assay) toxicity of melphalan in mice, through 
effects on pharmacokinetics and marrow cellular uptake. 
Verapamil increased the cytotoxicity of melphalan to murine 
bone marrov, in vitro (CFU-GM), and increased 14c...;melphalan uptake by 
the cells in a dose-related, reversible, calcium - independent, 
temperature-dependent way, and i nhi bi ted mel phal an efflux. Simi 1 ar 
effects were seen in disaggregated fi brosarcoma cells. Verapamil 
affected neither uptake nor cytotoxicity of melphalan in human bone 
marrow and HL60 cells, confirming that melphalan transport by human 
and muri ne marrow differs. Mel phal an transport is 1 ikely to be 
altered by verapamil in some human tumours, allowing an increased 
therapeutic index. Another calcium antagonist, flunarizine, had 
similar but smaller effects to verapamil. A component of transport 
of melphalan seems to be shared with other cytotoxic drugs and 
modified by calcium antagonists. 
Vasoactive intestinal peptide reduced blood flow but failed to 
reduce melphalan uptake or toxicity in the jejunum in mice. 
Epidermal grov,th factor, trophi"c and cytoprotect i ve to the 
gastrointestinal tract, failed to limit or enhance recovery from 
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CHAPTER 1 INTRODUCTION 
1-1 Introduction 
Despite the significant improvement in prognosis for patients 
with cancer over recent years (De Vita, 1983; Chabner et al, 1984), 
many tumours are not sensitive to chemotherapy while others develop 
resistance to cytotoxic agents. This resistance may be a feature of 
the tumour cells or be due to factors affecting delivery of 
chemotherapy to the eel 1 s. The anti tumour effect of a 
chemotherapeutic agent requires that it be present in the 
extracellular fluid bathing the tumour cells in adequate 
concentrations for long enough. This depends firstly on the area 
under the blood concentration versus time curve (AUC), in turn 
determined by the dose and route of administration, distribution, 
metabolism and elimination of the drug (De Vita, 1982). Secondly, 
delivery of chemotherapy requires an adequate blood supply and 
diffusion through the extracellular fluid. Finally, cytotoxicity 
depends on cellular processes, and resistant cells may .have changes 
in membrane transport of drugs, enhanced detoxification, alternatives 
to inhibited biochemical pathways, or enhanced repair of damaged DNA 
(Vistica, 1983; Connors, 1984; Fox, 1984). 
Melphalan is a bifunctional alkylating agent intensively studied 
in the Institute of Cancer Research and Royal Marsden Hospital, since 
its synthesis by Bergel and Stock in 1953. Melphalan is a valuable 
cytotoxic agent clinically, particularly in the treatment of multiple 
myeloma, breast and 
relapses are common. 
doses was therefore 
ovarian cancer, but failure to respond and 
Administration of melphalan in high intravenous 
explored in malignant melanoma, paediatric 
tumours, multiple myeloma and acute leukaemias, with higher response 
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rates than at conventional doses (McElwain et al, 1979; Pritchard et 
al, 1982; Cornbleet et al, 1983; Maraninchi et al, 1983; McElwain and 
Powles, 1983). The dose-limiting toxic effects of melphalan in 
animals and man were on the bone marrow, circumvented by autologous 
marrow transplantation, and on the gastrointestinal tract (Millar et 
al, 1978b,c; McElwain et al, 1979), both mitigated by a prior 
1 priming' dose of alkylating agent (Hedley et al, 1978; Millar et al, 
1978b,c; Cornbleet et al, 1983). A maximum dose of 240mg/m2, up to 
lOx conventional doses, could then be given with marrow rescue 
(Cornbleet et al, 1983). Another way of increasing the AUC without 
increasing bone marrow and gastrointestinal toxicity was hyperthermic 
isolated limb perfusion in the local control of malignant melanoma 
(~foaver et al, 1975; Ghussen et al, 1984). Although peak perfusate 
melphalan concentrations were 5-lOx greater than after maximal 
intravenous doses (Hafstrom et al, 1984; Briele et al, 1985; Minor et 
al, 1985), application of the technique is limited. 
New ways of increasing the antitumour effect of melphalan 
without increasing normal tissue toxicity are needed. This study 
considers whether uptake of melphalan by tumours, and cytotoxicity, 
could be promoted by changes either in tumour blood flow or in 
cellular melphalan transport, using mice bearing fibrosarcomas or 
human melanoma xenografts. Agents which potentiated melphalan 
cytotoxicity were also examined for their effects on normal tissue 
toxicity. Since further escalation of melphalan dose is limited by 
gastrointestinal toxicity in man, several ne\t approaches to reduce 
gastrointestinal toxicity were examined using mice. 
) 
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1-2 Tumour vascular system and blood flow 
1-2-1 Tumour angiogenesis and vascularisation 
Stimulation of capillary proliferation is a feature of neoplasia 
(Algire et al, 1954) and tumours fail to grow beyond a few mm in 
diameter without a blood supply (Gimbrone et al, 1972). When tumour 
cells are implanted in a mouse dorsal skin flap or rabbit ear, 
endothelial processes extend through the disrupted basement membrane 
of the host venules, forming capillary sprouts (Algire et al, ·1945; 
Kligerman and Henel, 1961; Ausprunk and Folkman, 1977). The sprouts 
make loops, canalise, elongate and widen, make connections with host 
arterioles, but do not themselves differentiate into arterioles or 
venules. Endothelial proliferation, maximal at 3-4 days just 
proximal to the tip of the capillary sprout (Ausprunk and Folkman, 
1977) is 10-lOOx greater in tumours than in most normal tissues and 
is exceeded only in the placenta (Tannock, 1970; Woods and 
Papadimitriou, 1979; Denekamp, 1984). A number of factors which 
direct the various processes in angiogenesis have been identified, 
including tumour angiogenesis factor (Folkman et al, 1971), heparin, 
copper and prostaglandins (Gullino, 1983; Schor and Schor, 1983; 
Folkman, 1984; Reinhold and Berg-Blok, 1984) prompting research into 
angiogenesis inhibitors. Recently Angiogenin, an angiogenic protein 
derived from a human adenocarcoma cell line, has been isolated and 
the sequence of amino acids and genes determined (Fett et al, 1985; 
Kurachi et al, 1985; Strydom et al, 1985). 
Tumour blood flm'I and vascular volume v1ere greatest 4-7 days 
after implantation (Krylova, 1977; Endrich et al, 1982; 
Paskins-Hurlburt et al, 1982). Thereafter mean vessel diameter 
increased while length and surface area decreased, vascular level 
5 
remaining constant, resulting in greater intercapillary distances 
(Vogel, 1965; Hilmas and Gillette, 1974; Woods and Papadimitriou, 
1979). The· vascular volume of experimental tumours was 1-15% by 
labelled albumin, dextran or red cells (Gullino and Grantham, 1964; 
Song and Levitt, 1971) and 4-16% by histological techniques (Vogel, 
1965; Woods and Papadimitriou, 1979), compared with an extracellular 
volume of 30-60% (Gullino et al, 1965; Peterson, 1979). The tumour 
vasculature. failed to increase to the level expected· from the 
metabolic demands, being limited by the arterial supply ·of the host 
tissue which the tumour had· replaced (Intaglietta et al, 1977; 
Reinhold and Berg-Blok, 1984). The hypoxic, acidotic environment, 
decreasing red cell deformability and increasing rouleaux formation, 
as well as thrombosis and compression by continued tumour growth, 
were felt to be more important limiting factors. in the delivery of 
nutrients and drugs than diffusion distance from capillaries (Tannock 
and Steel, 1969; Tannock, 1970; Hilmas and Gillette, 1974; Krylova, 





1-2-2 Measurement of blood flow to tumours 
Most early information on tumour blood flow came from 
observation of blood vessels in tumours grown in transparent chambers 
and from studies of the uptake of dyes. Even now there is only one 
way of directly measuring tumour blood flow (Gullino and Grantham, 
1961). When a tumour virtually replaces an isolated kidney or ovary, 
which is supplied by a single artery and vein, the venous outflow is 
the total tumour blood flow, but includes all flow whether through 
capillaries or nonnutritive shunts. Capillary blood flow can be 
determined from the clearance of radioactive, lipid-soluble inert 
gases such as 133xe-xenon, after local injection if the partition 
coefficient between tissue and blood is known. Measurements v1ere 
repeatable and performed in mice (Peterson et al, 1969; Kallman et 
al, 1972; Pallavicini and Hill, 1979) and in humans(Mantyla et al, 
1976), but only in superficial tumours. Results showed wide 
variation and injection artefacts, and were not representative of the 
whole tumour {Appelgren, 1979). 
Capi 11 ary blood fl ow to tumours in rats has most commonly been 
measured from the distribution of radiolabelled microspheres combined 
with determination of cardiac output by withdrawal of arterial blood 
at a constant rate ( 11 reference organ 11 ) (Heymann et al, 1977; Jirtle 
et al, 1978a; Appelgren, 1979). The size of microsphere determines 
the diameter of capillaries where trapping occurs. Untrapped 
microspheres collected in the lungs, reflecting passage through wider 
vascular channels or shunts; this increased in animals with older, 
larger tumours (Heymann et al, 1977; Hultborn et al, 1983). The 
requirements for perfect mixing of mi crospheres in the 1 eft heart 




organ, difficult at low flow rates (Heymann et al, 1977; Jirtle et 
al, 1978a; Appelgren, 1979; Messmer, 1979; Endrich et al, 1981; 
Peterson and Mattsson, 1984), could not be fulfilled in mice 
(Wetterlin et al, 1977). Tumour blood flow has been compared in rats 
before and after vasoactive agents, using 2 or 3 successive 
injections of microspheres with different radioisotopes, but the 
microspheres could redistribute or be dislodged by regurgitant blood 
flow (Messmer, 1979; Endrich et al, 1982) and the microspheres 
themselves increased vascular resistance and decreased oxygen tension 
(Jirtle et al, 1978a; Messmer, 1979). 
The distribution of radioactiveJ water-soluble tracers, 
42K-potassium and 86Rb-rubidium, and of lipid-soluble radioiodinated 
antipyrine has also been used to determine the fractional 
distribution of cardiac output (FDCO) (Sapirstein, 1958; Appelgren, 
1979). Although first pass extraction of antipyrine was greater, 42K 
and 86 Rb were preferred because of their much greater volume of 
distribution and stability. All three tracers detected nutritional 
blood flow (Friedman, 1968; Appelgren, 1979), but because cardiac 
output is very difficult to measure in mice could only give relative 
distribution of blood flow. Techniques continue to be developed for 
measuring tumour blood flow, particularly in humans (Minasian and 
Bamber, 1982), but 86Rb uptake emerged as the only practicable 




1-2~3 Measurement of blood flow using 86Rb-rubidium chloride 
The distribution of 86Rb reflects the FOGO so long as extraction 
is similar in all body tissues (Sapirstein, 1958). After a single 
intravenous injection, 86Rb is distributed to organs in proportion to 
the FOGO which reaches them. Non-extracted tracer, and later 
redistributing tracer, leaves in the venous effluent but because of 
the large intracellular pool of exchangeable potassium, loss of 86Rb 
is negligible compared with arterial delivery for at least a few 
minutes (Sapirstein, 1958; Zanelli and Fowler, 1974). The extraction 
ratio was 60% in all body tissues except brain, where extraction was 
less and accounted for 1-2% of the cardiac output in mice and rats, a 
negligible error (Sapirstein, 1958). Tissue and tumour 86 Rb content 
remained constant from 9 to at least 90 seconds (Sapirstein, 1958; 
Gullino and Grantham, 1961), values for tumour blood flow in 
anaesthetised rats being the same by 86Rb uptake and direct venous 
out fl ow {Gull i no and Grantham, 1961). However, some rat organs 
showed discrepancies between FOGO by 86Rb and mi crospheres (Mendell 
and Hollenberg, 1971; Foster and Frydman, 1978). 
Exchange of a substance between a tissue and the b 1 ood may be 
limited by flow or by permeability (Friedman, 1968; Bassingthwaite 
and Yipintsoi, 1974; Jain et al, 1980}. When permeability of the 
capi 11 ary and ce 11 membrane is so great that exchange proceeds to 
equilibrium at all flows, uptake is flow-limited. When permeation of 
the substance through the capillary endothelium or cell membrane is 
too slow to allow equilibration, extraction depends on the 
permeability, surface area for diffusion and concentration gradient, 
as v1ell as on flov,. Even for flov1-limited substances such as 42K 
and 86Rb, diffusion becomes limiting at very high flow rates 
} 
(Bassingthwaite and Yipintsoi, 1974). 
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In isolated dog skeletal 
muscle, 86Rb extraction was flow-limited for flov1s of 0.005-0.12 
ml/min/g in one study (Friedman, 1968), but diffusion-limited in 
another (Sheehan and Renkin, 1972). The greater uptake of 86Rb than 
mi crospheres in tissues with 1 ow flows, and the converse in those 
with high flows, was interpreted as evidence for diffusion-limitation 
of 86Rb at all flow rates (Foster and Frydman, 1978). Hml/ever micro-
spheres underestimate flow to liver, because of the post-capillary 
portal flow, and to tissues with very low flows, while lung uptake 
reflects systemic shunts (Mendell and Hollenberg, 1971; Messmer, 
1979). Once these tissues are excluded the data are not convincing, 
and the i dent i ca 1 va 1 ues by 86Rb and mi crospheres for the high rena 1 
flow remain unexplained. The discrepancies probably arise because 
the original assumption that every tissue has the same extraction 
ratio for 86Rb (Sapirstein, 1958) is not strictly true because of the 
different characteristics of i ndi vi dual capi 11 ary beds (Mendel 1 and 
Hollenberg, 1971; Appelgren, 1979). 
Nonetheless, 86Rb uptake is regarded a valid technique, and 
constant 86Rb di stri buti on to tissues and tumours for up to 60-90 
seconds was demon st rated in anaesthetised rats (Mende 11 and 
Hollenberg, 1971; Takacs et al, 1975; Kjartansson et al, 1976) and 
mice (Cataland et al, 1962; Zanelli and Fov1ler, 1974; Wetterlin et 
al, 1977; Stewart and Begg, 1983), and in unanaesthetised mice 
(Zanelli et al, 1975). Differences in FDCO to tumours and normal 
tissues have been detected after anaesthesia or treatment with 
vasoact i ve agents or hyperthermi a (Zane 11 i et a 1, 1975; Mattsson et 
al, 1978; Debreczeni et al, 1980; Robinson et al, 1982; Karlsson et 




Blood flow of experimental and human tumours, according to method of 
measurement 
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Rat Guerin ca axil la 0.19,0.26* 86 Rb 
Hamster mel. s.c. 0.68>', 1311-AP 





b. Local clearance of 133xe, hydrogen (H 2 ) or heat 
Blood flow 
Tumour Site (ml/min/g) Tracer Anaes. 
Mouse sarc {! .d. 0.21 
I .m. 0.61 
Mouse mam. i .m. 0.52 
133 
13le -} Xe 
Rat sa re s.c. 0.25 133Xe + 
Human lymphoma,9 0.38 133Xe 
anaplastic,9 0. 11 
differentiated,23 0. 14 
Rat hep. s.c. 0. 12 + 
i .m. 0. 1 0 
liver 0. 13 
Dog I ymphosa re, 1 ° 0.88-30.8 heat + 
Reference 
















Mantyla ,etc, 1976 




TABLE 1-1, continued 
c. Distribution of radiolabelled microspheres 
Diameter Mean blood flow 
of ms (ml/min/g) 
Tumour Site (um) Tumour Tissue Anaes. 
Rat mam. m.g. 25 1.2 0.3,m.g. 
Rat mam. m.g. 25 0.39 0.18,m.g. 
i .m. 0.40 0.21,muscle 
l .n .met 25 0.48 
Rat mam. 1 0 1 5 0.49 0.09,skin + 
(DMBA- 0.06,muscle 
induced) 1 0 15 0.49 0.09,m.g. + 
i .m. O .43 
Rat adenoca s.c. 15 0.27 0.05,skin + 
0.07,muscle 
Rabbit V2ca ,ear 15 O. 14 0. 025, ear + 
spleen 0.42 1 . 1 2 , s p l een 
liver 0.50 0.52,liver 
testis 0.55 0.19,testis 
kidney 1. 3 2.96,kidney 
Human, colorectal ,8 N.S. 1/3-1/30 of normal tissues -
bronchogenic,4 
other,2 
d. Direct venous outflow 
Tumour Site 
Rat sarc Kidney 
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adenocarcinoma 
anaesthetised (+) or not (-) when blood flow measured 
carcinoma 
dimethylbenzanthracene 
















decrease, but correlation poor 
~) 
TABLE 1-2 
Effect of tumour size on tumour blood flow 
Tumour Site Change in TBF Tumour Necrosis 
with't size size excluded 
Mouse 
mam. s.c. .(3g ,!, 0.2-lOg No 
sarc s .c. ,t, 0.1-3g No 
sa res s .c. ( ,i.) o.o8-1.3ml No 
mam. s.c. ( ,!. ) 0.1-0.6ml Yes 
2 ca, s.c. J, 0 .6-1 cm No 
2 sarc 
sa re i .d. + )0 .5 ml Yes 
i .m. ..l, 0.5g Yes 
mam. i .m. No 0.5-1.2g Yes 
Rat 
Guerin axi 1 la No 0. 39-849 Yes 
mam. m.g. -1., 0.1-0.2g No''' 
mam. m.9.,i.m No 2g Yes 
mam., 2 1 0 No 2. 1 g No''' 
(DMBA) 1 0 {, 2.8g 
Rabbit 
V2 ca 5sites No 0.4-8.7g Yes''' 
Abbreviations 1 isted with those for Table 1-1 
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1-2-4 Factors influencing tumour blood flow 
Table 1-1 shows values for tumour blood flow reported for 
experimental animal tumours and human tumours. All the studies noted 
wide variation in blood flow between individual tumours. The 
dependence of tumour blood flow on its implantation site and the host 
tissue, its age and size, and on anaesthesia have all been studied. 
1-2-4-1 Tumour site 
Tumour blood flow was independent of site for V2 carcinomas in 
rabbits by 86Rb uptake (Edl i ch et a 1, 1969) and for rat tumours by 
42K uptake (Gullino and Grantham, 1961), but depended on host tissue 
flow for rabbit V2 carcinoma and rat mammary carcinoma in 3 studies 
using microspheres (Young et al, 1979a, 1983; Jirtle, 1981). In 
mice, subcutaneous tumours had a higher take rate and growth rate 
more cranially (Auerbach et al, 1978), skin and mammary gland blood 
flow was greater more cranially (Minasian, 1983) and tumour blood 
flow was greater on the flank than the leg (Robinson et al, 1982). 
Blood flow to primary tumours or spontaneous metastases may not 
be the same as to implanted tumours. Although primary DMBA-induced 
mammary carcinoma and transplants to 4 sites in the same rat had very 
similar blood flm--,s (Tveit et al, 1984), blood flow to lymph node 
metastases of a mammary carcinoma was greater than to implants in 
mammary gland and muscle (Kaelin et al, 1984). 
1-2-4-2 Tumour size and age 
The decrease in FDCO to subcutaneous muri ne mammary carcinomas 
and sarcomas with increasing size (Cataland et al, 1962) (Table 1-2) 
was attributed to greater necrosis in larger tumours. 





carcinomas, range 0.39-84.0g, where necrosis never exceeded 4% 
(Takacs et al, 1975). However, the extent of necrosis had no effect 
on tumour blood flow in rabbit V2 carcinoma (Young et al, 1979a), and 
blood flow decreased with increasing size in KHT sarcomas but not 
mammary carcinomas when necrotic tissue was avoided using 
133xe-clearance in rats (Kallman et al, 1972; Pallavicini and Hill, 
1979). In many tumours, blood flow to the centre was less than to 
the periphery, but did not correlate with necrosis (Straw et al, 
1974; Jirtle, 1981; Blasberg et al, 1985). Red cells reached most 
parts of tumours (Tannock and Stee.l, 1969), and cells from the 
apparently avascular centre of large tumours were viable and 
proliferating (Woods and Papadimitriou, 1979). 
The data summarised in Table 1-2 lead to the conclusion that 
tumour blood flow falJs or remains constant with increasing tumour 
size; this depends on the tumour and its age, and not simply on 
necrosis. Blood flow fell by up to 50% over one week of tumour 
growth (Edlich-et al, 1966; Kjartansson et al, 1976; Endrich et al, 
1982; Paskins-Hurlburt et al, 1982). However, proliferation of 
tumours was not limited by blood flow, with identical tumour growth 
rates in ovary and kidney despite a 20-fold difference in host organ 
blood flows (Gullino and Grantham, 1961), and different rates of 
cellular proliferation for two tumours with identical vascular 
development (Gabbert et al, 1982). 
The cardiac output of rats v,as increased 12% by a mean tumour 
burden of 14.4g (Jirtle et al, 1978a) and 22% by up to 84g tumour 
(Takacs et al, 1975; Debreczeni et al, 1980). There was no change in 
FDCO measured with 86Rb, and the marked fa 11 in haematocrit from 47 




al, 1980). Most experiments use animals with much smaller tumour 
burdens, and cardiac output was the same in rats bearing similar 
amounts of tumour (Jirtle, 1981). 
1-2-4-3 Anaesthesia and stress in mice 
Restraint of mice reduced body core and tumour temperatures by 
1-2c0 (Sheldon and Chu, 1979; Pallavicini and Hill, 1983), and 
reduced tumour blood flow over the next 24-48 hours (Zanelli and 
Lucas, 1976). Anaesthesia reduced mouse and t_umour temperatures, by 
8-loc0 for pentobarbitone and chloral hydrate and by 1-2c0 for 
urethane (Johnson et al, 1976; Sheldon and Chu, 1979; Pallavicini and 
Hill, 1983). Pentobarbitone and urethane caused marked fal 1 s in 
tumour blood flow, measured by 133xe or thermal clearance (Kallman et 
al, 1972; Pallavicini and Hill, 1983) or microspheres (Jirtle et al, 
1978a). Pentobarbitone increased 86Rb uptake by tumours (Zanelli and 
Fowler, 1974; Robinson et al, 1982; Stewart and Begg, 1983), the fall 
in cardiac output being accompanied by redi stri but ion of fl ow away 
from muscle and skin (Zanelli and Fovller, 1977; Robinson et al, 1982; 
see Table 1-lc). Results for tumour blood fl ow in anaestheti sect 
animals must be interpreted cautiously. 
1-2-5 Vascular permeability of tumours 
Tumour vessels were several times more permeable to labelled 
albumin and Evan's blue dye than normal vessels (Zanelli et al, 1975; 
Ackerman and Hechmer, 1978; Peterson, 1979), reflecting fenestrations 
and gaps in the capillary endothelium and the presence of unlined 
sinusoids (Underwood and Carr, 1972; Willis, 1973; Papadimitriou and 
\~oods, 1975; Endrich et al, 1982). Although most chemotherapeutic 
agents are permeability-limited in normal tissues, permeation 1-1as 
greater in tumours even for' protein-bound drugs, so that delivery 
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depended on flow as well as on permeabilHy (Jain et al, 1980; Nugent 
and Jain, 1984). Thus selective increase in either perfusion or 
permeability of vessels and tumour cell membranes might enhance 
chemotherapy delivery (Nugent and Jain, 1984). However attempts to 
increase tumour vessel permeability with histamine. and serotonin 
failed (Ackerman et al, 1980) although widening of interendothelial 
gaps and leakage of particles was apparent histologically (Underwood 
·and Carr, 1972; Papadimitriou and Woods, 1975), perhaps becaus~ of 
the associated decrease in tumour blood flow (Cater et al, 1966; 
Hafstrom et al, 1980c). Modification of tumour blood flow is 
considered in section 1-3, and transport of chemotherapy through the 
cell membrane in section 1-4. 
1-2-6 Requirements for measurement of changes in tumour blood flow 
in mice using 86Rb 
The fractional distribution of 86Rb is the only practicable 
method for measuring blood flow distribution to tumours and normal 
tissues in mice. Unfortunately, cardiac output cannot be readily 
determined, so only relative flows are obtained. Nonetheless, 
changes in FDCO to tumours should be detectable. Blood flow varied 
in tumours even of the same age, size and passage, so as ma1zy tumours 
as practical should be used in control and treatment groups. The 
effect of tumour size on blood flow should be determined, and groups 
of mice matched for tumour weight and site, as well as for body 
weight. Anaesthesia should be avoided, and immobilisation minimal. 
Tumour and normal tissue blood flows can only be compared between 
matched groups of mice within an experiment. Even so, changes in 
tumour blood flow due to changes in cardiac output, without 
redistribution of blood flow, will be missed. 
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Ti\BLE l -3 
Vasoac ti ve agents reported to increase relative tumour blood flow 
Vasoact i ve agent Tumour Site TBF 
angiotensin l l , i C rat mam. m.g. ,l, 
iv rat hep. s.c. t 
iv rat sarc kidney ·k 
oxytocin, iv rat sarc kidney t 
verapami 1, iv rat mam. i.m.,m.g.t 
flunarizine, iv rat mam. i .m. ,m.g .t 
propranolol, iv mouse sarc s.c. 
noradrenaline, iv rat adenoca liver 





ic rat hep. s .c. 
iv rat sarc kidney 
rat ca.sarc kidney 
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1-3 Modification of tumour blood flow 
1-3-1 Smooth muscle and innervation of tumour vessels 
Si nee deli very of most chemotherapy agents to tumours is at 
least partly flow-limited, it might be promoted by selectively 
increasing tumour perfusion (Nugent and Jain, 1984). Only a few of 
the many vasoactive agents studied have increased tumour blood flow 
(Table 1-3), but the experiments have helped to elucidate the 
functi ona 1 characteristics of tumour vascu 1 atu re. 
blood vessels (section 1-2-1) become either 
The new tumour 
endothelial-lined 
capillaries or unlined sinusoids, without smooth muscle or nerves, in 
both animal and human tumours (Underwood and Carr, 1972; 
Papadimitriou and Woods, 1975; Gamill et al, 1976; Krylova, 1977, 
Woods and Papadimitriou,. 1979; Hafstrom et al, 1980a; Endrich et al, 
1982; Peterson and Mattsson, 1984), although occasional pericytes and 
single smooth muscle cells were observed (Mattsson et al, 1977,1982). 
Vasomot ion occurs, intermittent and regurgitant fl ow and spontaneous 
fluctuations in oxygen tension having been recorded in tumour 
capillaries (Kligerman and Henel, 1961; Reinhold et al, 1977; Endrich 
et al, 1982). The arteries and arterioles seen within a tumour are 
host vessels incorporated during growth (Algire et al, 1945; Willis, 
1973; Gami 11 et al, 1976; Intagl ietta et al, 1977; Falk, 1980; 
Peterson and Mattsson, 1984) and these have noradrenergic innervation 
and can constrict (Kligerman and Henel, 1961; Wickersham et al, 
1977). 
1-3-2 Effects of vasoconstrictors 
Noradrenaline, a vasoconstrictor, increased vascular resistance 
and reduced blood flow measured with microspheres, in mammary 
carcinomas in unanaesthetised rats (Jirtle et al, 1978b) and in V2 
carcinomas in unanaesthetised rabbits (Rankin and Phernetton, 1976). 
) 
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Absolute or relative blood flow was decreased by noradrenaline in 
several carcinomas and sarcomas in the muscle, skin, liver or kidney 
of anaesthetised rats (Cater et al, 1966; Mattsson et al, 1978, 1980, 
1982; Young et al~ 1979b; Tvete et al, 1981b; Hultborn et al, 1983), 
and tumour plasma volume was decreased (Karlsson et al, 1983). 
Isolated, perfused human renal carcinomas, maximally vasodilated with 
papaverine, showed a greater increase in vascular resistance with 
noradrenaline than the kidney (Tveit et al, 1981). Other 
vasoconstrictors, adrenaline, phenylephrine and methoxamine, had 
either no · effect on tumour blood fl ow or reduced it (Gull i no and 
Grantham, 1962; Edlich et al, 1966; Hafstrom et al, 1980a,c; Chan et 
al, 1984; Suzuki et al, 1984; Tveit et al, 1984). 
These results were taken as evidence that tumour vessels, 
probably of host origin, could vasoconstrict and were more sensitive 
to catecholamines than normal blood vessels, possibly because of 
hypoxia or denervation (Rankin and Phernetton, 1976; Mattsson et al, 
1980, 1982; Mattsson and Peterson, 1981; Peterson and Mattsson, 
1984). However propranolol, a beta-adrenoreceptor blocker with 
reflex sympathetic vasoconstriction (Gilman et al, 1980), \vhich had 
decreased absolute and relative blood flov~ to carcinomas in 
anaesthetised rats (Debreczeni et al, 1980), increased relative flow 
to sarcomas in mice (Bomber et al, 1986). Blood flow of sarcomas in 
the kidney (Tvete et al, 1981b), and of 2 tumours in the liver but 
not muscle (Hafstrom et al, 1980a,c) of anaesthetised rats, was 
reduced less by noradrenaline than blood flov~ of the host organ 
(Table 1-3). Furthermore, microscopic studies showed tumour vessels 
to vasoconstrict less than host vessels with adrenaline (Kligerman 
and Henel, 1961; Wickersham et al, 1977). 
) 
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1-3-3 Effects of vasodilators 
Attempts to decrease tumour vascular resistance and thereby 
increase blood flm'I had little success. The alpha-blocker 
phenoxybenzamine, beta-blocker isoprenaline, and vascular smooth 
muscle relaxants acetylcholine, hydralazine, papaverine, nitrates and 
prostaglandin E2 (Gilman et al, 1980) all failed to increase tumour 
blood flow, even relative to host tissues (Cater et al, 1966; Rankin 
and Phernetton, 1976; Jirtle et al, 1978a; Debreczen,i et al, 1980; 
Mattsson et al, 1980, 1982; Voorhees and Babbs,1982; Karlsson et al, 
1983; Young et al, 1983; Chan et al, 1984; Suzuki et al, 1984). The 
tumour vascular bed seemed to be maximally vasodilated. However 
adrenaline increased the vascu1ar volume of carcinomas in rat liver, 
without increasing blood flow (Ackerman and Hechmer, 1980), and 
haemodilution decreased vascular resistance and increased flow in a 
tumour in an isolated rat kidney perfused at constant pressure 
(Vaupel and Muller-Klieser, 1984; Table 1-3), suggesting that some 
tumour vessels could be further dil~ted. 
1-3-4 Dependence of tumour blood flow on systemic blood pressure 
Autoregulation of blood flow was absent in many tumours, the 
flow changing with perfusion pressure in kidney-isolated preparations 
(Vaupel, 1975) or with systemic blood pressure (Cater et al, 1966). 
Tumour blood vessels collapsed with systemic hypotension, with 
vascular stasis below 50-70 mml-lg arterial pressure (Algire et al, 
1954; Suzuki et al, 1981; Von Ardenne and Reitnauer, 1982). 
It was concluded that tumour blood vessels were less responsive 
to vasoactive agents than systemic vessels, were deficient in smooth 




according to systemic pressure changes (Tvete et al, 1981a; Young et 
al, 1983; Chan et al, 1984; Suzuki et al, 1984). Systemic 
vasodilatation would 'steal I blood from the tumour vessels leading to 
their collapse, and the observed increase in tumour vascular 
resistance. Systemic vasoconstriction with a rise in systemic 
pressure would increase tumour perfusion, so long as the arterial 
supply to the tumour did not vasoconstri ct to the same extent. The 
responses to vasoact i ve agents of different tumours in different 
sites and hosts, anaesthetised or not, depends on the relative 
sensitivities to the particular agent of the arteries supplying the 
tumour, host tissue and systemic circulation. These characteristics 
of tumour vessels are exemplified by studies with angiotensin II and 
calcium antagonists (Table 1-3), and are discussed in the next two 
sections. 
1-3-5 Increase in tumour blood flow by angiotensin II 
Angiotensin II is a potent arterial and venous vasoconstrictor, 
particularly in skin, gastrointestinal tract and kidney (Gilman et 
al, 1980; Mohama et al, 1984), which increases systemic vascular 
resistance and blood pressure. Angiotensin II infusion increased the 
vascular resistance in skin and mammary gland, but not in implanted 
mammary carcinomas, in unanaesthetised rats, so that despite an 
absolute decrease, tumour blood flow became 10 times greater relative 
to that of the host tissue (Jirtle et al, 1978b). A similar effect 
occurred in sarcomas in rat kidney and at a lower rate of angiotensin 
II infusion an absolute increase in tumour flm'I and fall in renal 
flo\'J obtained (Tvete et al, 1981a). Elevation of systemic pressure 
of anaesthetised rats to 150mmHg by angiotensin II infusion increased 




the increase sustained even after return to normotension. 
Angiotensin II also increased red cell velocity by a factor of 4, 
tumour oxygen tension 6-fold, doubled the vascular level with blood 
flow in previously unfilled vessels, raised intravascular pressure 
and increased lymph flow from the tumour, and had no local effect on 
developing tumour vessels (Hori et al, 1981, 1985; Suzuki et al, 
1982, 1984). Angi otensi n II enhanced mitomyci n C-i nduced growth 
delay of the hepatomas, but the rats were treated 1-Jhen I anaemic and 
in poor condition' (Suzuki et al, 1981). Angiotensin II infusion did 
not affect growth delay of sarcomas in rat kidney by adriamycin, but 
interpretation was complicated because adri amyci n constricted rat 
renal arteries (Tvete et al, 1982a, b). 
Angiotensin II infusion has been used clinically. Internal 
mammary artery infusion increased the relative flow to breast 
carcinomas 3-fold, and increased the response rate to adriamycin from 
7 /11 to 10/11 (Koyama et al, 1983), a change of doubtful 
significance, achieved with a marked increase in normal tissue 
toxicity (Koyama et ·al, 1985). Infusion of angiotensin II was 
claimed to increase response rates to adriamycin in combination 
chemotherapy in an uncontrolled study (Wakui and Suzuki, 1983), with 
no comment on toxicity. Neither group referred to effects on 
pharmacokinetics. Angiotensin II also finds application in 
angiography, because it improved delineation of tumour vasculature, 
demonstrating more tumour vessels with greater filling (Ekelund, 
1979). 
Two other potent vasoconstrictors might act like angiotensin II 
(Gilman et al, 1980; Mohama et al, 1984) - oxytocin increased blood 
flow to sarcomas in rat kidney (Tvete et al, 1981b), but had no 
_) 
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advantage over angiotensin II, while vasopressin reduced blood flow 
of tumours in rat liver and kidney (Hafstrom et al, 1980b; Tvete et 
al, 1981b; Jenkins et al, 1984) and of subcutaneous melanomas in 
anaesthetised hamsters (Edlich et al, 1966). 
1-3-6 Increase in tumour blood flow by calcium antagonists 
Verapamil and flunarizine are competitive calcium ion 
antagonists which inhibit excitation and excitation-contraction 
coupling in vascular smooth muscle, particularly in arterioles 
(Fleckenstein, 1977; Stone et al, 1980; McMahon and Sheaffer, 1982). 
The resulting peripheral vasodilatation stimulates reflex 
beta-adrenergi c activity which opposes their myocardial depressant 
effects, partially for verapamil and completely for flunarizine 
(Stone et al, 1980; Kaelin et al, 1984). Both verapamil and 
flunarizine reduced vascular resistance and increased blood flow 
about 1.5-fold (by microspheres) in mammary carcinomas implanted in 
the mammary gland and muscle of unanaesthetised rats (Kaelin et al, 
1982, 1984). Total peripheral resistan.ce decreased, cardiac output 
increased and blood pressure stayed constant. At higher doses of 
both drugs, blood pressure fell and tumour blood flow did not 
increase. . These results were attributed to greater reflex 
vasoconstriction in normal tissues than in the tumour, with 
maintenance of blood pressure, and to inhibition by verapamil and 
flunarizine of hypoxia-induced vasoconstriction and decreased red 
cell deformability in tumour vessels (Van Nueten and Vanhoutte, 1981; 
Kaelin et al, 1982, 1984). Bomber (personal communication) found no 
increase in relative blood flow in murine sarcomas with verapamil. 
Verapamil was recently reported to inhibit platelet aggregation 
in vitro and in man (Ikeda et al, 1981), and with other calcium 
antagonists, to inhibit tumour-induced platelet aggregation and 
) 
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experimental and spontaneous metastasis in mice (Honn et al, 1985; 
Tsuruo et al, 1985a). However the fibrinolytic combination of 
streptoki nase and pl asmi nogen had no effect on tumour blood fl ow 
(Peterson et al, 1969). 
) 
1-4 Melphalan, tumour uptake and resistance 
1-4-1 Melphalan hydrolysis and pharmacokinetics 
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Melphalan (L-phenylalanine mustard) is a bifunctional alkylating 
agent which, through an aziridinium ion intermediate, bonds 
covalently to nucleophilic substrates in normal and neoplastic cells 
(Gal den berg and Begl eiter, 1980). Cytotoxi city results from intra-
and inter-strand DNA crosslinks (Connors, 1984; Curt et al, 1984; 
Fox, 1984; Goldenberg and Begleiter, 1984). Melphalan readily 
hydrolyses to mono- and di-hydroxymelphalan, at 0.84/hour in water at 
37°c, but hydrolysis is slowed 30-50% by albumin or plasma, and to a 
smaller extent at low pH (Chang et al, 1978b; Flora et al, 1979; 
Furner and Brown, 1980; Evans et al, 1982; Honess et al, 1985). 
Melphalan is 30% more stable in normal saline than phosphate buffered 
saline because of the greater chloride concentration (Flora et al, 
1979; Bosanquet, 1985). Freezing arrests hydrolysis and melphalan 
can be stored in saline below -20°c for 6-12 months (Bosanquet, 
1985). 
Radiolabelled melphalan became widely distributed in mice and 
rats, with peak tissue levels 30-60 minutes after intravenous 
injection, and up to 2 hours after intraperitoneal or oral 
administration (Brown et al, 1980; Furner and Brown, 1980; Ahmed et 
al, 1982a,b). Levels were greatest in kidney, urine, bile and 
gastrointestinal tract, lm1est in the bone marrow, brain and fat, and 
intermediate in the liver. Melphalan labelled with 14c in the phenyl 
ring had slightly greater distribution to most tissues and slightly 
. lower urine and bile levels than melphalan labelled in the 





Melphalan metabolism was negligible (Alberts et al, 1979; Brox 
et al, 1979); hydrolysis and binding to cellular macromolecules, 
initially reversible but later covalent, accounted for most of the 
melphalan in blood or tissues after the first 24 hours (Ahmed et al, 
1982a,b; Evans et al, 1982; Farmer and Newell, 1983). Plasma 
elimination was biphasic in man, with marked disparity in reported 
half-lives (Tattersall et al, 1978; Alberts et al, 1979), and 
monophasic in mice with a half life of 41 minutes (Furner et al, 
1976). Excretion occurs in bile and urine (Furner and Brown, 1980; 
Farmer and Newell, 1983). About half of high intravenous doses 
appear in the urine in the first 6 hours (McElwain et al, 1979), 
compared with 13-15% of the parent melphalan dose, ~nd up to 50% of 
the total 14c-melphalan, in 24 hours following conventional oral or 
intravenous doses (Tattersall et al, 1978; Alberts et al, 1979). 
Di hydroxyme l pha l an predominates in the urine, but in some animals 
other products later appear suggesting a small degree of metabolism 
(Furner and Brown, 1980; Ahmed et al, 1982b). 
1-4-2 Melphalan uptake by murine tumours 
Melphalan can be measured independently of hydrolysed drug in 
protein-free tissue extracts, using high pressure liquid 
chromatography (HPLC), while melphalan covalently bound to 
macromolecules (not methanol-extractable) is determined by counting 
labelled melphalan in the precipitated protein (Furner et al, 1976; 
Brovm et al, 1980; Ahmed et al, 1982a,b; Honess et al, 1985). 
Me 1 pha l an 1 eve ls in mu ri ne sarcomas were 100-200% of blood 1 eve ls 
after 60 minutes, and similar to normal tissue levels, whether total 
radioactivity or parent compound \vas measured (Furner and Brmm, 




Tumour melphalan uptake correlated with sensitivity in some 
experimental tumours. Sensitive L1210 and P388 murine leukaemias, 
implanted subcutaneously in mice, took up more melphalan {parent 
drug, total radioactivity and bound drug) than resistant sublines 
(Brown et al, 1980). Melphalan uptake and cytotoxicity were both 
greater in smaller nodal metastases than primary human melanoma 
xenografts (Selby et al, 1979). However 4 different human 1 ung 
carcinoma xenografts showed no correlation between melphalan uptake 
and growth delay (Wist et al, 1981). Other factors such as cellular 
melphalan detoxification and DNA repair are also important in 
sensitivity (see section 1-4-4). 
1-4-3 Melphalan uptake by tumour cells in vitro 
Cellular melphalan accumulation has been extensively studied 
using murine L1210 leukaemia, L5178Y lymphoblasts and LPC-1 
plasmacytoma cells and human MCF-7 breast carcinoma cells (Goldenberg 
et al, 1977, 1979; Begleiter et al, 1979,1980; Goldenber~ and 
Begleiter, 1980; Redwood and Colvin, 1980; Martin et al , 1982; 
Vistica, 1983). Cells incubated with 14c-melphalan in amino 
acid-free medium are rapidly separated from the medium by 
centrifugation through oil or sucrose, sol ubil i sed and counted for 
14c. Determination of cell volume allows calculation of the cell: 
medium ratio of 14c-melphalan. For the first few minutes uptake is 
linear and reflects influx. A steady state is reached after about 20 
minutes at 37°c, with cell:medium ratios of 5-10 or more. 
Analysis of initial influx velocity showed that melphalan uptake 
\'las active, carrier-mediated by at least 2 carriers, specific to 
melphalan and not shared by hydrolysed melphalan nor 0-phenylalanine, 
and 11as inhibited by L-leucine, L-glutamine and other amino acids 
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(Goldenberg et al, 1977, 1979; Begleiter et al, 1979, 1980;Goldenberg 
and Begleiter, 1980; Redwood and Colvin, 1980; Vistica, 1983). 
Transport was by 2 amino acid systems, the low affinity, high 
capacity L system and the sodium-dependent, high affinity, more 
readily saturated ASC-like system, the latter predominating at 
melphalan concentrations below 15-20uM. Less than 10% of melphalan 
entered cells through other pathways, possibly by diffusion 
(Goldenberg and Begleit.er, 1980). Human peripheral blood lymphocytes 
had both carriers, but with lo1t1er affinity (Begleiter et al, 1980); 
human bone marrow had at least the L system (Dufour et al, 1985). In 
muri ne bone marrow progenitor cells the L system was either absent or 
of very low affinity, when indirectly assessed by clonogenic assay 
(Vistica, 1980). 
Free mel phal an accounted for 80-90% of the 14c accumulated by 
the tumour cells after 10 minutes at 37°c, and less than 7% was bound 
to cellular macromolecules and 4% to the membrane (Goldenberg et al, 
1977). After 10-20 minutes at 37°c, 75-80% of the 14c-melphalan was 
exchangeable, the remainder having hydrolysed or become bound 
(Redwood and Colvin, 1980; Begleiter et al, 1982). Melphalan efflux 
was as the parent drug, by an unknown temperature-dependent 
mechanism, and was promoted by extracellular amino acids (Redwood and 
Colvin, 1980; Begleiter et al, 1982; Vistica,1983). 
1-4-4 Cellular factors in melphalan resistance 
Development of resistance to melphalan has been associated with 
changes in cellular inactivation of melphalan, DNA repair and active 
influx (Vistica, 1983; Connors, 1984; Curt et al, 1984). Resistant 
1-1210 and ovarian carcinoma eel l lines shov1ed a 2-fol d increase in 
cellular glutathione, more rapid hydrolysis of melphalan and complete 
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restoration of sensitivity. when glutathione levels were reduced 
(Green et al, 1984; Somfai-Relle et al, 1984). Enhanced DNA repair 
was associated with melphalan resistance in another L1210 cell line 
(Zwelling et al, 1981) and a human melanoma xenograft (Parsons et al, 
1982). Resistance was accompanied by reduced active, 
carrier-mediated transport of melphalan in Ll210 cells (Redwood and 
Colvin, 1980), and mutations affecting L system transport occurred in 
chinese hamster ovary (CHO) cells (Goldenberg and Begleiter, 1984). 
It is possible that changes in membrane transport of melphalan 
underlie cross resistance to melphalan of tumour cells with 
pleiotropic drug resistance (PDR). First described in CHO cells with 
induced resistance to colchicine (Ling, 1975), PDR and the associated 
expression of the P170 (MW 170,000) membrane glycoprotein has been 
found in a wide range of tumour cells cultured from animals and 
humans (Ling, 1975; Kartner et al, 1983; Ling et al, 1983), and can 
be transferred to sensitive cells by DNA transfection (Debenham et 
al, 1982). Resistance occurred to many structurally unrelated drugs, 
predominantly antitumour antibiotics including anthracyclines, vinca 
alkaloids, actinomycin D, and also melphalan, the degree of 
resistance varying for each drug and cell line (Elliott and Ling, 
1981; Ling et al, 1983; Chabner et al, 1984; Curt et al, 1984). 
Resistance vrns accompanied by reduced cellular accumulation of the 
cytotoxic drugs, variously attributed to enhanced active extrusion, 
shared by vinca alkaloids and anthracyclines (Skovsgaard et al, 1984) 
or to alterations in cellular protein drug binding or in the membrane 
itself (Ling, 1975; Beck, 1984; Curt et al, 1984; Siegfried et al, 
1985). Although melphalan accumulation has not been studied in cells 
with PDR, changes in membrane phospholipids altered melphalan 
_) 
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transport (Burns and Dudley, 1982). 
1-4-5 Reversal of pleiotropic drug resistance by calcium antagonists 
and calmodulin inhibitors 
An important feature of PDR is that it can be reversed by 
verapamil and other calcium antagonists and by calmodulin inhibitors. 
These drugs enhanced the cytotoxicity of vincristine, adriamycin and 
daunorubicin to cell lines selected for resistance to one of these 
agents, including P388 leukaemia (Tsuruo et al, 1981, 1982b, 1983b; 
Ramu et al, 1984a; Ganapathi et al, 1984), Lewis lung, B16 melanoma 
and colon adenocarcinomas (Tsuruo et al, 1983a), Ehrlich ascites 
(Slater et al, 1982) as well as human leukaemia (Tsuruo et al, 1983b, 
c), ovarian (Rogan et al, 1984) and bladder (Simpson et al, 1984) 
carcinoma cell lines. Drug sensitivity was partially or completely 
restored, usually with a greater effect in more resistant cell lines. 
Drug accumulation was increased, usually by reduced efflux, but by 
increased influx in a human epithelial KB cell line (Fojo et al, 
1985). Verapamil a 1 so reduced efflux and enhanced cytotoxi city of 
etoposide in L1210 cells (Yalowich and Ross, 1984, 1985), and reduced 
cross-resistance to most of the drugs associated with PDR in P388 
cells resistant to adriamycin or vincristine (Tsuruo et al, 1985b). 
This effect of calcium/calmodulin antagonists was not simply 
correlated with calmodulin inhibition (Tsuruo et al, 1982a; Ganapathi 
et al, 1984) nor with calcium channel blockade (Murray et al, 1984; 
Ramu et al, 1984d; Kessel and Wilberding, 1985), although calcium was 
necessary in one cell line (Yanovich and Gerwitz, 1984) and resistant 
cells contained more calcium (Tsuruo et al, 1984a). An alteration of 
the cell membrane, possibly through calmodulin-mediated cellular 
processes (Beck, 1984; Ramu et al,1984a,c; Veigl et al,1984), is 
thought likely (Curt et al,1984; Tsuruo et al, 1985b). Support comes 
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from similar reduction of resistance by the membrane-active drugs, 
reserpine, quinidine and tamoxifen (Curt et al, 1984; Ramu et al, 
1984b; Tsuruo et al, 1984b), changes in adriamycin sensitivity with 
changes in membrane phosphol i pi ds (Guffy et al, 1984) and induction 
of phosphorylation of a membrane glycoprotein by verapamil and 
trifluoperazine (Center, 1985). 
Resistance susceptible to reversal by calcium/calmodulin 
inhibitors is not the only mechanism of resistance even in cells with 
PDR (Chabner et a 1, 1984; Rogan et a 1, 1984; Kaye and Merry, 1985; 
Kessel and Wilberding, 1985), and whether PDR occurs in human tumours 
in vivo remains uncertain (Chou et al, 1984; Harker et al, 1984). 
Nonetheless, verapami 1 reduced resistance in human 1 eukaemi a ce 11 s 
(Pradhan et al, 1984; Stark, 1984) and in some human solid tumours 
cloned in vitro (Dana and Woodruff, 1984; Goodman, 1984), and 
clinical trials have begun using verapamil and analogues with 
vincristine or anthracyclines in ovarian carcinoma and leukaemia 
(Rogan et al, 1984; Benson et al, 1985; Tsuruo et al, 1985b). 
Little is known about calcium/calmodulin inhibitors and 
melphalan sensitivity, except that verapamil failed to restore 
sensitivity to a melphalan-resistant human ovarian carcinoma line 
(Rogan et al, 1984) or to an adriamycin-resistant human sarcoma line 
cross-resistant to melphalan (Harker et al, 1984). However 
vincristine, adriamycin and chlorpromazine (a calmodulin inhibitor) 
each reduced melphalan accumulation by L1210 cells (Martin et al, 
1982) suggesting interact i ans in the transport of the cytotoxic 
agents, and that it would be worth exploring the effects of verapamil 
on melphalan transport. 
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CHAPTER 2 MATERIALS AND METHODS 
2-1 Mice and tumours 
Male and female cba/ca mice, obtained from the National 
Institute of Medical Research, Mill Hill, were maintained in the 
Institute of Cancer Research (!CR) and used when at least 10 weeks 
old. For normal tissue toxicity, pharmacokinetic and bone marrow 
experiments, mice of either sex were used; females were used for 
implantation of murine fibrosarcomas, and males for human melanoma 
HX46 xenografts. In every experiment, mice in treatment groups were 
matched for sex, age and weight. 
Three benzpyrene-induced fi brosarcomas stored in 1 iquid nitrogen 
were obtained from Dr. Sue Eccles (!CR), and passaged every 2-3 weeks 
in female cba mice, average weight 20g. Tumour was finely minced 
with crossed scalpels and incubated 1 hour at 37°c in phosphate 
buffered saline (PBS) containing 0.5mg/ml pronase, 0.2mg/ml DNAse and. 
0.2mg/ml collagenase. The disaggregated tumour cells were washed in 
PBS, and O. 7 x 106 ce 11 s in O. lml injected subcutaneously into the 
flank, usually bilaterally. Passages 12-15 of FS12, 5-12 of FS13 and 
8-10 of FSM19 fibrosarcomas were used, 10-18 days after implantation. 
The human melanoma HX46 xenografts, established by Selby et al 
{1980), were taken from liquid nitrogen, and 1-2mm pieces implanted 
subcutaneously in male cba mice. These mice were immunosuppressed by 
thymectomy, and 9 Gray total body irradiation from a 60co-cobal·t 
source, preceded 48 hours by cytosine arabinoside 200mg/kg by 
intraperitoneal (ip) injection (Millar et al, 1978a; Steel et al, 
1978). Passages 5-7 were used, 18-24 days after implantation. The 
HX46 xenografts retained their original histology and human karyotype 




Preparation of mononuclear cell fraction of bone marrow and 
fibrosarcoma cell suspension 
Mouse bnne marrow was obtained by flushing the femurs with 
heparinised PBS. Human bone marrow was obtained from normal donors 
at the Royal Marsden Hospital. The marrow was layered over a 
Fi coll /sodium rnetri zoate solution (lymph op rep, specific gravity 
1.077, Nyegaard) and centrifuged at 400g for 30 minutes. The 
mononuclear cell fraction was taken from the interface, washed and 
resuspended in PBS. For mouse marrow, mononuclear cells made up 81 + 
3% of the cells after Lymphoprep (10 experiments). 
Disaggregated fibrosarcoma cells in PBS were treated in the same 
way. The resulting cell preparation was 42 ~ 7% mononuclear cells, 
90% viable, compared with 22 ~ 2%, 20-40% viable before Lymphoprep (4 
experiments). 
Human promyelocytic leukaemia HL60 cells, growing in logarithmic 
phase in RPMI 1640 medium,were obtained from Dr. Janet Bell, ICR, and 
washed in PBS before use. 
) 
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Modification of Eagle 1 s 
medium without nucleosides, powder preparation for 10 litres 
(Flow Laboratories, Catalogue No. 10-311-22), mixed with 
100ml Eagles MEM vitamins, 10ml of 1% phenol red and 
distilled water to 1700ml. 
* Obtained from CSSD, ICR 
BSA=bovine serum albumin 
) 
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2-3 Media, drugs and isotopes 37 
2-3-1 Media 
Phosphate buffered saline (PBS) and balanced salt solution 
(BSS), both free of calcium and magnesium, were obtained from Central 
Sterile Supplies Department (CSSD), ICR. Human and mouse 
double-strength alpha media were prepared from Alpha Modification of 
Eagle 1 s Medium (Flow Laboratories), and were diluted 1:1 with 0.67% 
or 1% agar (Difeo) immediately before plating cells. The composition 
of these media is shown in Table 2-1. The RPMI 1640 medium was 
prepared by CSSD from the powder (Gibco), supplemented with sodium 
bicarbonate 2g/litre, penicillin and streptomycin. 
2-3-2 Drugs and isotopes 
Melphalan (Alkeran, Burrough 1 s Wellcome) and 14c-melphalan (SRI 
International), 14c label in the chloroethyl side chain, specific 
activity (s.a.) 33.7 uCi/mg, were dissolved in acid alcohol (5M 
HCL:ethanol 1:50), usually 20mg/ml or lmg/ml, stored belm'I o0c, and 
diluted in saline or PBS immediately before use. Tritiated thymidine 
(s.a. 119mCi/mg), 14c-xylose (s.a. > 50mCi/mmol), 59Fe-ferric chloride 
(s.a. 12.8 uCi/ug) and 86Rb-rubidium chloride (s.a. l-8mCi/mg) were 
obtained from Amersham International. 
Verapami 1 hydroch 1 ori de (Cordilox, Abbott), propranol ol 
{Inderal, ICI), methoxamine (Vasoxine, Calmic Medical), adrenaline 
(Macarthys), fl unari zi ne and placebo ( gifts of Janssen 
Pharmaceutical) were used as supplied or diluted with normal saline. 
Cisdiamminedichloroplatinum II (Cisplatin, David Bull), lmg/ml in 
normal saline, contained lmg/ml mannitol and was diluted 1:1 in 
saline. Epoprostenol (Flolan, gift of the Hellcome Foundation) was 
diluted first in glycine buffer (~.Jellcome) and then 1:4 in normal 
saline. Vasoactive intestinal peptide (VIP) (Sigma) and angiotensin 
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II (aspl-ileu5 , human, MRC Research Standard A, National Institute 
for Biological Standards and Control) were dissolved in saline, 50 
ug/ml and 24.3 ug/ml respectively, frozen and diluted immediately 
before use. Human epidermal growth factor (hEGF) (gift of ICI 
Pharmaceuticals and GO Searle) and mouse EGF (mEGF) (Collaborative 
Research) were dissolved in water for injection and frozen until 
used. 
2-3-3 Administration of drugs ·to mice 
The concentration of drugs was adjusted so that lOml/kg 
{O.Olml/g) was given by the intrap.eritoneal (ip) or intravenous (iv) 
route, or the desired dose given in O.lml/minute by iv infusion. For 
iv admi ni strati on, the unanaesthet i sed mouse was he 1 d by the tail in 
a V-frame, and a tourniquet (Minasian, 1980) used to engorge the tail 
veins. A 25 gauge needle, broken from its hub and connected by 10cm 
of Portex tubing to another 25 gauge needle was inserted into the 
tail vein; saline, drugs or isotopes were administered through this 
tubing, from 1ml tuberculin syringes. 
disturbed by tail vein injection. 
Mice appeared minimally 
The dose of vasoact i ve agents se 1 ected was that causing about 
0 .5-1.oc 0 depression in mouse rectal temperature, measured ~Jith a 
thermocouple probe (VA Howe), length 3.0cm, diameter 0.15cm, with 
o.1c 0 resolution. Temperature was measured every 5-10 minutes after 
administration of drug or saline to mice, grouped 4-6 to a box 
between measurements. Uptake of 86 Rb was determined at the nadir in 
temperature, since a vasoactive effect should then be evident. This 
is further discussed in Chapter 4. 
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2-4 Normal tissue toxicity of melphalan in mice 
2-4-1 Jejunum microcolony assay 
Groups of 3-4 mice were treated with melphalan, with or without 
a vasoactive drug, or EGF, and killed 4 days later (also at 7 or 8 
and 13 days in EGF experiments) when toxicity should be maximal 
(Millar et al, 1978b). Three portions of jejunum per mouse were 
excised, fixed in 10% neutral buffered formalin, and 4-5 um thick 
transverse sections stained with haematoxylin and eosin. Surviving 
cryptogenic cells were assessed using a modification from Withers and 
Elkind (1970) (Millar et al, 1978b). The number of regenerating 
crypts per circumference was expressed as a fraction of the number in 
the jejunum of untreated normal mice, and reported as the mean + 
standard error of the ratio {SER). 
2-4-2 Uptake of 14c-xylose 
In experiments with EGF, 14c-xyl ose uptake was determined every 
3-5 days after melphalan treatment. Mice anaesthetised with ether 
were given 0.5 uCi 14c-xylose by oropharyngeal tube, and tail vein 
blood collected 30 minutes later. Blood 14c, determined as described 
in section 2-7-1, was expressed as %dose/ml, and reported as mean+ 
standard error of the mean {SEM). 
2-4-3 Spleen colony assay (CFU-S) 
The spleen colony forming cells (CFU-S) of mouse bone marrow 
were assayed by the method of Ti 11 and McCulloch {1961). Groups of 
3-4 mice were treated with ip melphalan and/or verapamil. One day 
later a cell suspension of their femoral marrow was given 
intravenously to lethally irradiated mice, 5 recipients for each 
treatment group. Spleen colonies 7 days later were expressed as a 




2-5 Cytotoxicity of melphalan 
2-5-1 Tumour growth delay 
Tumour-bearing mice were divided into treatment groups of at 
least 5 mice with 8-10 tumours of similar volume distribution. 
TI Dd2 Tumour volume was calculated from V= 6 where D is the longest 
diameter and d the perpendicular diameter, measured with calipers. 
Volume at various times after treatment (Vt) was expressed as a ratio 
of the vo 1 ume on the day of treatment, day O (Vo). The means of 
Vt/Vo±_ SER were plotted as growth delay curves. To compare growth 
delay by different treatments, individual tumour doubling times were 
determined and the Mann-Witney U test applied. 
2-5-2 Clonogenic assay, CFU-GM 
The granu 1 ocyte macrophage colony forming ability (CFU-GM) of 
the mononuclear cell fraction of mouse and human bone marrow was 
assayed by the method of Bradley and Metcalf (1966). The cells were 
incubated in PBS with melphalan (0.01-2 ug/ml) and/or verapamil 10 
ug/ml at 37°c for 60 minutes, then washed and resuspended in 
drug-free, single-strength alpha medium. An underlayer (1ml) of 
alpha medium with 0.5% agar, with colony stimulating factor (CSF), 
was pipetted. into 35mm diameter petri dishes (Sterilin). The cells 
were then overlaid in alpha medium (0.5ml) with 0.33% agar, each 
treatment group plated in triplicate. Dishes ~'/ere gassed with 85% 
nitrogen/10% carbon dioxide/5% oxygen, sealed in plastic boxes, and 
incubated at 37°c for 10 days (mouse) or 14 days (human). Colonies 
of 50 or more cells were counted using an inverted, phase-contrast 
microscope (Wild), and CFU-GM expressed as a fraction of that of 
control, untreated marrow+ SER. Absence of colonies when no CSF was 





and plated in greatest numbers, excluded auto-stimulation. 
The CSF was derived from pregnant mouse uterus for mouse, and 
from 5637 cell secretions for human marrow (Myers et al, 1984). 
This yielded plating efficiencies of 1:150-1:200 for untreated mouse 
marrow, and 1: 700 for human marrow. 
2-6 Uptake of 86 Rb-rubidium chloride in mice 
The relative blood flow to tumours and other tissues was 
determined from the distribution of 86Rb, in a method adapted from 
Zanell i and Fowl er (1974) and Sapi rstei n (1958). Unanaestheti sed, 
tumour-bearing mice were given 86Rb-rubidium chloride, a weighed dose 
of 3-5 uCi in 0.1ml saline (isosmolal), through the tail vein, 
flushed with 0.1ml saline. The mouse was killed 60 seconds later by 
iv injection of 0.2ml saturated potassium chloride (KCl). Vasoactive 
agents were given iv or ip, usually 3-20 minutes before 86Rb. The 
86Rb dose was given 60 seconds before completing iv infusion of 
angiotensin II and VIP. Mice from treatment and control groups were 
treated alternately to control for circadian variations. Each 
experiment was usually completed within a day. 
On sacrifice, the mice were exsanguinated from the neck to 
standardise residual blood. The tumours, liver, spleen, kidneys, 
lungs, proximal small intestine (jejunum) cleaned of faeces, 
quadriceps muscles, femurs and a portion of unshaved abdominal skin 
were excised and weighed. Large haemorrhagic areas of tumours 
(uncommon) were excluded. The tissues, tail, Portex tubing and 6 
dose standards (made up to 1ml with saline) were counted in double 
glass tubes for 10 mi nut es in a gamma-counter (Kontron). Tail and 





Mice with more than 20% dose in the tail were rejected, as were 
tumours weighing less than 40mg. The fractional distribution of 
cardiac output (FDCO) to tumours and tissues was calculated as %dose 
per gram of wet tissue, and expressed as mean+ SEM for groups of 5 
or more mice, with bilateral or unilateral tumours. Further details 
of the method are discussed in chapter 3. 
2-7 Uptake of 14c-melphalan 
2-7-1 In vivo 14c-melphalan studies in mice 
The pharmacokinetics of 14c-melphalan were determined after 
administration to mice, with or without a vasoactive agent. Blood 
(20 ul) was taken from the tail vein for up to 4 hours and 14c 
determined. In other experiments, groups of tumour-bearing mice were 
treated with 14c-melphalan, with or without a vasoactive agent, and 
killed 5,20,30,60 minutes or 4 hours later. The mice were bled from 
the neck under ether anaesthesia, and tumours, skin, kidney or 
jejunum excised and weighed. 
The 14c content of blood and tissue samples placed on 
cumbustopads in combustocones (Packard), was determined using a 
Packard Oxidiser 306 (United Technologies Packard). In an automatic 
sequence, 14c rel eased during complete combustion was trapped in 
9-lOmls of Carbosorb (Packard) and added to 13mls Permafluor 
scintillant (Packard). Samples and dose standards were then counted 
in a liquid scintillation counter (Intertechnique), and 14c expressed 
either as %dose or as ug melphalan, per ml of blood or per gram of 
wet tissue. 
In a 11 these in vivo experiments, me 1 pha 1 an was I spiked I with 
14c-melphalan. Melphalan was diluted in normal saline just before 
administration, so that mice received acid alcohol:saline 1:20 (aa 
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1:20), in all pharmacokinetic experiments and in most tumour uptake 
experiments. However, different acid alcohol concentrations were 
explored in two experiments (see section 3-3), and 14c-melphalan in 
acid alcohol :saline 1:50 (aa 1:50) was used in three experiments 
(Figures 5-3, 6-7, 6-19). 
2-7-2 In vitro cellular 14c-melphalan uptake 
The mononuclear cell fraction of bone marrow, fibrosarcoma cells 
and HL60 cells (section 2-2) ~I/ere adjusted to 2-3 x 106 cells/ml in 
PBS, no amino acids being present in the medium (Goldenberg and 
Begleiter, 1980; Vistica, 1983). Cells were incubated at 37°c for 
30-60 minutes in the presence of 14c-melphalan, usually 1 ug/ml, with 
or without verapamil (0.1-100 ug/ml). The 14c-melphalan (no 
unlabelled drug), lmg/ml in acid alcohol, was diluted in PBS at the 
beginning of incubation. At various times, duplicate 0.5 or 1ml 
aliquots of incubated cells were layered over 0.5ml oil (mineral 
oil:silicone oil (Dow Corning) 1:4 by volume, specific gravity 1.025) 
and spun at 12 ,OOOg for 2-3 minutes in a mi crocentrifuge (320a, 
Burkard). The exact oil composition is empirical, depending on 
density of cells and oil, and other unknown factors, but effectively 
removes all extracellular 14c-melphalan (Wohlhueter et al, 1978; 
Goldenberg and Begleiter, 1980; Redwood and Colvin, 1980; Martin et 
al, 1982.). The supernatant medium was drawn off, replaced once with 
di st i 11 ed water to rinse, and the oil tipped out. The ce 11 pe 11 ets 
were sol ubil i sed overnight in P rotosol (New Engl and Nuclear), added 
to lOmls of ACS scintillant (New England Nuclear), containing acetic 
acid 37 •. ? ml/gallon to counteract chemiluminescence, and counted 24 .. 
hours later in a refrigerated liquid scintillation counter 
(Intertechnique), with standards and samples of supernatant medium. 
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Cellular 14c-melphalan as ng/106 cells was usually expressed as a 
fraction of that of control cells incubated in verapamil-free, 
calcium-free medium for 30 or 60 minutes. No correction was made for 
initial adsorption of 14c-melphalan to the cell membrane, usually 
less than 10% of steady state cellular 14c-melphalan (Begleiter et 
al, 1979, 1980; Goldenberg et al, 1979). 
For 14c-melphalan efflux studies, cells were loaded by 30 
minutes incubation in 1 ug/ml 14c-melphalan at 37°c. After duplicate 
1ml samples were taken, the remaining cells were rapidly spun down 
and resuspended in melphalan-free medium at o0c to prevent immediate 
efflux (Goldenberg et al, 1977; Begleiter et al, 1982; Martin et al, 
1982). Incubation was then continued at 37°c, with or without 
verapamil, samples being taken immediately and up to 30 minutes 
later. 
Most experiments were performed at least twice, and the results 
combined. Medium 14c-melphalan concentration, cell counts (by 
Coulter counter) and cell viability (by trypan blue dye exclusion) 
were determined at the beginning and end of incubation, and 
immediately after resuspension of cells. Cell size was determined 
using a modified Coulter counter (Coulter Electronics) ca 1 i brated 
with latex particles. 
2-7-3 High pressure liquid chromatography (HPLC) of melphalan 
Melphalan and hydrolysis products were determined in the 
mononuclear cell fraction of murine bone marrow and the PBS medium 
after 30 minutes incubation with 14c-melphalan at 37°c with or 
without verapamil, using HPLC in a method adapted from Chang et al 
(1978a). Cells, separated from the supernatant by centrifugation 




sonicated, extracted with 100% methanol, filtered through a 0.2 
micron polysulfone filter (Gelman Acrodisc, product No. 4192), which 
does not retain me l pha l an (Bosanquet, 1985) and injected onto the 
column. The supernatant was also immediately frozen, then at o0c, 
diluted 1:2 with 100% methanol and filtered. A reversed phase 25cm x 
4 .6mm I.D. column with Cl8 Bondapak, lOu (Waters) packing, was used, 
and a sample size of 50 ul. The solvent system was isocratic, 1:1 
water:methanol with 1% acetic acid (Fison 1 s, HPLC grade), degassed, 
run at a flow rate of 1.4ml/min and run time 18 minutes (Constametric 
I II pump, Laboratory Data Control (LDC)). Melphalan \I/as detected 
at 263nm, 0.001 AUFS sensitivity (Spectromonitor III, model 1204A, 
LDC) and the peaks plotted (Cl-10 Integrator, LDC).· Thirty-second 
(0.7ml) effluent fractions were collected, lOmls ACS scintillant 
added, and counted for 14c. This allowed estimation of the two 
me l pha 1 an hydrolysis products despite background interfere nee from 
proteins in the sample (Chang et al, 1978b). 
In addition, the rate of hydrolysis of melphalan in PBS at 37°c 
in the presence and absence of verapamil was determined using HPLC. 
2-8 Distribution of 59Fe-labelled red cells in mice 
The vascular volume of fibrosarcomas was determined as described 
by Wist et al (1981). Two cba mice received 15 uCi 59Fe-ferric 
chloride in 0.5% sodium citrate and 0.75% sodium chloride, in 3 doses 
over one week. Their blood was collected under ether anaesthesia, 
diluted in heparinised saline, and 0.2ml doses given iv to mice 
bearing fibrosarcomas. Mice were killed 20 minutes later, when red 
cell distribution should have reached a steady state in tumours 
(Tannock and Steel, 1969; Song and Levitt, 1971); blood, tumours, 
kidney and muscle were collected, weighed and counted in a gamma-
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counter (Kontron). The red cell volume was expressed as %dose, or ul 
blood, per gram wet tissue, as the mean+ SEM. 
2-9 l-!Q!:.!t,~_s,f P.1-~Ql.i~ 
Mice with fibrosarcomas were treated ~vith cisp'latin, 5mg/kg, 
either ip or iv, with or w-Jthout a vasoactive agent. Mice were 
lei 11 ed at 60 mi nut es, exsangui nated, tumours and kidneys excised and 
weighed. After solubilisation hyami ne hydroxide 
(methyl benzethoni um hydroxide, s·i gma), samples ivere diluted with O. lN 
hydrochloric acid~ Total platinum content was determined by 
flameless atomic absorption spectroscopy using i ntc~rna·1 standards for 
each sample, as described by Siddik et a1 (1985). Platinum was 
expressed as ~g/g wet tissue, as mean+ SEM. 
2-10 Statistics ------
Results are presented as the mean+ standard error of the mean 
(SEM) or of the ratio (SER)·, or the range if 2 observations. Means 
were compared using the t test for small samples (Baney, 1981). When 
more than 2 groups were compared one-way analysis of variance (ANOVA, 
MINITAB software) was performed. The mean of the control group 11ms 
compared with the means of the test groups using Dunnett I s test and 
the 1% level of significance (Zar, 1984). Growth delays and some in 
vivo uptake studies were compared using the 2-tailed Mann-Witney U 
test (Siegel, 1956). The significance of linear correlation 
coefficients was expressed as p values (Bailey, 1981). The area under 
the blood melphalan concentration time curve was estimated for 
individual mice~, using the trapezoida1 rule, taking the arithmetic 
mean of concentrations at successive time points from zero to 240 
minutes. 
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CHAPTER 3 UPTAKE OF 86 Rb AND 14C-MELPHALAN BY TUMOURS AND NORMAL 
TISSUES IN CBA MICE 
3-1 Uptake of 86Rb-rubidium chloride 
3-1-1 Uptake of 86Rb at 60 seconds 
The distribution of 86Rb in tissues and tumours was constant 
from 10-20 seconds until at least 60 seconds, reflecting the 
fractional distribution of cardiac output (FDCO) (Sapirstein, 1958; 
Gullino and Grantham, 1961; Cataland et al, 1962; Zanelli and Fowler, 
1974; Wetterlin et al, 1977; Stewart and Begg, 1983). Demonstration 
of this plateau in the tumours and tissues under study is necessary 
to validate the use of 86Rb for FDCO (Sapirstein, 1958). 
Mice bearing FS12 fibrosarcomas were given 86Rb and killed 15, 
30, 60 or 90 seconds later. A further 3 mice without tumours were 
given 86 Rb flushed in with KCl, killed in less than 5 seconds. The 
86Rb content of tumours and tissues, as %dose/g wet tissue, is shown 
according to time from administration of 86Rb, in Figures 3-1 and 
3-2. There were no significant differences in 86Rb content for each 
tissue and the tumours between 15 and 90 seconds. Blood levels fell 
from 17 %dose/ml immediately after 86Rb administration, to be 3-4 
%dose/ml from 15-90 seconds. Pairs of mice were killed 1, 4 and 24 
hours after 86Rb doses, and gradual redistribution of 86Rb occurred 
(Figure 3-3). 
The plateau for 86Rb uptake was also confirmed for mice bearing 
FS13 fibrosarcomas (Figure 3-4). Tissue and tumour 86Rb contents at 
30 and 90 seconds did not differ significantly from 60 second values. 
In all subsequent experiments, mice were killed 60 seconds after the 
86Rb d-ose. 
) 
FIGURE 3-1 49 
Distribution of 86Rb with time after iv injection in FS12 
fibrosarcomas (*), muscle, skin and liver in cba mice 
(unilateral tumours) 
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FIGURE 3-2 50 
Distribution of 86Rb with time after iv injection in FS12 
fibrosarcomas (*), kidney, heart and jejunum in cba mice 
(unilateral tumours) 
mice 3 6 6 8 5 
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FIGURE 3-3 51 
Redistribution of 86Rb over 24 hours after iv injection in cba mice 
(2 mice at 1, 4, 24 hrs) 































Distribution of 86Rb with time after iv injection in FS13 
fibrosarcomas and tissues in cba mice 
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3-1-2 Effect of tumour weight on 86Rb u12take 
Bilateral implantation of fibrosarcomas enabled 86Rb uptake to 
be compared in the 2 tumours in the same moose. Figure 3-5 shov,s the 
·86Rb uptake in each of the FS13 fibrosarcomas in 19 control mice from 
3 experiments. Although some tumour pairs had similar 86Rb contents, 
others differed widely. The 86Rb content of tumours of similar 
weight varied up to 2.5-fold. 
The means for FS13 tumour weight and 86Rb uptake for the control 
mice in the first 24 experiments are plotted in Figure 3-6, while the 
individual values for each tumour are shown in Figure 3-7. Uptake of 
86Rb, as %dose/g tumour, decreased with increase in weight, 
correlation coefficient r=-0.5272, p <0.001. 
A decrease in 86Rb uptake with increase in tumour weight was 
also found for FS12 (r=-0.4283, p < 0.002) (not shown) and FSM19 
(r=-0.4954, p <0.01) (Figure 3-8) fibrosarcomas, but the trend was 
not significant (r=-0.3448, 0.05 < p < 0.10) for human melanoma HX46 
xenografts (Figure 3-9). The range and means of tumour weights were 





Uptake of 86Rb by bilateral FS13 fibrosarcomas in cba mice 
(controls from 3 experiments) 
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Weight and 86Rb uptake of FS13 fibrosarcomas in cba mice 
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3-1-3 Uptake of 86Rb by tumours and tissues in mice 59 
The results from experiments using verapamil and angiotensin II 
are shown in Figures 3-10 and 3-11, to show 86Rb uptake by normal 
tissues in cba mice. In Figure 3-10, mice \\lith unilateral FS12 
fibrosarcomas were treated with salirie lOml/kg ip (6 mice) or 
verapamil lOmg/kg ip {8 mice, matched with saline controls for tumour 
and body weight), and 86Rb uptake determined 30 minutes later. In 
Figure 3-11, mice with bilateral FS13 fibrosarcomas were treated with 
saline or angiotensin II 1.2 ug/kg/min by iv infusion. Comparing 
86Rb uptake as %dose/g tissue, the FDCO was greatest to kidney, heart 
and then jejunum, lungs, spleen and liver. The FDCO to fibrosarcomas 
usually exceeded that to muscle, bone and skin, having a value 
similar to liver and blood. These values are comparable with those 
obtained by Zanelli et al (1975) in unanaesthetised mice. 
The data from Figure 3-11 are listed in Table 3-1 alongside the 
86Rb uptake for whole organs. Mice are not all the same size, and 
86Rb uptake in %dose/g tissue varies with body weight. Thus an 
average tissue taking 5 %dose/gin a 20g mouse would take 4 %dose/g 
in a 25g mouse. The difference is less when 86Rb uptake per organ is 
compared, because organ size tends to vary with body weight, but not 
all tissues can be removed as organs. It was therefore simplest to 
use mice of the same body weight in an experiment, and compare 86Rb 
uptake as %dose/g wet tissue, using a fixed dose of 86Rb. 
Although 86Rb uptake to all the tissues shown in Figures 3-10 
and 3-11 and blood 86Rb were measured in most experiments, spleen and 
lung 86Rb uptake tended to vary widely and inconsistently (in repeat 
experiments), whi 1 e bone uptake never changed. Only results for 
tissues expected to show a change in FDCO, and those showing changes, 




Uptake of 86Rb by FS12 fibrosarcomas and tissues in cba mice 
30 min after verapamil 
{10 tumours, 6 mice, control; 13 tumours, 8 mice, verapamil) 
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FIGURE 3-11 61 
Uptake of 86Rb by FS13 fibrosarcomas and tissues in cba mice after 
angiotensin II 1.2ug/kg.min iv infusion for 5 min (12 tumours,6 mice) 
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Uptake of 86Rb by FS13 tumour and tissues in cba mice, after 
angiotensin II 1.2 ug/kg/min iv infusion, expressed per organ or per 
gram tissue+ 
Control Angiotensin II 
No. mice 6 6 
Wt. mice (g) 19.8 + 0.3 20.3 + 0.4 
No. tumours 12 11 
Wt. tumours (g) 0.14 + 0.01 0.14 + 0.02 
86Rb 86Rb 
%dose/organ %dose/g %dose/organ %dose/g 
Tumour 0.56 + 0.06 4.03 + 0.15 0.80 + 0.07 ** 5.38 + 0.48 ** 
Liver 4.71 + 0.27 4.38 + 0.27 5.46 + 0.34 5.20 + 0.29 * 
Spleen 1.00 + 0.10 9.12 + 0.82 0.75 + 0.04 * 7.87 + 0.63 
Kidneys 8.56 + 0.76 33.29 + 2.68 4.14 + 0.43*** 16.64 + 1.72*** 
Heart 1.72 + 0.09 26.07 + 1.50 2.08 + 0.07 ** 32.14 + 1.85* 
Femurs 0.16 + 0.01 2.29 + 0.15 0.17 + 0.02 2.52 + 0.26 
Lungs 1.48 + 0.19 10.19 + 0.82 2.41 + 0.25 ** 11.12 + 0 • 85 
Blood# 3.72 + 0.33 3.83 + 0.23 
+ Same data as in Figure 3-11 




3-1-4 Differences in tumour 86Rb uptake 
The majority of results of 86Rb ~ptake experiments with 
vasoactive agents were compared using the t test for small samples 
(Table 3-1). The results for tumour 86Rb uptake in ·Figures 3-10 and 
3-11 were also compared using the Mann-Witney U test. The difference 
after verapamil (Figure 3-10) was not significant by either test. 
The difference after angiotensin II, p~ 0.01 by t test (Figure 3-11 
and Table 3-1) was also significant (alpha< 0.02) in the 2-tailed 
Mann-Witney U test. Thus, despite marked variation in tumour 86Rb 
uptake, differences after vasoactive agents could be detected, and 
the t test was generally used ~analysis of variance ('MINITAB 1 software) 





3-1-5 Effect of saline administration on 86Rb uptake 
In 86Rb uptake experiments, a 20g mouse would receive 0.4-0.5ml 
fluid over 1 minute, besides 0.2-0.3ml ip or iv through 
administration of a vasoactive agent up to 20 minutes earlier. 
Administration of saline, lOml/kg ip 15 minutes before the 86Rb dose, 
was compared with no prior treatment (Figure 3-12). There was no 
difference in FDCO to FS13 tumours nor other tissues, except for a 
small increase in the lung (p< 0.02) after saline. Results pooled 
from 3 experiments, where mice had been untreated or given saline 10 
ml/kg ip or iv, also showed no difference in tumour 86Rb uptake 
(Figure 3-13). Giving mice an iv bolus of 1ml saline (about 50ml/kg) 
had no significant effect on 86Rb uptake by FS13 tumours (Figure 
3-13), and decreased jejunum and increased skin 86Rb slightly 
(results not shown), at 15 minutes, when compared with untreated 
mice. 
Haemodilution, which would occur acutely on iv administration of 
saline, did not increase tumour blood flow, in contrast to findings 
of Vaupel and Muller-Klieser (1984) in tumours in the isolated kidney 
preparation. In 86Rb uptake experiments controls for ip vasoactive 
agents were often untreated, but controls for drugs given by iv bolus 
or infusion always received saline in a similar way to control for 
any effects of restraint in the V-frame. 
J 
FIGURE 3-12 65 
Administration of saline ip and 86 Rb uptake by FS13 fibrosarcomas 
and tissues in cba mice, at 15 min 
saline lOml/kg ip (shaded) 
(26-28 tumours, 13-14 mice) 
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Saline administration and 86 Rb uptake by FS13 fibrosarcomas 
in cba mice, at 15 min 
saline lOml/kg iv or ip {8-19 tumours,7-11 mice) 
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3-2 Uptake of 14c-melphalan 
3-2-1 .. Uptake of 14c-mel phal an at 60 seconds 
This investigation had the aim of increasing uptake of melphalan 
by tumours in order to increase antitumour effect. Therefore the 
effects of a number of vasoacti ve agents on 14c-mel phal an uptake by 
tumours and some normal tissues in cba mice were studied. The 
uptakes of 86Rb and 14c-melphalan at 60 seconds were compared (Table 
3-2). The mice receiving 86Rb were given acid alcohol:saline 1:20 
(aa 1:20), 10 ml/kg iv, to control for the melphalan solvent, 
although from section 3-3-1 no effect on 86Rb uptake occurred in the 
first 3 minutes. The FS13 fi brosarcomas took up 63% as much 14c 
melphalan as 86 Rb over the first minute. It was not technically 
possible to count 86Rb and 14c-melphalan together in the same tissue 
samples, precluding a double label experiment. The 14c-me1phalan 
appeared to be rapidly distributed to most tissues, roughly in 




Uptake of l4c-melphalan and 86Rb by FS13 fibrosarcomas and tissues in 
cba mice, 60 seconds after iv administration 
No. mice 
No. tumours 








0.27 + 0.03 
4.26 + 0.35 
31.6 + 3.2 
13.0 + 0.6 




0.25 + 0.02 
2.68 + 0.17 
24.4 + 1.8 
7.1 + 0.3 
2.23 + 0.09 
Ratio 
14c;86Rb 
0.63 + 0.07 
0.77 + 0.10 
0.55 + 0~03 
0.82 + 0.05 
! • 
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3-2-2 Effect of tumour weight on 14c-melphalan uptake 
In most experiments, 14c-melphalan uptake by tumours was 
determined 30 or 60 minutes after administration. The 14c-melphalan 
uptake by FS13 (in %dose/g) is plotted against tumour weight, as the 
mean+ SEM for control groups from 13 experiments in Figure 3-14~ and 
for individual tumours in Figure 3-15, 60 minutes after ip melphalan. 
The 14c-melphalan uptake was greater in larger tumours, r=+0.5384 
(p<0.001). The trend was not significant when me·lphalan was given iv 
but the number of tumours was much less. Too few HX46 tumours were 
studied for a correlation. It may be that during 60 minutes, 
14c-mel phal an slowly permeates poorly perfused parts of the tumour 
which would receive little blood flow in the minute of 86Rb 
equilibration. Also, there are more dilated vascu·lar channels in 
larger tumours (section 1-2-1) and these may trap more blood 
including 14c-melphalan. 
The 30 and 60 minute time points used in 14c-melphalan uptake 
studies were chosen for several reasons. These times were used in 
other murine studies (Selby et al, 1979; Brown et al, 1980; Furner 
and Brown, 1980; Wist et al, 1981; Honess et al, 1985) allowing 
comparisons to be made. Furthermore, melphalan reached peak levels 
in blood and most tissues within 30-60 minutes of ip administration, 
so that changes in tissue uptake might be greatest at 30-60 minutes. 
These same times were used for in vivo cellular uptake studies. In 
two experiments (Figures 5-2, 6-4), 4 hours was also used, because 





Weight and 14c-melphalan content of FS13 fibrosarcomas, at 60 min 
melphalan (aa 1:20), lOmg/kg ip (•), lOmg/kg iv (o) 
5mg/kg ip ( .. ), 2.5mg/kg ip ( T) 
melphalan (aa 1:50), 5mg/kg ip (•), 5mg/kg iv (o) 
(controls from 13 experiments) 
4.5 FS 13 
- + s.... :::J 0 
E 
+ :::J 3.5 -+-' 0, -Cl.) 
+ 
V) + 0 -0 ~ 




0.2 0.4 0.6 










----------4 -j 0 ----- 0 0 0 6) 0 O 0 0 




en 0 0 
0 00 
3 8 8~~ 
0 ........ 0 
0 
Oo 0 
OJ ,I;}-., 0 
(/) 
0 oo u --0 0 0 0 0 0 
N oo oa90 0 
.._, 2 0 Oo 0 0 0 Coo o o 
0 














0 0.2 0.4 0.6 0.8 1 1. 2 
weight ( g ) 
FIGURE 3-15 Weight and 14c-melphalan content of individual FS13 fibrosarcomas at 60 min -.....J 
Controls from 7 experiments (melphalan (aa 1 :20), 2.5-lOmg/kg i p) 
) 
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3-2-3 _Differences in tumour 14c-melphalan uptake 
The 14c-me 1 pha 1 an uptake by bil at era 1 FS13 fi brosarcomas from 2 
different experiments is shown in Figure 3-16. In one experiment 
mice were treated with 14c-melphalan 10 mg/kg ip, with or without 
verapamil 10 mg/kg ip, and tumour 14c-melphalan determined at 60 
minutes. In the other experiment, mice were treated with 
l4c-melphalan 10 mg/kg iv, with iv infusion of angiotensin II 1.2 
ug/kg/min or saline for 5 minutes, tumour 14c-melphalan being 
determined at 30 minutes. The two tumours from each mouse had very 
similar 14c-melphalan contents despite sometimes having markedly 
different weights. Verapamil treatment significantly increased 
tumour 14c-melphalan content, by t test (p < 0.001) and by Mann-Witney 
U test (alpha< 0.002); the increase in tumour 14c-melphalan was 
also significant after angiotensin II by both tests (p< 0.02; alpha 
< 0.05). · Thus, despite nearly 2-fold variation in tumour 
14c-melphalan uptake, significant differences were detectable, and 
the t test was usually used. 
) 
) 
FIGURE 3-16 73 
Uptake of 14c-melphalan by bilateral FS13 fibrosarcomas in cba mice 
treated with verapamil or angiotensin II 
(Details in section 3-2-3) 
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3-2-4 Distribution of 14c-melphalan by autoradiography of murine 
fibrosarcomas 
Two mice bearing FS13 tumours, 15 and 21 days from implantation, 
were treated with ip 14c-melphalan (all labelled), 10 mg/kg (about 8 
uCi/mouse), to maximise specific activity of the very long half-life 
14c. The tumours were excised as usual 60 minutes later and fixed in 
10% neutral buffered formalin. The sections were exposed to silver 
emulsion for 6 weeks and stained with haematoxylin and eosin (Figure 
3-17). The 14c-melphalan was located in both viable and necrotic 
regions of the tumour and in blood vessels, suggesting extensive 
permeation over 60 minutes. Some 14c was localised over tumour cell 
nuclei. 
The light microscope appearance of the 3 fibrosarcomas is shown 
in Figure 3-18a,b,c. Tumour cells predominated, forming whorls, with 
frequent mitoses. Blood vessels were seen as small thin walled 
channels and as larger endothelial lined vessels (Figures 3-17 and 
3-18a,b,c). The human melanoma HX46 xenograft is shown in Figure 
3-18d, and had a more obvious connective tissue component. The HX4.6 
xenografts have been shown to have a human karyotype (Selby· et al, 
1980). All 4 tumours shovied areas of necrosis, especially centrally, 
which had not been apparent macroscopically • 
FIGURE 3-17 
Autoradiography of 14c-melphalan 
(haematoxylin and eosin) 
800x, oil immersion 
75 
in an FS13 fibrosarcoma 
0 
FIGURE 3-18 
Light microscope appearance of murine fibrosarcomas and 
human melanoma HX46 xenograft 
(haematoxylin and eosin) 




FIGURE 3-18 contd 








3-3 Effects of melphalan acid alcohol solvent on tumour 
uptake of 86Rb and 14c-melphalan 
3-3-1 Melphalan and acid alcohol solvent : tumour 86Rb uptake 
78 
The usual dose of melphalan, 10 mg/kg, uses a lmg/ml solution 
prepared from melphalan 20 mg/ml in acid alcohol by dilution 1:20 in 
normal saline (aa 1:20). The effects of melphalan and its solvent on 
·35Rb uptake were studied as a control for 14c-mel phal an uptake 
studies. Figure 3-19 shows the effects on temperature of mel phal an 
in aa 1:20, 10 mg/kg ip, the solvent aa 1:20 10 ml/kg ip alone, and 
melphalan in aa 1:20 with verapamil, both 10 mg/kg ip. Melphalan (aa 
1:20) increased temperature, while the combination of melphalan (aa 
1:20) with verapamil resulted in a smaller decrease than with 
verapamil alone. The solvent aa 1:20 had no effect on temperature. 
The effects of melphalan (aa 1:20) and the solvent aa 1:20 on 
86Rb uptake by FS13 fibrosarcomas were studied in 2 experiments 
\ tended to . 
(Figure 3-20). Acid alcohol i:20Aincrease tumour 86Rb 20 minutes 
1 tended to 
after iv or ip administration. Melphalan (aa 1:20) also/\increase. 
tumour 86Rb uptake 20 minutes after ip administration, but not 3 
minutes after iv administration. Melphalan dissolved in saline 
without acid alcohol had no effect on tumour 86Rb uptake. However the 
concentration of melphalan was much lower because of its lower 
solubility in aqueous solution than in aa 1:20. The effect of aa 1:20 
solvent seemed due to its ethanol component, in that ethanol :saline 
1:20, 10 ml/kg ip, also increased tumour 86Rb at 20 minutes. In some 
of the treatment groups tumour weight tended to be greater than 




Effect of melphalan, acid alcohol solvent and verapamil 
given ip on temperature of cba mice 
{3 mice/group) 
• saline 
o acid alcohol 1:20 (aa) i. p. 
• melphalan (with aa) lOmg/kg i.p. 
o verapamil lOmg/kg i. p. 





Eff86t of melphalan, acid alcohol solvent and ethanol on Rb uptake by FS13 fibrosarcomas 
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The effects of melphalan (aa 1:20) and aa 1:20 solvent on 86Rb 
uptake by normal tissues as well as FS13 fibrosarcomas are shown in 
Figure 3-21. The data for aa 1:20 are from the experiment shown in 
Figure 3-20, while those for melphalan (aa 1:20) are results combined 
from 2 experiments, both of which showed a significant increase in 
tumour 86Rb. No consistent changes were seen in normal tissue 86Rb 
uptake, although liver 86Rb tended to decrease after melphalan (aa 
1: 20). 
Mice with HX46 xenografts were treated with aa 1:20 10 ml/kg ip, 
but showed no significant change in tumour 86Rb uptake at 20 minutes, 
and as in the mice with fi brosarcomas, no significant changes in 




Uptake of 86Rb by FS13 fibrosarcomas and tissues in cba mice after 
acid alcohol 1:20 solvent and melphalan (aa 1:20), at 20 min 
acid alcohol 1:20, 10m1/kg ip (12-14 tumours, 6-7 mice) 
melphalan (aa 1:20) lOmg/kg ip (26 tumours, 13 mice) 
**p ,( 0. 01 
FS 13 
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Uptake of 86Rb by HX46 xenografts and tissues in cba mice after 
acid alcohol solvent, lOml/kg ip (shaded), at 20 min 


























3-3-2 Con cent ration of acid alcohol sol vent : tumour 86Rb uptake 
The effect of the acid alcohol solvent was further studied to 
discover whether it had a dose- related effect on 86Rb uptake, and 
hence whether it was important to control the concentration of acid 
alcohol when treating mice with different doses of melphalan. 
In a single experiment (Figure 3-23), mice with FS13 
fibrosarcomas were treated with different concentrations of acid 
alcoho1:saline, from 1:50 to 1:5, 10 ml/kg ip. The greatest tumour 
86 Rb uptake at 20 minutes occurred after aa 1:20, the commonly used 
concentration for melphalan doses of 10 mg/kg. However, none of the 
increases in tumour 86Rb uptake reached significance, at the 0.01 
level on analysis of variance. The greater tumour weight in mice 
treated with aa 1:50 may have resulted in a smaller increase in 
tumour 86Rb. Kidney and jejunum 86Rb uptake were increased at higher 
acid alcohol concentrations," maximally (and significantly) after aa 
1:5. 
A lower concentration of solvent, aa 1:100 was compared with 
untreated controls (Table 3-3). Although 86Rb uptake was 
significantly increased, the lower weights of both FS13 tumours and 
mice in the aa 1:100 group would both have tended to increase 86Rb 
uptake. However aa 1:100 probably still increased 86Rb uptake by the 
tumours to a small extent. 
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FIGURE 3-23 Concentration of acid alcohol solvent and 86 Rb uptake by FS13 fibrosarcomas 
and tissues in cba mice, 20 min after lOml/kg ip 







Effect of acid alcohol solvent 1:100 on 86Rb uptake by FS13 
fibrosarcomas and normal tissues in cba mice, at 20 minutes 
No. mice 
No. tumours 





20.8 + 0.3 
Weight tumours (g) 0.17 + 0.03 
86Rb (%dose/ g) 
Tumours 3.49 + 0.11 
Jejunum 13.8 + 0.9 
Kidney 42.1 + 4.3 
Skin 1.94 + 0.18 
* p<0.05 
Acid alcohol 1:100 
10 ml /kg i p 
6 
11 
19.5 + 0.8 
0.14 + 0.02 
4.39 + 0.39 * -
13.6 + 1.1 -
45.9 + 4.8 -
1.83 + 0.10 -
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3-3-3 Concentration of acid a1coho1 solvent tumour 14c.:.m~JphalJ!n .. 
1LP.tak£_ 
Uptake of 14c-melphalan was compared in mice bearing FS13 
fibrosarcomas, after treatment with melphalan 5 mg/kg ip with ac·id 
alcohol solvent concentrations of 1:50, 1:20 and 1:5 (Figure 3-24a). 
The fibrosarcomas tended to take up less 14c-melphalan at 20 minutes 
with aa 1:5 than with aa 1:20 or aa l:50s but this difference was not 
significant. No significant differences were seen in tumour 
14c-me 1 pha 1 an content at 60 minutes and 4 hours. M"ice treated w"ith 
aa 1:5 became slow and ataxic, most apparent from 15-30 minutes, and 
recovered by 60 minutes. Reduced blood pressure during the first 30 
minutes may explain the somewhat lower 14c-me1phalan uptake by the 
tumours at 20 minutes. The lower dose of melphalan was used because 
of the limits of solubility of melphalan in the acid alcohol 
solvent. 
The lower concentration of solvent aa 1:100 was compared with aa 
1:20, the maximum dose of melphalan poss·ible being 2.5 mg/kg ip 
(Figure 3-24b). No significant differences were seen in 14c-melphalan 
uptake by the FS13 fibrosarcomas and blood melphalan levels, at 20 or 
60 minutes or 4 hours. Thus no differences could be detected "in 
14c-melphalan uptake after ip administration for acid alcohol solvent 
concentrations o"f 1:100 to 1:20, although aa 1:5 tended to reduce 
uptake at 20 minutes, presumably because of hypotension. Despite the 
effect on 86Rb uptake, there were no differences in tumour 
14c-melphalan uptake at 1 or 4 hours, for aa 1:100 to aa 1:5. 
) 
FIGURE 3-24a 
Concentration of acid alcohol solvent and 14c-melphalan content of 
FS13 fibrosarcomas, after 5mg/kg ip with aa 1:50, 1:20 and 1:5 
(10-12 tumours, 5-6 mice) 
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Concentration of acid alcohol solvent and 14c-melphalan content of 
FS13 fibrosarcomas, after 2.5mg/kg ip with aa 1:100 and 1:20 
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3-3-4 Concentration of acid alcohol solvent : tumour growth delay 
Mice with FS13 fibrosarcomas were treated with melphalan 7 mg/kg 
ip with aa 1:20 or aa 1:50. No difference in growth delay was 
detected (Figure 3-25), by Mann-Witney U test. Lower solvent 
concentrations could not be used because lower melphalan doses would 




Growth delay of FS13 fibrosarcomas following melphalan 
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• Control (10) 
o Melphalan 7mg/kg (aa 1:20) i. p. (10) 






A plateau of 86Rb uptake occurred in tissues and fibrosarcomas 
of cba mice, from 30-90 seconds, validating the use of the method of 
Sapirstein (1958).' The fibrosarcomas, but not HX46 xenografts, 
showed a fall in 86Rb uptake with increase in tumour weight. Tumour 
uptake of 14c-melphalan 60 minutes after ip administration, increased 
with weight of FS13 fibrosarcomas. Uptake of 86Rb and 14c-melphalan 
varied 2-2.5-fold for tumours of similar weight; 86Rb uptake also 
varied between tumours in the same mouse. However, differences in 
tumour uptake of both 86Rb and 14c-melphalan could be detected after 
vasoactive agents. 
The solvent for melphalan, acid alcoho\ tended to increase 86Rb 
uptake by fi bros a rcomas, but not HX46 xenografts, 20 mi nut es after 
admi ni strati on, due to its ethanol component. The effect appeared 
greatest for aa 1:20. However, tumour uptake of 14c-melphalan was 
the same in solvent concentrations of 1:100 to 1:20, at 20 minutes, 1 
and 4 hours, and growth delay by melphalan the same with aa 1:20 and 
aa 1:50 • 
J 
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CHAPTER 4 EFFECT OF VASOACTIVE AGENTS ON 86Rb UPTAKE BY MURINE 
FIBROSARCOMAS AND HUMAN MELANOMA HX46 XENOGRAFTS 
4-1 Effect of vasoactive agents on mouse temperature 
4-2 Verapami l 
4-3 Flunarizine 
4-4 Epoprostenol 
4-5 P ropranol ol 
4-6 Methoxami ne 
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Chapter 4 EFFECT OF VASOACTIVE AGENTS ON 86Rb UPTAKE BY MURINE 
FIBROSARCOMAS AND HUMAN MELANOMA HX46 XENOGRAFTS 
4-1 Effect of vasoactive agents on mouse temperature 
94 
Blood flow to tumours has been increased by vasoactive agents 
\'lhich cause systemic hypertension, favouring perfusion of the 
relatively passive tumour vasculature, and by some vasodilators at 
doses which did not cause systemic hypotension (section 1-3). Only 
one agent, propranolol, has been sho1'in to increase relative blood 
flow to tumours in mice (Bomber et al, 1986). Information on 
appropriate doses of vasoactive agents in mice is scarce. 
Measurement of mouse blood pressure would be the best guide to dose, 
but this requires anaesthesia (Van Nimwegen et al, 1973; Johnson et 
al, 1976). Therefore, it was assumed that a detectable (0.5-1C 0 ), 
but not excessive fall in mouse core temperature, measured with a 
rectal probe indicated an appropriate vasoactive dose. Greater 
temperature changes were avoided because of possible changes in blood 
melphalan levels (Hinchliffe et al, 1983), cardiac output and blood 
flow distribution (Barnes and Strahlendorf, 1982). 
The mean changes in core temperature for various vasoactive 
agents, relative to control mice treated with saline 10 ml/kg by the 
same route, are shown in Table 4-1. The nadir (or peak) in 
temperature occurred 5-20 mi nut es after admi ni strati on, and usually 
lasted 40-60 minutes, exemplified in Figure 4-1. The temperature of 
control mice tended to fall during the 2 hour experiment. When these 
same mice were followed for 24 hours (Figure 4-2), temperature fell 
unt i 1 mid afternoon, and increased overnight. A 11 mice in 
temperature experiments were treated together, at 1000 hours or 1500 
hours to control for effects of diurnal variation. 
95 
TABLE 4-1 





























































































































FIGURE 4-1 96 
Effect of ip verapamil on temperature of cba mice 
verapami 1 5mg/kg( o), lOmg/kg( 1:c,.), 15mg/kg( o) 20mg/kg ( v) 
saline ip(•), or untreated(•) 
(3-4 mice/group) 
a. 1. 0 
0. 5 
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Verapami l increased blood fl ow to mammary carcinomas in 
unanaesthetised rats (Kaelin et al, 1982; section 1-3-6). From 
Figure 4-1 it was seen that verapamil 10 mg/kp ip resulted in the 
desired 0.5 c0 fall in temperature, and 15 mg/kg ip a 1 c0 fall. 
Verapamil 2.5 mg/kg iv caused a 1 c0 fall in temperature (Figure 4-3) 
and 1 mg/kg iv had no effect. This would be consistent with the 8-10 
fold greater potency of verapamil given iv compared with ip or oral, 
due to first pass hepatic metabolism (Stone et al, 1980; McMahon and 
Sheaffer, 1982). 
The effect of verapami l 10 mg/kg i p on 86Rb uptake of FS12 
fibrosarcomas, matched for weight, and normal tissues in mice has 
al ready been shown in Figure 3-10. There was no difference in 86Rb 
uptake by FS12 fi brosarcomas 20 minutes after verapami 1. The 
experiment was repeated using FS13 fibrosarcomas (Figure 4-4); again 
no increase in tumour 86 Rb was detected. Verapamil increased 86Rb 
uptake by liver and jejunum, and reduced uptake by kidney and skin, 
the change in jejunum being significant in both experiments. One 
hour after verapamil 10 mg/kg ip, 86Rb uptake by FS13 tumours was 
2.77 ! 0.16 %dose/g, the same as in controls (2.64 ! 0.16 %dose/g), 
and the heart was the only tissue to shov, a change in 86Rb after 
verapamil, 30.5 ! 1.1 compared with 36.4 !. 2.5 %dose/g, p 0.05 (Data 
not shown). This probably reflects the much longer duration of the 
effects on myocardi a 1 conduction than the vasodil atory effects (Stone 
et al , 1980) • 
Uptake of 86Rb was reduced (p(0.05) in FS13 fibrosarcomas 20 
minutes after verapamil 2.5 mg/kg iv (Figure 4-5). Skin and kidney 
86Rb contents were reduced, but no change in jejunum 86Rb occurred 
.) 
99 
after iv verapamil. In unanaesthetised rats, iv infusion of 
verapamil had increased skin blood flow measured with microspheres 
but had no effect on renal blood flow, at a dose which had no effect 
on systemic blood pressure (Kaelin et al, 1982). No increase was 
reported in hepatic flow, but if this had been due to increased 
portal flow as a result of increased gastrointestinal flow, as 
appears likely from the results in mice, it would not be detected 
from the distribution of microspheres (Mendell and Hollenberg, 1971; 
Messmer, 1979). In man, oral verapamil increased hepatic (and 
splanchnic) and renal blood flow at 1 hour (Meredith et al, 1985). 
In male cba mice bearing the human melanoma HX46 xenografts, 
verapami 1 10 mg/kg i p had no effect on 86Rb uptake by the tumours 
(Figure 4-6). A vasoactive effect was again evident, with increases 
in 86Rb content in liver and jejunum, and decreases in skin and 
kidney. All values for 86Rb uptake as %dose/g were lower than in 
Figures 3-10 and 4-4, because of the greater weight of the mice, 30g 




Effects of iv verapamil and iv propranolol on temperature 
verapamil iv, lmg/kg ( •), 2.5mg/kg(.6.), and 5mg/kg(O) 
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Verapamil and 86Rb uptake by FS13 fibrosarcomas and tissues 
in cba mice, 20 min after lOmg/kg ip (shaded) 
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FIGURE 4-5 102 
Verapamil and 86Rb uptake by FS13 fibrosarcomas and tissues 
in cba mice, 20 min after 2.5mg/kg iv (shaded) 
(12-14 tumours, 6-7 mice) 
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FIGURE 4-6 103 
Verapamil and 86Rb uptake by HX46 xenografts and tissues 
in cba mice, 20 min after lOmg/kg ip (shaded) 
(10 tumours, 5-6 mice) 
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Flunarizine is a calcium antagonist with greater specificity for 
arterial smooth muscle and minimal myocardial depressant effects, so 
might cause less hypotension than verapamil (Stone et al, 1980; 
Kaelin et al, 1984; section 1-3-6). Flunarizine is poorly soluble in 
aqueous solution, and was supplied in a solvent containing ethanol 
39.5 mg/ml, mannitol 45.0,mg/rnl and lactic acid 3.2 mg/ml. Therefore 
all experiments included a group of mice treated with the solvent, 
supplied as 1 placebo 1 • F1unarizine 10 mg/kg, ip caused a 2.5 c0 fall 
in mouse body temperature (Figure 4-7) compared with a 2 c0 fall 
after placebo treatment. The acid alcohol solvent, aa 1:20 (or 5%), 
had no effect" on temperature (section 3-3-1), so the effect of 
placebo was not due solely to its ethanol component (about 4%). A 
lower dose of flunarizine, 5 mg/kg ip was used for 86Rb uptake 
studies (Figure 4-8). Flunarizine had no effect on the FDCO to FS13 
fibrosarcomas at 20 minutes, and increased FDCO to muscle. The 86Rb 
content of tumours in placebo-treated mice tended to be greater than 
after flunarizine, perhaps because the ethanol component {about 2%) 
of the placebo tended to increase 86Rb uptake (see section 3-3-1) and 
flunarizine to decrease it. The increase in tumour blood flow by 
flunarizine found by Kaelin et al (1984) in rat mammary carcinomas, 





Effect of flunarizine and placebo on temperature of cba mice 
(3 mice/group) 
+l. 0 


























Time from treatment (minutes) 
• Control 
o Placebo i. p • 
... I. p. 







0. 3 6 60 





c:J2. __. c:J2. __. 
~ 0.1 c2 2 c2 20 
'° co 
o~-
Tu mou r 
FIGURE 4-8 
O Tumour Liver Muscle Skin 
D Sa line i. p. 
[a Placebo i. p. 
~ F I u n a r i z i n e 5 mg/kg i. p. 
,..o 
C>O 
0 .. . m 
Flunarizine and placebo and 86 Rb uptake by FS13 fibrosarcomas and tissues 







4,-4 . Ie.Qe.r~~.teno1 
Epoprosteno1 ( formerly known as prostacyc1 in or prostag·l andi n 
I2) inhibits platelet aggregation and is a direct arted o1 ar 
vasodilator, these effects lasting up to one hour after infusion 
(Vane, 1983). Epoprosteno1 is generated from arachidon·i c a.ci d in 
most blood vessels, and is itself unstable, breaking down with a half 
life of 2-3 minutes (Vane, 1983). Like the calcium antagonists, 
epoprostenol inhibited spontaneous and experimental metastases in 
mice (Honn et al, 1984). It was hoped that low doses might enhance 
tumour blood flow without caus'ing excessive hypotension. 
Mice bearing bilatera·l FS13 fibrosarcomas were given either an 
iv bolus of 50 ng/kg epoprostenol, with 86Rb 15 minutes later, or a 
bolus of 25 ng/kg fol 'lowed by 50 ng/kg over one minute, and then the 
86Rb dose (upper part of Figure 4·-9). The experiment was al so 
p~rformed with a 5-fold greater dose (lower part of Figure 4-9). No 
significant changes· in tumour 86Rb uptake were detected. Heart 86Rb 
was . reduced 15 minutes after 50 ng/kg iv bolus and k·idney 86Rb 
decreased immediately after the one minute infusion of 250 ng/kg, 
evidence of a vasoactive effect. Higher doses would be unlikely to 
favour tumour blood flow, because of hypotension. Thus, epoprostenol 
did not enhance tumour blood flow at these doses and time intervals. 
The doses of 5-20 ng/kg/min used to inhibit platelet aggregation in 
man cause hypotension, while 100 ug boluses were reported to inhibit 
metastases in mice (Vane 1983; Honn et a 1 , 1984). However, the 
p9ssibilit,y that this comparatively huge dose might have inhibited 
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FIGURE 4-9 Epoprostenol and 86 Rb uptake by FS13 fibrosacromas and tissues in cba mice 







4-5 Propranol ol 
A l_though the beta-adrenergi c blocker propranol ol reduces blood 
pressure and cardiac output, compensatory sympathetic reflexes 
increase peripheral resistance (Gilman et al, 1980) and might 
redistribute blood flow into the tumour vasculature. Propranolol had 
no effect on 86Rb uptake by Guerin carcinomas in anaesthetised rats, 
and reduced both cardiac output and tumour blood fl ow (Debreczeni et 
al, 1980). However Bomber et al (1986) reported increased 86Rb 
content of subcutaneous RMS sarcomas in unanaesthetised balb/c mice, 
10-15 minutes after propranolol, 5-10 mg/kg iv. 
In the cba mice, propranolol 10 mg/kg iv did not increase 86Rb 
uptake by FS13 or FSM19 fi brosarcomas at either 5 or 15 minutes 
(Figures 4-10, 4-11). Indeed, FS13 showed a fall in 86Rb uptake at 
15 minutes. Lung 86Rb uptake increased in both experiments at 15 
minutes, heart and muscle uptake tended to fall and skin uptake to 
increase. At a lower dose, propranolol 5 mg/kg iv had no significant 
effect on FDCO to FSM19 tumours at 3 minutes, with tumour 86Rb of 
5.24 + 0.27 %dose/g in controls and 4.14 + 0.70 %dose/g after 
propranol ol. 
Propranolol 10 mg/kg iv caused a 2 c0 fall in temperature in 
these cba mice (Figure 4-3), a greater effect than selected for the 
other drugs. When given by the i p route, propranol ol 10 mg/kg 
produced only 0.5 c0 fall in temperature (Figure 4-12), but still 
caused a fal 1 in 86 Rb uptake by FSM19 fi brosarcomas at 20 minutes 
(Table 4-2). Thus propranolol did not enhance relative blood flow to 
the fibrosarcomas in cba mice, possibly reflecting differences in the 
tumour, its implantation or in mouse strain compared with Bomber et 
a 1 ( 1986 ) . 





Propranolol and 86Rb uptake by FS13 fibrosarcomas and tissues 
in cba mice, 5 and 15 min after lOmg/kg iv (shaded) 
(6-9 tumours, 6-9 mice) 
*p .(0 .05, **p.( 0 .01, ***p .( 0 .001 
FS 13 
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Propranolol and 86Rb uptake by FSM19 fibrosarcomas and tissues 
in cba mice, 5 and 15 min after lOmg/kg iv (shaded) 
(4-8 tumours, 4-8 mice) 
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FIGURE 4-12 112 






o adrenaline 0. 5mg /kg i. p. 
1:,. adrenaline 1. Omg/kg i. p. 
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Uptake of 86Rb by FSM19 fi brosarcomas and tissues in cba mice 20 
minutes after methoxamine or propranolol 
No. tumours 
No. mice 











0.09 + 0.03 
7. 57 + 1.03 
6.06 + 0.73 
54. 9 + 1.6 
30.9 + 2.6 
2.19 + 0.16 
2.31 + 0.25 
Methoxamine 
2 mg/kg ip 
7 
7 
0.11 + 0.02 
5.19 + 0.50 
5.57 + 0.41 
63.1 + 3.3 
27.9 + 3.0 
1.78+ 0.16 
2.07+ 0.08 
** p <0.01, compared with controls 
Propranol ol 
10 mg/kg ip 
8 
8 
0.12 + 0.03 
4.12 + 0.79** 
5.44 + 0.35 
46.1 + 4.4 
25.l + 1.0 
2.29 + 0.21 





Methoxamine is an alpha-adrenergic agonist, which causes 
vasoconstriction of renal, splanchnic, cutaneous and limb 
circulations and increases blood pressure (Gilman et al, 1980), which 
should favour blood flow to the tumour. A dose of 2 mg/kg 
methoxamine ip appeared appropriate (Table 4-1), causing a 0.5 c0 
fall in temperature. However, this dose caused a fall in 86 Rb uptake 
at 20 minutes in FSM19 fibrosarcomas (Table 4-2). Renal 86Rb uptake 
tended to increase , , an effect not seen in man. In anaesthetised rats, 
methoxami ne and phenyl ephri ne, another al pha-agoni st, both reduced 
tumour blood flow (Debreczeni et al, 1980; Chan et al, 1984; Suzuki 
et al , 1984) • 
115 
4-7 Adrenaline 
Adrenaline had increased the vascular volume of tumours in the 
liver of anaesthetised rats (Ackerman and Hechmer ,1980), suggesting 
potential to increase tumour blood flow. The preliminary temperature 
studies (Figure 4-12), showed an initial increase in mouse 
temperature, followed by a fall of 1.5 c0 by 30 minutes after 1 mg/kg 
i p. Therefore 86Rb uptake was determined at both 5 and 30 minutes 
after adrenaline administration (Figure 4-13). 
At 5 minutes, after 1 mg/kg ip adrenaline, FS13 tumours showed 
no change in 86Rb uptake. Skin and jejunum 86Rb uptake were 
decreased, the latter probably due to local effects of ip adrenaline 
(Gilman et al, 1980); liver and kidney 86Rb content were 
increased. At 30 minutes, FSM19 tumours showed lower 
86Rb uptake after adrenaline than controls. The greater weight of 
the FS13 tumours in the adrenaline-treated group might account for 
some of thetrdecrease in 86Rb uptake, but the slope of the line in 
Figure 3-7 makes it very unlikely that an increase in 86Rb has been 
missed. At 30 minutes, liver and kidney 86Rb uptake were still 
increased, and skin decreased, as expected from cardiovascular 
effects of adrenaline (Gilman et al, 1980). A lower dose of 
adrenaline, 0.5 mg/kg ip, had no effect on tumour 86Rb uptake at 30 
minutes - control FS13 tumours took up 4.91 + 0.52 %dose/g and 
adrenaline-treated tumours 5.14 ! 0.79 %dose/g. 
These results agreed \tith the literature in that adrenaline 
failed to increase tumour blood flow (Gullino and Grantham, 1962; 
Edlich et al, 1966; Hafstrom et al, 1980a; Tveit et al, 1984). 
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FIGURE 4-13 Adrenaline and 86 Rb uptake by FSM19 and FS13 fibrosarcomas and tissues, 
5 and 30 min after lmg/kg ip (shaded) 
(FSM19, 12-13 tumours, 12-13 mice; FS13, 6-9 tumours, 6-9 mice) 






Phentolamine is an alpha-adrenergic blocker, a direct-acting 
vasodilator, and also diverts blood to nutrient capillaries (Gilman 
et al, 1980), potentially useful for enhancing drug delivery. 
Phentolamine, 4 mg/kg ip had no significant effect on 86Rb uptake by 
unilateral FS13 or FSM19 tumours at 20 minutes (Figure 4-14). The 
FDCO was increased to heart and muscle, and decreased to kidney. 
These results agreed with those for anaesthetised rats with Guerin 
carcinomas treated with phenoxybenzamine, another alpha-blocker 
(Debreczeni et al, 1980) • 
FIGURE 4-14 118 
Phentolamine and 86Rb uptake by FSM19 and FS13 fibrosarcomas 
and tissues, 20 min after 4mg/kg ip 
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4-9 _Angi ote_nsi n I I 
, An.giotensin II (asp1-ileu5), the octapeptide from man, horses 
rat and pig (Gilman et al, 1980), is rapid"ly metabolised to the 
heptapept i de and must be infused iv for cont 'inued effect o In rats, 
its hypertensive effect persisted for 3-5 minutes after infusion 
ceased (Jirtle et al, 1978b; Suzuki et al, 1981), so that a 5 minute 
infusion could be expected to elevate blood pressure for 8-10 
minutes. An iv bolus of angiotensin II 2.4 ug/kg caused a 0.5··1C 0 
fall in temperature, maximal at 5 minutes, resolved by 15 minutes 
(Figures 4-15, 4-16). This experiment also demonstrated that holding 
mice by the tail and giving a bolus of iv saline 10 ml/kg caused a 
transient sma)l decrease in temperature 9 with recovery in 5 minutes 
(Figure 4-15), suggesting only minimal stress from immobilisation for 
injection and frequent temperature measurements. (It was not possible 
to measure temperature during infusion in unanaesthetised mice$) 
The effect on 86Rb uptake of angiotensin II iv infusion at 1.2 
ug/kg/min, shown in Figure 3-11, was one of a series of 3 experiments 
to determine the effect of i nfus·l on rate on FDCO to FS13 
fibrosarcomas (Figures 4-17). The 86Rb was given 60 seconds before 
the end of the 5 minute infusion. At 1.2 ug/kg/min angiotensin II 
significantly increased 86Rb uptake by the tumours, while 0.8 mg/kg/ 
min caused a nonsignificant increase. However, in the experiment 
comparing L,2 and 2.4ug/kg/min 1tdth controls (lower part of Figure 
4-17), the increase after 1.2ug/kg/min was not significant (F=3.339, 
p=0.0478). At 2 .4ug/kg/min, tumour 86Rb was not increased, while 
kidney and skin 86Rb were markedly reduced, as found in rats {Tvete 
et al, 1981a; Jirtle et al, 1978b; Suzuki et al, 1984). The infusion 
rate which increased blood flow to subcutaneous tumours in rats was 
l-2ug/kg/min (Suzuki et al, 1981), the effect being lost at higher 
) 
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FIGURE 4-15 120 
Effect of angiotensin II on temperature of cba mice in first 10 min 
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FIGURE 4-17 122 
Angiotensin II infusion rate and 86Rb uptake by FS13 fibrosarcomas 
and tissues in cba mice, at 5 min 
(10-12 tumours, 5-6 mice) 
*p<0.05, **p(0.01, ***p"-0.001 
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Angiotensin II is thought to increase tumour blood flow 
because tumour vascular resistance increases less than systemic 
resistance (J·irt1e et al, 1978b; Suzuki et al, 1981, 1984). At 
higher doses although relative blood flow to the tumour exceeds that 
to normal tissues, absolute flow falls~ and the fall in cardiac 
output in response to hypertension further decreases tumour blood 
flow (Jirtle et al, 1978b; Suzuki et al, 1981, 1984; Tvete et al, 
1981a; Mohama et al, 1984). The increase in 86Rb uptake by heart and 
jejunum after angiotensin II 1.2 ug/kg/min shown in Figure 3-11 did 
not occur in the repeat experiment, nor at 0.8 or 2.4 ug/kg/min (data 
not shown). 
In male- mice bearing HX46 xenografts, angiotensin II 1.2 
ug/kg/mi n had no effect on tumour 86Rb uptake in 2 experiments 
(Figure 4--18). In the first experiment, where mice weighed 30g, 
jejunum and liver 86Rb were increased and skin and kidney 86Rb 
decreased. In the second experiment using 23g mice, tumour 86Rb was 
greater after angiotensin II, but not significantly, and only renal 
86Rb uptake was significantly reduced. Thus it may be that the dose 
of angiotensin II increasing tumour 86Rb differs in mice of different 
weight, and should perhaps be calculated by surface area. 
Alternatively these mice may have differed in sensitivity to 
angiotensin II, perhaps because of recent total body irradiation, 
sodium dep·letion for example re_duc'ing sensitivity by a factor of 10 
in man (Ekelund, 1979). This problem could be overcome in larger 
an·imals by adjusting the infusion rate to achieve a certain level of 
systemic hypertension (Suzuki et al, 1981). However, it was more 
likely that the HX46 xenografts were 1 ess able to increase 86Rb 
uptake than the fibrosarcomas, for they also fa'iled to show increased 





Angiotensin II and 86Rb uptake by HX46 xenografts and tissues 
in cba mice, after 1.2ug/kg/min iv for 5min (shad~d) 
(2 experiments, each 11-14 tumours, 6-7 mice) 
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Angiotensin II was also administered as an iv bolus (Table 4-3), 
over a 10-fold dose range. No increase in 86Rb uptake by unilateral 
FS13 tumours occurred after 2.4 ug/kg at 3 minutess despite this 
being the nadir of the temperature change. No change was seen 20 
minutes after boluses of 0.24 or 1.2 ug/kg 1 but would not be expected 
in view of the short ha 1 f-1 ife of angi otens in II. Thus, the 1 ess 





Uptake of 86Rb by FS13 tumours after angi otensi n II iv bolus, at 3 
and 20 mi nut es 
Control Angiotensin II iv bolus 
0.24 ug/kg 1.2 ug/kg 2.4 ug/kg 
3 mins 
No. tumours 7 6 
Wt. tumours (g) 0.10 + 0.02 0.13 + 0.03 
86Rb (%dose/g) 4.31 + 0.47 4.60 + 0.39 
20 mins 
No. tumours 9 7 5 
Wt. tumours(g) 0.62 + 0.09 0.62 + 0.06 0.67 + 0.07 




Verapamil 10 mg/kg ip failed to increase 86Rb uptake by FS12 and 
FS13 fi brosarcomas and human melanoma HX46 xenogra fts. Verapamil 
increased the FDCO to jejunum and liver, and decreased FDCO to skin 
and kidneys. Verapamil 2.5 mg/kg iv decreased 86Rb uptake by FS13 
tumours. The vasodilators, f1 unari zi ne, epoprostenol and 
phentolamine, and the vasoconstrictors, propranolol, adrenaline and 
methoxamine, all failed to increase relative blood flow to murine 
fibrosarcomas, in the doses and protocols employed. 
The hypertensive agent angi otensi n II increased 86Rb uptake by 
FS13 fi brosarcomas, but not HX46 xenografts, \\!hen infused iv at 1.2 
ug/kg/min. Uptake of 86Rb was decreased in skin and kidney. 
128 
CHAPTER 5 EFFECT OF ANGIOTENSIN II ON TUMOUR UPTAKE, CYTOTOXICITY 
AND TOXICITY OF MELPHALAN 
5-1 Angiotensin II and pharmacokinetics of melphalan 
5-2 Angiotensin II and 14c-melphalan uptake by tumours 
5-3 Angiotensin II : duration of infusion 
5-4 Angiotensin II and growth delay by mel phal an 
5-5 Angiotensin II and platinum uptake by fibrosarcomas 
5-6 Angiotensin II and vascular volume of fibrosarcomas 













CHAPTER 5 EFFECT OF ANGIOTENSIN II ON TUMOUR UPTAKE, CYTOTOXICITY 
AND TOXICITY OF MELPHALAN 
5-1 Angiotensin II and pharmacokinetics of melphalan 
Blood 14c-melphalan was determined after administration of 
14c-melphalan (in aa 1:20 solvent) iv, with sa'line or angiotensin II 
1.2ug/kg/min iv infusion for 5 minutes (Figure 5-1). Angiotensin 
II-treated mice had higher blood 14c-melphalan at some time points 
but the area under the curve, 542 ± 36% dose/ml.min, was not 
significantly greater than for the controls, 452 ~ 21. The trend to 
higher 14c-melphalan levels with angiotensin II could be due to 
decreased rena·l blood flow (section 4-9). The 14c-melphalan was 
rapidly cleared from the blood·, the curve suggesting at least 2 
compartments, but there are too few data points to calculate half 
lives. ,Furthermore, this would be misleading because with time, 
14c-increasingly represents hydrolysis products and protein-bound 
melphalan (Alberts et al, 1979; Brown et al, 1980; Furner and Brown, 




Effect of angiotens1~ II infusion on blood l4c-melphalan 
in cba mice, after C-melphalan lOmg/kg iv, with 
AT II 1.2ug/kg/min iv for 5 min (o) or saline iv(•) 
(3-9 mice) 
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5-2 Angiotensin II and 14c-melphalan uptake by tumours 
It has already been mentioned that uptake of 14c-melphalan by 
FS13 fibrosarcomas was increased by angiotensin II infusion (Figure 
3-16, section 3-2-3). The result shown in Figure 3-16 was taken from 
the experiment shown in Figure 5-2. Groups of mice (weight 20g) were 
treated with 14c-melphalan lOmg/kg iv, with saline or angiotensin II 
1.2ug/kg/min iv infusion for 5 minutes. Mice were killed 5, 30 and 
60 minutes and 4 hours after melphalan administration. The only 
significant changes were increases in 14c-mel pha l an uptake at 30 
minutes by FS13 fibrosarcomas (p(0.02) and kidney (p(0.02) in 
angiotensin II-treated mice (Figure 5-2). Blood 14c-melphalan levels 
(not shown) were the same in angiotensin II-treated mice and 
controls. 
It was shown in section 3-3-1 that the acid alcohol solvent 
itself increased 86Rb uptake by FS13 tumours; such an effect 
occurring in both treatment and control groups of mice might limit 
the possible increase in blood flow with angiotensin II, and hence 
limit an increase in tumour 14c-melphalan uptake. Although no 
significant differences in tumour 14c-melphalan uptake had been 
detected using aa 1:20 or aa 1:50 solvent (section 3-3-3), the 
experiment shown in Figure 5-2 was repeated, using 14c-melphalan, in 
a dose of 5mg/kg with aa 1:50 solvent, 30 and 60 minute time points, 
and 20g mice (Figure 5-3). Uptake of 14c-melphalan by the FS13 
fi brosarcomas was increased after angi otensi n I I, by 1.35x at 30 
minutes and 1.31x at 60 minutes (compared with 1.23x at 30 minutes 
and nonsignificant 1.12x at 60 minutes in aa 1:20, Figure 5-2). 




seen at the lower acid alcohol solvent concentration, but this was 
associated with elevated (p<0.05) blood 14c-melphalan levels (Figure 
5-3), and therefore may reflect a sma 11 difference in · dose or 
pharmacokinetics of melphalan rather than a greater vasoactive effect 
of angiotensin II. 
Male mice (weight 30g) bearing HX46 xenografts were treated with 
14c-melphalan 2.5mg/kg iv (in aa 1:20), with saline or angiotensin II 
l.2ug/kg/min iv infusion for 5 minutes (Figure 5-4). There was no 
increase in tumour 14c-melphalan levels at 30 minutes, and although 
blood l4c-melphalan was significantly increased the difference was 
small. Thus angiotensin II had no effect on either 86Rb uptake, or 
14c-melphalan uptake at 30 minutes, in the HX46 xenografts. 
) 
FIGURE 5-2 
Angiotensin II infus{~n and 14c-melphalan content of FS13 
fibrosarcomas after C-melphalan lOmg/kg iv, with 
AT II l.2ug/kg/min iv for 5 min (shaded) or saline iv 
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Angiotensin II infusi~n and 14c-me1pha1an content of FS13 
fibrosarcomas after C-me1pha1an (aa 1:50) 5mg/kg iv, with 
AT II 1.2ug/kg/min iv for 5 min (shaded) or saline iv 
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FIGURE 5-4 135 
Angiotensin I
14
infusion and 14c-melphalan content of HX46 xenografts 
30 min after C-melphalan 2.5mg/kg iv, with AT II 1.2ug/kg/min iv 
for 5 min (shaded) or saline iv 



























































Uptake of 14c-melphalan by FS13 fibrosarcomas in cba mice 
60 minutes after melphalan with 10 minute infusion of 
angiotensin II 
No. mice 
Wt. mice (g) 
No. tumours 









21.5 + 0.6 
10 
0.35 + 0.04 
5 .11 + 0 .22 
8.75 + 0.44 
3 • 85 + 0 • 21 ( n=4 ) 
Angiotensin II 
5 
21.0 + 0.8 
10 
0.47 + 0.06 
6.66 + 0.24 *** 
10.84 + 0.39 *** 
5 .17 + 0. 21 *** 
Mice \I/ere treated v.Jith melphalan lOmg/kg iv (aa 1:20), during the 
first minute of infusion of saline (control) or angiotensin II 







5-3 Angiotensin II : duration of infusion 
It is important to establish whether the infusion of angiotensin 
II lasted long enough to affect the distribution of melphalan. The 
temperature change due to an iv bolus of angiotensin II lasted at 
least 10-15 minutes {Figures 4-15, 4-16), and others found 
hypertension to persist 5 minutes after completing 5-10 minute 
infusions in rats (Jirtle et al, 1978b; Suzuki et al, 1981). Blood 
levels of 14c-melphalan fell rapidly during the first 10-15 minutes 
after iv administration (Figures 5-1, 6-3), so that greatest effect 
on melphalan delivery by enhanced tumour blood flow would be expected 
at this time, and indeed tumour l4c-melphalan was elevated at 30 
minutes (Figure 5-2). Furthermore, tumour blood flow was found to 
stay elevated even after recovery of normotension, presumably because 
newly dilated blood vessels remained dilated (Suzuki et al, 1984). 
Enhanced cytotoxicity of mitomycin C occurred with 10 minute 
infusions of angiotensin II in rats (Suzuki et al, 1981, 1984). 
Angiotensin II infusion for 10 minutes at 1.2ug/kg/min (and 
0.05ml/min), increased 14c-melphalan uptake by FS13 fibrosarcomas by 
a factor of 1.3 at 60 minutes (Table 5-1). Although this increase 
was significant, and greater than that seen after a 5 minute 
infusion, also with aa 1:20 solvent (Figure 5-2), this experiment was 
unsatisfactory in that the tumours in the treated group were heavier, 
which would tend to increase 14c-melphalan (section 3-2-2). 
Furthermore, the similar significant increases in 14c-melphalan 
uptake in fibrosarcomas, blood and kidney, despite increased FDCO in 
tumours and reduced FDCO in kidney with angiotensin II, suggest that 
an increased AUC accounted for the changes in tumour 14c-melphalan, 
and not changes in blood flow. Longer infusion may have a greater 
138 
effect on 14c-melphalan pharmacokinetics. However, the major problem 
of longer infusions of angiotensin II in mice was the administration 
of such small volumes at a constant rate, when the effective dose 
rate range was so narrow (section 4-9), combined with the likelihood 
of greater effects of immobilisation itself when this was prolonged. 
Longer infusions were therefore not pursued in mice, but would be 
practicable in larger animals. 
5-4 Angiotensin II and growth delay by melphalan 
The effect of angiotensin II on melphalan cytotoxicity was 
determined from tumour growth delay. Groups of 5 mice (weight 20g) 
bearing bilateral FS13 fibrosarcomas were treated with melphalan (in 
aa 1:20) lOmg/kg iv with infusion of angiotensin II 1.2ug/kg/min or 
saline for 5 minutes (Figure 5-5). There was no significant 
difference in the growth delay by melphalan and that by melphalan 
with angiotensin II (alpha) 0.10, Mann-Witney U test). Angiotensin 
II infusion alone had no effect. 
The growth delay experiment was repeated, using melphalan 8mg/kg 
iv, with either aa 1:20 or aa 1:50 solvent concentration (Figure 
5-6). This experiment demonstrated no difference in growth delay by 
melphalan, given iv, v,ith aa 1:20 or aa 1:50, as was found for ip 
administration (section 3-3-4). Melphalan in aa 1:20 increased the 
doubling time of FS13 from 3 days to 6 days, and angiotensin II had 
no modifying effect (alpha) 0.10, Mann-Witney U test). Melphalan in 
aa 1:50 increased the doubling time to 6 days, while angiotensin II 
significantly reduced this effect of melphalan (alpha(0.05). This 
unexpected protective effect is difficult to explain and is probably 
spurious . .A. significantly greater grov,th delay by angiotensin II 




inconsistent with the smaller increase in tumour 14c-melphalan at 60 
minutes with aa 1:20 (Figure 5-3). The acid alcohol solvent 
probably has little effect on either uptake or cytotoxicity. It can 
still be concluded that angiotensin II had no potentiating effect on 
the cytotoxicity of melphalan in the fibrosarcomas. 
Similarly, no potentiation of melphalan growth delay was seen in 
mice (weight 30g) with HX46 xenografts, treated with melphalan (in aa 
1 :20) 7 .5mg/kg iv, when angiotensin II l.2ug/kg/min was infused 
( F i g u re 5 -7) • 
5-5 Ang..iotensin II and platinum uptake by fibrosarcomas 
The presence of acid alcohol solvent with melphalan complicated 
in vivo uptake- experiments. Therefore cisplatin, a cytotoxic agent 
which acts by crosslinking DNA (Roberts, 1982), was used because it 
is not formulated with ethanol, can be given iv or ip, and can be 
readily measured by flameless atomic absorption spectroscopy (Siddik 
et al, 1985). Mice with bilateral FS13 tumours were treated with 
cisplatin 5mg/kg iv with saline or angiotensin II l.2ug/kg/min iv for 
5 minutes (Figure 5-8). At 60 minutes, total tumour platinum was 
greater (l.16x) in the angiotensin II-treated mice (alpha <.0.05, 
Mann-Witney U test), although the difference in the means was just 
not significant at the p=0.05 level. Thus angiotensin II increased 
tumour platinum at 60 minutes, the time when tumour 14c-melphalan was 
marginally increased after angiotensin II. As discussed in section 
6-3, the method determines total platinum, including active cisplatin 
and inactivated tissue-bound platinum. 
) 
) 
FIGURE 5-5 140 
Growth delay of FS13 fibrosarcomas after melphalan and angiotensin II 
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FIGURE 5-8 
Platinum content of FS13 fibrosarcomas 60 min after cisplatin 
5mg/kg iv with angiotensin II infusion (shaded, o) 
(12 tumours, 6 mice) 
talpha~0.05, Mann-Witney U test 
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5-6 Angiotensin II and vascular volume of fibrosarcomas 
Angi otensi n II was found to double the vascular space of rat 
hepat9mas grown in a sandwich chamber (Hori et al, 1985). Therefore 
59Fe-ferric chloride labelled red cells were used to determine the 
vascular volume of FS13 fi brosarcomas in 20g mice after saline or 
angiotensin II l.2ug/kg/min iv infusion. Figure 5-9 shows the 59Fe 
content of blood, tumours and kidney 20 minutes after administration, 
as %dose/g or %dose/ml. No differences were seen in the angiotensin 
II-treated mice. The red cell volume of the control tumours, 
14.4ul/g (or 1.44%), compares with 1% in rat fibrosarcomas and 2-9% 
in other rat tumours (Gullino and Grantham, 1964), 7.9ul/g in Walker 
carcinoma (Song and Levitt, 1971) and 2.7-6.3ul/g for 4 human lung 
carcinoma xenografts (Wist et al, 1981). 
5-7 Angiotensin II and gastrointestinal toxicity of melphalan 
Combined administration of angiotensin II 1.2ug/kg/min as a 5 
minute iv infusion with melphalan iv had no significant modifying 
effect on jejunum microcolony survival, compared with melphalan iv 
alone (Figure 5-10). 
J. 
FIGURE 5-9 
59Fe-labelled red cell content of FS13 fibrosarcomas 20 min after 
iv administration with angiotensin II infusion (shaded) 
(12 tumours, 6 mice) 
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Jejunum microcolony survival in cba mice after melphalan iv and 
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Angiotensin II, l.2ug/kg/min by iv infusion i'n mice increased 
14c-melphalan uptake by FS13 fibrosarcomas at 30 minutes whether the 
solvent was aa 1:20 or aa 1:50. Angiotensin II did not significantly 
increase blood 14c-melphalan levels, but in an experiment using aa 
1:50, both blood and tumour 14c-melphalan were increased at 60 
minutes. Human HX46 xenografts showed no increase in 14c-melphalan 
uptake at 30 minutes, consistent with no change in 86Rb uptake with 
angiotensin II. Melphalan cytotoxicity by growth delay was not 
potentiated by angiotensin II, in either FS13 or HX46 tumours. 
Angiotensin II had no effect on melphalan gastrointestinal toxicity. 
Uptake of platinum was increased in FS13 fibrosarcomas by 
angi otens in I I. No increase in vascular space of the fi brosarcomas 
with angiotensin II was detected using 59Fe-labelled red cells. 
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CHAPTER 6 EFFECT OF VERAPAMIL ON TUMOUR UPTAKE, CYTOTOXICITY AND 
TOXICITY OF MELPHALAN 
It was shown in sect"ion 4-2 that verapamil (lOmg/kg ip) had no 
effect on 86Rb uptake by fibrosarcomas and HX46 xenografts. However, 
verapamil increased uptake of 14c-mel phal an by FS13 fi brosarcomas 
(Figure 3-16), and this effect will be explored in Chapters 6 and 7. 
6-1 Verapamil and pharmacokinetics of melphalan 
Administration of 14c-me1phalan lOmg/kg ip with verapamil 
lOmg/kg ip increased the area under the blood concentration versus 
time curve {AUC) (Figure 6-1). An increased AUC also occurred for 
veraparnil 5mg/kg ip but not for 2.5mg/kg ip. Verapamil lOmg/kg ip 
increased jejunum 86Rb uptake, and this increased blood flow might 
enhance absorption of ip melphalan. This seemed to be supported by 
finding no effect on blood 14c-melphalan levels of verapamil 2.5mg/kg 
iv, given either with or 10 minutes before ip melphalan (Figure 6-2), 
for verapamil 2.5mg/kg iv had the same effect on mouse temperature as 
15mg/kg ip, but no effect on jejunum 86Rb uptake (section 4-2). 
Verapamil lOmg/kg ip tended to increase the AUC for melphalan lOmg/kg 
given iv (Figure 6-3), suggesting that verapamil affects melphalan 
pharmacokinetics other than by promoting absorption. The decreased 
r~nal 86Rb uptake after verapami1 lOmg/kg ip might slow excretion of 
melphalan, but this is difficult to reconcile with a similar fall in 
renal flow after 2.5mg/kg iv and no change in melphalan AUC. The 
temperature and pharmacokinetic effects of lOmg/kg ip and 2.5mg/kg iv 
were disparate. 
The fall in blood 14c-me1pha1an levels after iv administration 
was rapid (Figure 6-3), as also seen in Figure 5-1 • 
l 
FIGURE 6-1 150 
t!fect of verapamil ip on blood 14c-melphalan of cba mice after 
C-melphalan lOmg/kg ip, given with verapamil ip (•) or saline(•) 
(3 mice) 
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3 : - . .I. 
fl'f' 1-········· ... 
2 ~ "' ·. 

























30 60 120 180 240 
Time (minutes) 
FIGURE 6-2 151 
H'fect of verapamil iv on blood 14c-melphalan of cba mice after 
C-melphalan lOmg/kg ip, given with (a) or 10 min after (b) 
verapamil, 2.5mg/kg iv (0) (control (e); 3 mice) 
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FIGURE 6-3 152 
f !f ect of verapamil i p on b 1 ood 14c-me 1 pha 1 an of cba mice after 
C-melphalan lOmg/kg iv, given 20 min after verapamil lOmg/kg ip{o) 
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6-2 Verapamil and 14c-melphalan uptake by tumours 
Mice bearing FS13 fibrosarcomas were treated with 14c-melphalan 
lOmg/kg ip, with or without verapamil lOmg/kg ip, and sacrificed 30 
minutes, 60 minutes (2 experiments) and 4 hours later (Figure 6-4). 
At 60 minutes tumour 14c-melphalan was significantly increased 
(p(0.001) in verapamil-treated mice, by factors of 1.35 and 1.36 in 
the 2 experiments. No other significant changes were seen. The 
experiment was repeated at 60 minutes (Figure 6-5), to include 
determination of blood 14c-melphalan levels and also the 2.5mg/kg ip 
dose of verapamil, which had not altered the AUC for mel phal an 
(Figure 6-1). Both blood and tumour (1.32x) 14c-me1phalan were 
significantly increased after lOmg/kg i p verapamil; blood 
14c-melphalan was slightly increased and tumour 14c-melphalan not 
affected by 2.5mg/kg ip (Figure 6-5). Thus the changes in tumour 
14c-melphalan uptake were linked to the pharmacokinetic effects of 
verapamil. 
Verapamil 2.5mg/kg iv had no effect on blood or tumour levels of 
14c-melphalan, 60 minutes after ip melphalan, in mice with FS13 
fibrosarcomas (Figure 6-6). This dose of verapamil (2.5mg/kg iv) had 
reduced 86Rb uptake by the fi bros a rcomas (section 4-2), so that 
tumour 14c-melphalan uptake had been maintained despite a fall in 
blood flow, with no change in blood melphalan levels. 
The in vivo 14c-melphalan experiments thus far have used aa 1:20 
solvent with melphalan. Uptake of 14c-melphalan was also determined 
using 14c-melphalan with aa 1:50, 5mg/kg ip, given to mice bearing 
bil atera 1 FS13 fi brosarcomas, with or without verapamil lOmg/k g i p 





verapamil-treated mice, and blood 14c-melphalan was also increased. 
In another experiment, 14c-melphalan (.C.lmg) was dissolved directly 
in saline·, and immediately given ip to mice bearing FS13 tumours, 
with or without verapamil lOmg/kg ip (Figure 6-8). The 
verapamil-treated group had l.29x greater tumour 14c-melphalan 
content at 60 minutes. Only 3 blood samples were obtained from the 6 
verapamil-treated mice so, although blood levels appeared higher no p 
value is given. Thus, 14c-melphalan levels in tumours and blood were 
increased by veraparili 1 · when the sol vent concentration was reduced 
from aa 1:20 to aa 1:50, or omitted, but not to a greater extent than 
with aa 1:20. 
Human melanoma HX46 xenografts showed no increase in 
14c-melphalan content 60 minutes after administration of 
14c-melphalan lOmg/kg ip (aa 1:20) with verapami 1 lOmg/kg i p' 
compared with controls (Figure 6-9). Blood 14c-melphalan levels were 
not significantly increased, yet jejunum 14c-melphalan was increased, 
a change which was not significant for mice with fibrosarcomas 
(Figures 6-4, 6-6, 6-7). This suggests a difference in the effects 
of verapamil either on 14c-melphalan pharmacokinetics in these 
irradiated mice, perhaps related to the effects of total body 
irradiation on normal tissues, or on melphalan uptake by the 
xenografts. 
, The 30 and 60 minute and 4 hour time points were selected from 
~1gure 6-1. _ !ecaus:: tumour 14c-me1pha1an content was detectably 
increased only.a~ 60 minutes after verapamil (Fiaure 6-4) 60 ~ t · used f ti b .., D minu es was 
. or 1~ su sequ~nt experi°l~nts (Figures 6~·5 to 6~·9). It was not 
pr~c~1cable to ~etermrne, t~mour C-melphala.n 1eve·ls over a range of time 
porn~s, und?r eac!: cond1t10n, when each pornt rt:!quired 5 mice with an 
f~mours berng O"f~ the same age and passage. Changes in tumour 
C-melph~la~ l~ve1s at other time_p~ints would thus be missed, but this 
seems unl1_~ely in view of the prel1mrnary studies of b·lood .tllc-me1ph;flan 
lev~ls _(F1gm:e~ 6-1, 6-2, 6-3) using the same doses and ro•stes of 
verapam11 adm1n1stration. ~ 
FIGURE 6-4 155 
14rapami 1 i p and 
14c-mel phal an uptake by FS13 fi brosarcomas after 
C-melphalan lOmg/kg ip, given with verapamil lOmg/kg ip (shaded) 
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FIGURE 6-5 156 
Verapamil io dose and l4c-melphalan uptake by FS13 fibrosarcomas 
60min after '14c-melphalan lOmg/kg ip 
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Verapamil iv f~d 14c-melphalan uptake by FS13 fibrosarcomas 
60 min after C-melphalan 5mg/kg ip, verapamil 2.5mg/kg iv 
(shaded) given 10 min before melphalan 
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FIGURE 6-7 158 
~8take of 14c-melphalan by FS13 fibrosarcomas 60 min after 
C-melphalan (aa 1:50) 5mg/kg ip and verapamil lOmg/kg ip (shaded) 
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~Rtake of l4c-melphalan by FS13 fibrosarcomas 60 min after 
C-melphalan in saline (without acid alcohol) ip and 
verapamil lOmg/kg ip (shaded) 
(10 tumours, 6 mice) 
*p < 0.05 
FS 13 4 
- * E 01 - -0.3 Q) 3 Q) V) V) 3 0 0 
-0 -0 - ~ ~ g 
:c 0. 2 C 2 C 2 ro ro 
01 ro ro 
Q) ...c ...c 
$ Cl.. Cl.. 





.0 .....-i 0 
.....-i 0 




Verapamil ip and 14c-melphyJan content of HX46 xenografts 
and tissues, 60 min after C-melphalan lOmg/kg ip with 
verapamil lOmg/kg ip (shaded) 
(11-12 tumours, 6 mice) 
* 10 * HX46 
-- 8 CJ") 8 !I.... -::J Q.) 
0 V) 
E 0 -"O ::J 
~ ~3 0.6 ........ 6 6 CJ") -C Q.) - V) CJ") C'O 0 
:i C'O '"O - ..c 4 ~2 en 0.4 -4 Cl. - C ........ C'O Q.) C ..c E C'O CJ") C'O I ..c (_) C'O Q.) 






0 \ 0 
(_) 0 r---i """ r---i 
160 
. ~~~'\ <:)()~ <:)'0 <:)'0 \i\· 
'\'00 '\'0'0 t." <o~ 
) 
161 
6-3 Verapamil and platinum uptake by fibrosarcomas 
Cisplatin was used to measure tumour uptake of a cytotoxic agent 
which did not need an acid alcohol solvent. Mice bearing FS13 
fibrosarcomas were treated with cisplatin 5mg/kg ip with either 
saline, acid alcohol 1:20 lOml/kg ip or verapamil lOrng/kg ip (Figure 
6-10). Mice treated with verapamil showed a nonsignificant increase 
in tumour pl at i num at 60 mi nut es, and a doubling of renal pl at inum 
content. The presence of aa 1:20 had no effect on platinum content 
of tumours nor kidney (Figure 6-10). This increase in renal platinum 
may be due to the reduction in rena·1 blood flow by verapamil delaying 
the usually rapid early clearance from the kidney (Benard et al, 
1983; Siddik ~t al, 1984), and makes it likely that verapamil 
increased tumour platinum uptake through a pharmacokinetic effect. 
It also appears possible that verapamil might potentiate the 
nephrotoxicity of cisplatin. 
Total platinum determined by flameless atomic absorption 
spectroscopy is made up of ultrafilterable platinum, which is active 
and ·includes parent cisplatin and some reactive intermediates, 
together wHh platinum bound to proteins and other macromolecules 
(Siddik et al, 1984; Sternson et al, 1984). The proportion of total 
platinum which is active decreases as extensive tissue binding occurs 
(Siddik et al, 1984), such that in man cisplatin accounts for 50%
1
of 
platinum at 5 mins and 25% at 60 mins (Himmelstein et al, 1980 ). 
Total platinum therefore may not reflect cisplatin accurately, but is 
often used to follow platinum d·istribut"ion (Benard et al, 1983; 
Siddik et al, 1984; Boven et al, 1985). If these initial experiments 
were pursued, an HPLC method would be preferredo These values for 
platinum content, 0.76ug/g in control tumours and 3.6ug/g in kidney 
at one hour, may be compared with O. 68 and O. Blug/g in 2 human 
ovarian carcinoma xenografts, and 5.5 and 3.7ug/g in kidneys, in nude 
mice, 24 hours after 5mg/kg cisplatin iv (Boven et al, 1985). 
1. Himmelstein KJ, Patton TF, Belt RJ, Taylor S, Repta AJ, Sternson 
LA(198l). Clinical kinetics of intact cisplatin and some related 
species. Clin.Pharmacol.Ther.29:658-664 
FIGURE 6-10 
Platinum content of FS13 fibrosarcomas and kidney of cba mice 
60 min after cisplatin 5mg/kg ip with verapamil or acid alcohol 
(8-11 tumours, 5-6 mice) 
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6-4 Verapamil and growth delay by melphalan 
The effects of verapamil to promote tumour melphalan uptake 
would be useful if they correlated with enhancement of cytotoxicity. 
For FS12 fibrosarcomas, melphalan lOmg/kg ip increased the doubling 
time from 4.5 days to 10 days (alpha <.0.002, 2-tailed Mann-Witney U 
test) (Figure 6-11); combined treatment with verapamil lOmg/kg ip 
increased the doubling time a further 11 days to 21 days (alpha( 
0.002). The fibrosarcoma FS13 was more sensitive to melphalan with 
an increase in doubling time from 4 days to 19.5 days after melphalan 
lOmg/kg ip (alpha( 0.002) (Figure 6-12); verapamil lOmg/kg ip with 
mel pha l an resulted in a further 7 day increase to 26. 5 days, of 
borderline significance (0.05( alpha ( 0.10). Verapamil 2.5mg/kg ip 
had no significant modifying effect on melphalan growth delay in this 
experiment (data not shown). The doubling time of HX46 , 3 days, was 
prolonged to 16 days by melphalan 7.5mg/kg ip (alpha(0.002) (Figure· 
6-13), and delayed a further 4 days by addition of verapamil lOmg/kg 
ip (alpha(0.05). The lower dose of melphalan was used for mice with 
HX46 xenografts because of predicted greater marrow suppression 
following recent total body irradiation. 
Verapamil enhanced melphalan cytotoxicity against FS12 (by a 
factor of 2.7) and HX46 (l.3x), and marginally for FS13 (l.5x). 
Verapamil lOmg/kg ip alone had no effect on the growth of any of the 
tumours. It would have been helpful to know whether in Figure 6-13 
verapamil had altered the AUC for melphalan in the mice with the HX46 
xenografts, no effect having occurred in Figure 6-9. 
) 
FIGURE 6-11 164 
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Verapamil and melphalan toxicity in gastrointestinal tract 
and bone marrow in mice 
An improved therapeutic index of melphalan when given with 
verapamil requires that enhanced cytotoxi city not be accompanied by 
increased normal tissue toxicity. Melphalan damage to the jejunum, 
assessed by crypt survival at 4 days was greater in the presence of 
verapamil lOmg/kg ip, for melphalan doses of 15-20mg/kg ip (which 
caused 60-70% microcolony survival in controls) (Figure 6-14). 
Jejunum 14c-melphalan uptake was increased significantly at 60 
minutes by verapamil lOmg/kg ip in only one experiment (Figure 6-9) 
but a trend to an increase occurred in 2 other experiments (Figures 
6-4 and 6-7). This might be attributable to the increased AUC for 
me l pha l an after verapamil (section 6-1). 
Bone marrow toxicity in vivo was assessed by the spleen colony 
assay (CFU-S). Results pooled from 3 experiments (Figure 6-15) 
showed significant potentiation of melphalan cytotoxicity to the bone 
marrow stem cells by verapamil lOmg/kg ip, but not for verapamil 
doses of 2.5 and 5mg/kg ip. 
These effects on gastrointestinal and bone marrow toxicity could 
have been explained by the pharmacokinetic effects of verapamil on 
melphalan in mice (Figure 6-1), and enhanced jejunum 14c-melphalan 
uptake, except for the finding that verapamil potentiated melphalan 
cytotoxicity to murine bone marrow in vitro (section 6-6). 
) 
J 
FIGURE 6-14 168 
Jejunum microcolony survival in cba mice treated with melphalan 
and verapamil lOmg/kg i p ( o) or sa 1 i ne i p ( •) 
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Effect of verapamil ip on CFU-S after melphalan in cba mice 
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Verapamil and melphalan cytotoxicity in murine and human bone 
marrow in vitro 
The clonogenicity (CFU-GM) of the mononuclear cell fraction of 
murine bone marrow was determined after exposure to melphalan, with 
or without verapamil lOug/ml, for 60 minutes at 37°c (Figure 6-16). 
Verapamil potentiated melphalan cytotoxicity by a factor of 2. 
Verapamil alone did not have a significant cytotoxic effect in this 
assay. Verapamil was minimally cytotoxic to P388 cells at 23uM 
(lOug/ml) and to 4 tumour cell lines at 6.6uM (3ug/ml) (Tsuruo et al, 
1981, 1983a). The plating efficiency of murine bone marrow 1,vas 
1:150-1:200 with the colony stimulating factor used. Even in the 
absence of a pharmacokinetic effect, verapamil enhanced melphalan 
cytotoxicity to murine bone marrow. 
The effect of verapamil on melphalan cytotoxicity to the 
mononuclear cell fraction of human bone marrow was also studied 
(Figure 6-17). The plating efficiency of the human marrow was about 
1:700, and it was 4-5 times more sensitive to melphalan than murine 
marrow. No effect on melphalan cytotoxicity by verapamil was 
detected (Figure 6-17), the results pooled from 7 experiments. 
This difference in effect of verapamil on murine and human 
marrow might be due to differences in ce 11 s of human origin. The 
clonogenicity of the human promyelocytic leukaemia HL60 cell line was 
studied after exposure to melphalan, with or without verapamil 
lOug/ml, for 60 minutes at 37°c. The 1 ogarithmi c phase HL60 cells 
were less sensitive to melphalan than human marrow, and verapamil had 




Verapamil and CFU-GM of mouse bone marrow incubated 
with melphalan, for 60 min at 37°c 
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Verapamil and CFU-GM of human bone marrow incubated 
with melphalan, for 60 min at 37°c 
(verapamil lOug/ml, o ; control, • ; 7 experiments pooled) 
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Verapamil and clonogenicity of HL60 cells incubated 
with melphalan for 60min at 37°c 
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Effect of flunarizine on tumour uptake and cytotoxicity 
of melphalan 
Flunarizine, a calcium antagonist like verapamil, which also 
failed to increase 86Rb uptake by FS13 fibrosarcomas (section 4-3}, 
might have similar effects on tumour uptake and cytotoxi city of 
melphalan. Uptake of 14c-melphalan by FS13 fibrosarcomas was 
determined 60 minutes after treatment with 14c-melphalan 5mg/kg ip 
(in aa 1:50} and either flunarizine 5mg/kg ip or placebo 5mg/kg ip 
(Figure 6-19). The flunarizine solvent (and placebo} contained 
ethanol 20mg/ml, and melphalan in aa 1:50 15mg/ml ethanol, so that 
treated mice received 2.3x more ethanol than controls, a dose just 
less than with aa 1:20. Since the 14c-melphalan content of FS13 
fibrosarcomas 60 minutes after melphalan ip with aa 1:20 and aa 1:50 
was the same (section 3-3-3}, this should not affect the result. 
There was no difference in tumour 14c-melphalan uptake after 
flunarizine, or placebo, although blood levels tended to be higher 
after flunarizine (Figure 6-19}. 
Flunarizine 5mg/kg ip increased the doubling time of FS13 
fibrosarcomas by a further 3 days (l.3x) beyond the prolongation by 
melphalan lOmg/kg ip given with placebo (Figure 6-20). This 
difference had borderline significance, 0.05 < alpha < 0.10, by 
Mann-Witney U test. Thus fl unari zi ne did not significantly enhance 
melphalan uptake and cytotoxicity, but trends \I/ere similar to the 
effects of verapamil. 
,_) 
) 
FIGURE 6-19 175 
Effect of flunarizine and ~~cebo on 14c-melphalan content of FS13 
fibrosarcomas, 60 min after C-melphalan (aa 1:50) 5mg/kg ip 
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FIGURE 6-20 176 
Growth delay of FS13 fibrosarcomas after melphalan 







0 5 10 15 20 25 
Time from treatment (days) 
• Control (10) 
o Flunarizine Smg/kg i. p. (10) 
o Melphalan lOmg/kg i. p. + placebo i. p. (14) 
• Melphalan lOmg/kg i. p. + flunarizine 





Verapamil lOmg/kg i p increased the area under the b 1 ood 
concentration time curve for melphalan given ip or iv, and increased 
uptake of 14c-melphalan by FS13 fibrosarcomas at 60 minutes. 
Mel phal an uptake by HX46 xenografts was not increased by verapami 1, 
but neither was blood 14c-melphalan. Verapamil enhanced growth delay 
by melphalan in FS12, FS13 (borderline) and HX46, and increased 
gastrointestinal and bone marrow toxicity in mice. Potentiation by 
verapamil of me l pha 1 an cytotoxi city to mu ri ne bone marrow in the in 
vitro CFU-GM assay suggested a cellular effect of verapamil in 
addition to the pharmacokinetic effect. Verapamil had no effect on 
melphalan cytotoxicity to human bone marrO\tl or HL60 cells. An 
analogue of verapamil, flunarizine failed to significantly enhance 
melphalan tumour uptake and growth delay, but similar trends 
occurred. 
) 
CHAPTER 7 VERAPAMIL AND CELLULAR UPTAKE OF 14C-MELPHALAN . 
7-1 Mouse bone marrow-: 14c-melphalan uptake and.verapamil 
7-1-1 Verapamil concentration 
7-1-2 Medium calcium concentration 
7-1-3 Medium 14c-melphalan concentration 
7-1-4 Melphalan hydrolysis in cells and medium 
7-1-5 Reversibility of the effect of verapamil 
7-1-6 Efflux of 14c-melphalan 
7-1-7 Influx of 14c-melphalan 
7-2 Mouse bone marrow: 14c~melphalan uptake and flunarizine 
7-3 Disaggregated murine fibrosarcoma cells : 14c-melphalan 
uptake and verapamil 
7-4 Human bone marrow: 14c-melphalan uptake and verapamil 
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7-5 Human promyelocytic leukaemia HL60 cell line : 14c-melpha1an 




CHAPTER 7 VERAPAMIL AND CELLULAR UPTAKE OF 14C-MELPHALAN 
7-1 Mou~e bone marrow: 14c-melphalan uptake and verapamil 
Verapamil increased melphalan cytotoxicity to the mononuclear 
cell fraction of murine bone marrow in vitro (section 6-6), 
suggesting that mel phal an potenti ati on by verapamil was more than a 
pharmacokinetic effect. In a preliminary experiment using whole 
murine bone marrow, cells had been plated for CFU-GM assay and 
14c-melphalan uptake determined after 60 minutes at 37°c in 
14c-melphalan lug/ml with verapamil at 0.1, 1 and lOug/ml (Figure 
7-1). For verapamil lOug/ml, but not 0.1 and 1 ug/ml, CFU-GM was 
reduced compared with melphalan alone, and cellular 14c-melphalan 
uptake increased 2-fold. These findings were pursued, but the 
mononuclear eel 1 fraction of bone marrow ( red eel 1 s excluded) was 
used in all subsequent experiments. 
7-1-1 Verapamil concentration 
When the mononuclear cell fraction of mouse bone marrow was 
incubated with 14c-melphalan lug/ml at 37°c for 60 minutes, the 
presence of verapamil at 10 and lOOug/ml increased cellular 
melphalan uptake, by a factor of 1.5 (Figure 7-2). A small effect 
was evident with lug/ml verapami 1. Cell vi abi 1 ity was greater than 
90% throughout each experiment. 
The time course of melphalan uptake is shown in Figure 7-3. 
Uptake was initially rapid and reached a plateau (of about 3.5ng/lo6 
cells) after 10-20 minutes, as also reported for murine Ll210 
leukaemia cells, L5178Y lymphoblasts and LPC-1 plasmacytoma cells 
(Goldenberg et al, 1977; Martin et al, 1982; Vistica, 1983). The 
cell volume was 0.35ul/106 cells for the mononuclear cell fraction of 
murine bone marrow, and mean steady state melphalan uptake 3.5ng/106 
cells, giving a cell:medium ratio of 10:1 for control cells. 
FIGURE 7-1 
Effect of verapamil on 14c-melphalan uptake and CFU-GM of 
T~use bone marrow (with red cells) incubated in 
C-melphalan lug/ml, 60 min at 37°c 
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Verapamil and 14c-mei~halan uptake by mouse bone marrow 
cells, incubated in C-melphalan lug/ml, 60 min at 37°c 
(no. experiments on bar) 
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FIGURE 7-3 182 
Uptake of l4c-~elphalan by mouse bone marrow cells with time of 
incubation in 1 C-melphalan lug/ml at 37°c, with verapamil 























o Verapamil 10 µg/ml 
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Cellular 14c-melphalan uptake was greater with verapamil 
lOug/ml, at 10 minutes by a factor of 1.41 ~ 0.10, at 30 minutes by 
* 1.45 ~ 0.08 and at 60 minutes by 1.47 + 0.15 (means~ SER from 2,4 
and 9 experime~ts respectively). 
7-1-2 Medium calcium concentration 
* :t.range 
Verapamil is a calcium antagonist and its effect might be 
modified by the presence of calcium in the medium. Calcium at 
concentrations from 0.125 to 2.50 mM had no effect on accumulation of 
14c-melphalan by the mononuclear cell fraction of murine bone marrow, 
nor on its enhancement by verapamil (Table 7-1). The second 
experiment was performed in BSS to avoid calcium phosphate 
precipitation; addition of 14c-melphalan decreased pH but cell 
viability was still maintained for 60 minutes. The effect of 
verapamil on cellular melphalan uptake was independent of external 
calcium. 
7-1-3 Medium 14c-melphalan concentration 
Enhancement of 14c-mel phal ah uptake by the mononuclear cell 
fraction of murine bone marrow also occurred with incubation at 37°c 
for 30 minutes in 0.5 or 2.0 ug/ml 14c-melphalan (Figure 7-4). All 
cells were exposed to the same acid alcohol concentration, 0.2%. The 
single experiment using O.lug/ml 14c-melphalan also showed enhanced 
melphalan uptake with verapamil. Cell viability was 92-100% in these 




Murine bone marrow : cellular 14c-melphalan accumulation after 60 
minutes at 37°c, with lug/ml melphalan, in the presence or absence of 
verapamil lOug/ml and calcium 
Medium Ca(mM) l4c-melphalan (fraction of control) 
Control Verapamil lOug/ml 
A. In PBS 0 1.00 + .07 1.50 + .18 ** 
0.125 1.12 + .07 1.53 + .10 **. 
0.25 1.15 + .05 1.47 + .08 **' 
B. In BSS 0 1.00 + .06 1.18 + .06 
1.25 1.02 + ,13 1.46 + .10 ** 
2.50 1.07 + .06 1.34 + .06 ** 
Mean .:!:_ 1range· duplicates (A ),1SER trip 1 i cat es ( B) 
I i 
2 way ANOVA ** p(0.01 
) 
FIGURE 7-4 
r!llular 14c-melphalan of mouse bone marrow incubated in 
c-melphalan 0.1-2 ug/ml with verapamil lOug/ml (o), 
for 30 min at 37°c 
(control, • ; 5 experiments pooled) 
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7-1-4 Melphalan hydrolysis in cells and medium 
Measuring melphalan as 14c-melphalan does not distinguish parent 
melphalan, its hydrolysis products and covalently bound melphalan. 
Melphalan became 30% hydrolysed in PBS after 60 minutes at 37°c 
(Figure 7-5), with tt of 2 hours, the rate being unaffected by 
verapamil. When melphalan and its hydrolysis products were measured 
in cells or medium, the peaks of the two main hydrolysis products 
(Figure 7-6a) became obscured by cellular proteins (Figures 7-6b, 
7-7), as found by Chang et al (1978b). However the proportions of 
parent and hydrolysed drug could be obtained by counting the HPLC 
fracti ans for 14c, and are shown for cells incubated in 2ug/ml 
14c-melphalan for 30 minutes at 37°c in Figure 7-8 and Table 7-2. 
Melphalan was 30% hydrolysed in the supernatant after 30 minutes 
at 37°c (Table 7-2). A supernatant sample taken at the start of 
incubation showed melphalan to be 16.5% hydrolysed, this occurring 
during dilution of 14c-melphalan, centrifugation through oil, and 
sample preparation for HPLC. Thus the rate of hydrolysis was little 
different from that in PBS alone. Melphalan in control bone marrow 
cells was also 30% hydrolysed (Table 7-2), but cells incubated with 
verapamil contained more 14c-melphalan, and a greater proportion (72% 
compared with 63%) of this was parent drug. In this experiment 
(Table 7-2), cells exposed to verapamil contained 6.2ng/106 cells of 
unhydrolysed melphalan at 30 minutes, and controls 5.2ng/i06 cells, 
measured with HPLC at the limit of its sensitivity, analysing 4x the 




Hydrolysis of melphalan in PBS medium at 37°c, 




















FIGURE 7-6 188 
Chromatograph of melphalan (M) and hydrolysis products in PBS (a). 
and in supernatant ( b), _2:. ve rapami 1 ( V), by HPLC 
(at 0.001 AUFS, 263nm) 
a. PBS, 2 hours 




b. Supernatant, 30 mins 
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FIGURE 7-7 189 
Chrf~atograph of melphalan (M) in mouse bone marrow cells incubated 
in C-melphalan 2ug/ml, 30 min at 37°c, ±. verapamil, by HPLC 
(at 0.001 AUFS, 263nm) 
Mouse bone marrow 
Control + Verapamil lOµg/ml 
0 5.47 0 
I 
5. 52 
Retention time (minutes) 
) 
) 
FIGURE 7-8 190 
Hydrolysis of l4c-melphalan in murir~ bone marrow and supernatant 
medium, .:!:_ verapamil, determined from C in 30 sec HPLC fractions 
Muririe bone marrow cells, 
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Hydrolysis of melphalan in murine bone marrow cells and supernatant 





















Melphalan hydrolysis was also determined in human plasma at 
37°c, using 300ug/ml melphalan for greater accuracy; melphalan was 
30% hydrolysed in 60 minutes, with t! of 2 hours, consistent with 
other reports (Chang et al, 1978a; Bosanquet, 1985) and, similar to 
the rate in PBS. Besides hydrolysis, melphalan gradually becomes 
irreversibly, covalently bound to proteins and macromolecules, as 
alkylation occurs. Bound melphalan is not methanol-extractable and 
not measured by HPLC. In plasma, less than 10% is irreversibly 
protein-bound within 60 minutes, in vitro (Chang et al, 1978b; Evans 
et al, 1982) and in vivo (Ahmed et al, 1982a)(although Tattersall et 
al (1978) reported more than 50% protein-bound at 1 hour in humans), 
protein-binding increasing to 70-90% by 8-12 hours. In other cell 
uptake studies, 4-7% of melphalan was protein-bound at 10 minutes, 
and 12% at 30 minutes (Goldenberg et al, 1977; Martin et al, 1982). 
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7-1-5. Reversibility of the effect of verapamil 
The experiment shown in Figure 7-9 was designed to show whether 
the effect of verapamil was reversible and whether verapamil had any 
effect on cells already loaded with 14c-melphalan. The mononuclear 
cell fraction of murine bone marrow was incubated at 37°c for 30 
minutes in lug/ml 14c-melphalan, with {upper part of Figure 7-9) or 
without verapamil lOug/ml (lower part of Figure 7-9). Verapamil 
caused 1.5-fold greater accumulation of 14c-melphalan, but when these 
cells were spun down and resuspended without verapamil, in lug/ml 
14c-melphalan prepared at the beginning of incubation and kept at 
37°c to control for hydrolysis, 14c-melphalan was lost. The cells 
resuspended still with verapamil had the same 14c-melphalan content 
at 70 minutes as 30-40 minutes, but cells from which verapamil had 
been removed had a 14c-me 1 pha l an content at 70 minutes similar to 
that of cells never exposed to verapamil. 
When verapamil was added to cells already incubated for 30 
minutes with lug/ml 14c-melphalan, 14c-melphalan content increased 
compared to control cells remaining verapamil-free (lower part of 
Figure 7-9). However cellular 14c-melphalan did not become as high 
as in cells incubated with verapamil throughout, probably because 
hydrolysis had reduced the concentration of parent melphalan in the 
medium. Hydrolysed melphalan is not actively transported into cells 
by the same transport systems as theunhydrolysed drug (Goldenberg et 
al, 1977 ,1979; Begleiter et al, 1979). 
The experiment was performed twice, each time with duplicate 
samples; cell viability remained greater than 90% throughout the 
experiments. Verapamil could increase melphalan accumulation by 
cells already loaded with melphalan, and its effect was reversible. 
FIGURE 7-9 
Changes in 14c-melphalan of mouse bone marrow cells 
on addition or14emoval of verapamil lOug/ml, after incubation in C-melphalan lug/ml, 30 min at 37°c 
(hatched bar, centrifugation and resuspension) 
\mean~ SER (2 experiments, each in duplicate) 
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7-1-6 Efflux of 14c-melphalan 
The mononuclear cell fraction of mouse bone marrow was loaded 
with 14c-melphalan by incubation in lug/ml melphalan at 37°c for 30 
minutes. The cells were spun down and resuspended in melphalan-free 
medium with or without verapamil (Figure 7-10). At both 1 and 
lOug/ml, verapamil prevented loss of 14c-melphalan from the cells. 
Thirty minutes from resuspension, 20% of the 14c-melphalan remained 
in cont ro 1 ce 11 s, and 30% in ve rapamil -treated ce 11 s. The f i na 1 
medium 14c-melphalan concentration was less than 0.03ug/ml. This 
implies that not more than 20% of the 14c-melphalan taken up by 30 
minutes in control cells was bound to cellular proteins. The HPLC 
method was not sensitive enough to measure this residual melphalan 
but it seems unlikely that verapamil directly increased cellular 
binding of melphalan, having increased predominantly parent 
melphalan, rather than hydrolysis products, in the cells (Table 7-2). 
The results were pooled from 5 experiments; cell viability always 
exceeded 90%. 
7-1-7 Influx of 14c-melphalan 
The previous section showed that verapamil inhibited 
l4c-melphalan efflux. Influx is more difficult to study but is 
approximated by the rate of uptake of 14c-melphalan in the first 1-2 
minutes of incubation. Time intervals shorter than 2 minutes could 
not be achieved with accuracy with the technique used, and it is 
uncertain exactly when uptake ceases as the ce 11 s are spun through 
the oil. In 3 experiments, uptake of 14c-melphalan by the 
mononuclear cell fraction of murine bone marrow, preincubated at 37°c 
with or without verapami l lOug/ml, was the same (factor of 1.05 ~ 
0.14) in verapamil-treated cells as in controls 2 minutes after 
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addition of lug/ml 14c-melphalan. (One of the experiments was shown 
in Figure 7-3). Thus verapamil had minimal effect on influx of 
melphalan. 
Uptake of 14c-me1pha1an was also studied at 0-4°c, to determine 
initial adsorption of melphalan to the cell membrane and the effect 
of verapaniil on melphalan influx. One experiment was performed on 
ice in the cold room (8-10°c), in PBS at 1°c, using ice-cold pipettes 
and mi crocentrifuge tubes, and the other on ice in the 1 aboratory 
(about 22°c), in PBS at 4°c without precooled pipettes and tubes 
(Figure 7-11). Uptake of 14c-me1pha1an was 0.3ng/106 cells after 2 
minutes at 1 °c, and ce 11 : medium ratio 1: 1, 1 ess than 10% of steady 
state cellular 14c-melphalan at 37°c. Initial adsorption of 
l4c-me1phalan to the cell membrane, determined as uptake during the 
first minute at 0-4°C, was less than 5% of the final steady value for 
tumour cell lines, and about 10% for human lymphocytes (Begleiter et 
al, 1979, 1980; Goldenberg et al, 1979). Errors from initial 
adsorption of 14c-me 1 pha 1 an are therefore sma 11 when steady state 
levels are studied, and no correction was made in uptake 
experiments. 
In the laboratory experiment (Figure 7-11), uptake of 
14c-me1phalan was greater, presumably because of the higher 
temperatures during incubat·ion, pipetting and centrifugation. 
Equilibrium ~ad not been reached in either experiment after 30 
minutes. Although verapamil had no effect on early transport, 
verapamil-treated eel ls began to show greater uptake by 20 and 30 
minutes in the laboratory experiment. Thus verapamil did not affect 
initial influx, and its effect was temperature-dependent. 
) 
FIGURE 7-11 
Uptake of 14c1~elphalan by mouse bone marrow cells incubated in C-melphalan lug/ml at 1 and 4°c, 
with ( o) or without ( •) verapamil lOug/ml 
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Mouse bone marrow: 14c-melphalan uptake and flunarizine 
Flunarizine is a calcium channel blocker analogue of verapamil. 
The mononuclear cell fraction of mouse bone marrow was incubated in 
lug/ml l4c-melphalan at 37°c for 30 minutes, with verapamil lOug/ml, 
flunarizine in doses of 1, 5 and lOug/ml, or placebo 1 lOug/ml 1 
(Figure 7-12). Cellular 14c-melphalan was increased by verapamil, 
and also by flunarizine 1 and 5ug/ml. Cell viability was greater 
than 95% for the control, verapamil, placebo and flunarizine lug/ml 
groups, but was 93% for flunarizine 5ug/ml and 76% for lOug/ml. Thus 
at flunarizine concentrations of 5-lOug/ml and greater a toxic effect 
occurred and uptake fell. In 816 melanoma cells, flunarizine 
concentrations of 5ug/ml and greater were toxic (Sezzi et al, 1984), 
the surviving fraction falling to 60%. 
) 
FIGURE 7-12 
Flunarizine and 14c-T!lphalan uptake by mouse bone marrow 
cells, incubated in C-melphalan lug/ml, 30 min at 37°c 
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7-3 Disaggregated murine fibrosarcoma cells 
uptake and verapamil 
201 
14c-melphalan 
Disaggregated muri ne fi brosarcoma eel ls ( centrifuged over 
Lymphoprep) were incubated at 37°c for 60 minutes in lug/ml 
l4c-melphalan with or without verapamil (Figure 7-13). Cells from 
FS12 and FS13 accumulated 1.7x and 1.25x more 14c-melphalan 
respectively, in the presence of verapamil lOug/ml. Viability of the 
cells was 70-85%, and was constant through each experiment. 
Enhancement of 14c-mel phal an uptake was greater· for FS12, less 
sensitive to melphalan in the growth delay studies and showing 
greater enhancement of melphalan-induced growth delay by verapamil 
(section 6-4). Melphalan_ uptake by the fibrosarcoma cells was 
5-6ng/106 cells, with a cell:medium gradient of 8:1. 
The effect of verapamil was not related to damage of the cell 
membrane during enzyme disaggregation. Cells from FS13 disaggregated 
without enzyme, incubated in lug/ml 14c-melphalan at 37°c for 30 
minutes, took up 1.22 + 0.10 times more 14c-melphalan in the presence 
of verapamil lOug/ml (2 experiments). In one experiment the cells 
loaded with 14c-melphalan for 30 minutes were centrifuged and 
resuspended in melphalan-free medium, with or without verapamil 
lOug/ml, at 37°c. Thirty minutes later 47% of the 14c-melphalan was 
still present in the cells exposed to verapamil and 36% in controls. 
The medium 14c-melphalan concentrations were 0.04ug/ml at the end of 




FIGURE 7-13 202 
Verapamil and · 14c-melphalan uptake by disaggregated murine 
fibrosarcoma cells, incubated in 14c-melphalan lug/ml, 60 min at 37°c 
(no. experiments on bar) 
I mean + SER ( or range where n=2) 
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7-4 Human bone marrow: 14c-melphalan uptake and verapamil 
The presence of verapamil had no effect on mel phal an 
cytotoxicity to human bone marrow (section 6-6), and this was 
associated with no effect of verapamil on 14c-me l pha l an uptake by the 
mononuclear cell fraction of human bone marrm<1 (Figure 7-14). The 
presence of verapamil, 0.1 to lOOug/ml, had no effect on cellular 
14c-melphalan content of human marrow incubated for 60 minutes in 1 
ug/ml l4c-melphalan. Cell viability exceeded 95% throughout each 
experiment. The cell volume was 0.29ul/106 cells, and mean melphalan 
uptake lOng/106 cells, giving a cell:medium ratio of 34:1. This can 
be compared with a cell volume of 0.31ul/106 cells and cell:medium 
ratio of 3:1 in lOOuM (31ug/ml) melphalan for human peripheral blood 
lymphocytes reported by Begleiter et al (1980). 
Uptake of 14c-melphalan by human and murine marrow was directly 
compared after incubation for 60 minutes at 37°c in 0.1 and 1.0ug/ml 
14c-melphalan, in the presence and absence of verapamil lOug/ml 
(Figure 7-15). There was a 3-fold greater gradient of cell :medium 
melphalan concentration in human than murine marrow. Mouse marrov,, 
14c-melphalan uptake was greater with verapamil at lug/ml melphalan, 
but not O.lug/ml in this experiment (cf Figure 7-4), but the errors 
in counting 14c are great at such low concentrations. Verapamil had 
no effect on 14c-me l pha l an uptake by human marrow at either 
concentration. 
) 
FIGURE 7-14 204 
Verapamil and 14c-melphalan uptake by human bone marrow cells, 
incubated in 14c-melphalan lug/ml, 60 min at 37°c 
(no. experiments on bar) 
mean+ SER (or range where n=2) 
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FIGURE 7-15 205 
Cellular 14c-1~lphalan uptake by human and murine bone marrow, 
incubated in C-melphalan for 60 min at 37°c, with (shaded) or 
without verapamil lOug/ml 
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Human promyelocytic leukaemia HL60 cell line 14c-melphalan 
uptake and verapamil 
Verapamil had no effect on melphalan cytotoxicity to logarithmic 
phase HL60 cells (section 6-6). When these cells were incubated in 
lug/ml 14c-melphalan for 60 minutes at 37°c, the presence of 
verapamil lOug/ml had no effect on cellular 14c-melphalan uptake 
(Table 7-3), whether or not calcium was present in the medium. The 
cell volume of the HL60 cells was 0.53ul/106 cells, and mean steady 
state melphalan content 12ng/106 cells giving a cell:medium gradient 
of 23: 1. 
Verapamil lOug/ml had no effect on efflux of 14c-melphalan from 
HL60 cells loaded by incubation for 30 minutes at 37°c in lug/ml 
14c-melphalan (Figure 7-16). Thirty minutes after resuspension 30% 
of the l4c-melphalan remained in the cells. 
TABLE 7-3 














14c-melphalan (fraction of control, no Ca) 
Control Verapamil lOug/ml 
0 1.00 + .06 1.00 + .06 
1.25 0.98 + .05 1.00 + .05 
2.50 1.00 + .06 1.03 + .06 
Cell viability 90-95% 




Verapamil and loss of 14c-melphalan from HL60 cells at 37°c 
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Verapamil lOug/ml increased 14c-me 1 pha 1 an uptake by the 
mononuclear ce 11 fraction of mouse bone marrow, disaggregated FS12 
and FS13 fi brosarcoma ce 11 s, but not by human bone marrow nor HL60 
cells. This effect of verapamil was independent of medium calcium 
concentration and was reversible. Verapami 1 reduced efflux from 
murine bone marrow and fibrosarcoma cells, but had no effect on 
influx. Human bone marrovJ took up 3 times more 14c-melphalan than 
murine bone marrow. Enhancement of cellular 14c-melphalan uptake by 
verapamil correlated with enhancement of melphalan cytotoxicity by 
verapamil. Verapamil had no effect on melphalan hydrolysis, and the 
excess melphalan accumulated was unhydrolysed parent drug. 
Flunarizine, another calcium antagonist, also increased uptake 
of 14c-melphalan by murine bone marrow cells. 
I 
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CHAPTER 8 MODIFICATION OF GASTROINTESTINAL TOXICITY OF MELPHALAN 
8-1 Vasoactive intestinal peptide (VIP) 
8-1-1 Effect of VIP on 86Rb uptake by fibrosarcomas and jejunum 
Vasoactive intestinal peptide (28 amino acid residues) is widely 
distributed as a neurotransmitter in the central nervous system and 
also in the intestine, lungs and adrenals (Said and Mutt, 1970; 
Fahrenkrug, 1979). Although VIP caused systemic vasodi1atation and 
hypotension and increased superior mesenteric blood flow (Said and 
Mutt, 1970; Thulin et al, 1984), it decreased blood flow in rat 
jejunum microvi11i (Ho11iger et al, 1979) suggesting pot~ntial to 
reduce damage to the jejunum epithelium by me1pha1an. 
The initial temperature study showed a 1c 0 fall in temperature 
after VIP, 5ug/kg/min by iv infusion for 3 minutes {Figure 8-1). 
However, this dose caused a marked reduction in 86Rb uptake by FS13 
fibrosarcomas (Figure 8-2), although the tumours were poorly matched 
for weight, and reduced kidney and jejunum 86Rb. By reducing the 
dose of VIP to lug/kg/min by iv infusion, tumour 86Rb uptake was not 
affected, yet jejunum 86Rb uptake was markedly reduced, as was kidney 
86Rb. 
FIGURE 8-l 
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FIGURE 8-2 213 
86Rb uptake of FS13 fibrosarcomas after VIP 3 min infusion (shaded) 
{8-12 tumours, 4-6 mice) *p<0.05, **p<'..0.01, ***p.::.0.001 
VIP lug/kg/min 
0. 7 7 
0.6 6 -01 -......., 












0.2 ~ 4 -..a 
e::: 









~ 0.1 ~2 
'° 00 
* * * 
* 



























* * * 








8-1-2 Effect of VIP on 14c-melphalan uptake and toxicity in mouse 
jejunum 
The uptake of 14c-mel phal an was determined 30 minutes after 
melphalan 5mg/kg (in aa 1:50}iv, given with VIP lug/kg/min or saline 
by iv infusion (Figure 8-3}. No reduction in 14c-melphalan uptake by 
the jejunum occurred, and the tendency to an increase may reflect the 
small increase in blood 14c-melphalan after VIP. Tumour 
14c-melphalan uptake was not affected. 
Jejunum microcolony survival was determined after iv melphalan, 
given with or without VIP lug/kg/min by iv infusion (Figure 8-4). No 
protective effect of VIP was seen. The duration of the VIP infusion 
may have been too short, but the temperature changes {Figure 8-1) 
suggested that the effects lasted 10-15 minutes, at least as long as 
those of angiotensin II. 
FIGURE 8-3 215 
Effect of VIP infusion on 1\
4c-melphalan uptake by FS13 fibrosarcomas 
and jejunum, 30 min after C-melphalan (aa 1:50) 5mg/kg iv, 
with VIP lug/kg/min iv for 3 min (shaded) 
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FIGURE 8-4 216 
Jejunum microcolony survival after treatment of cba mice with 
melphalan iv and VIP infusion, lug/kg/min iv for 3 min (o) 
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8-2 Effect of epidermal growth factor on murine intestine epithelial 
damage and regeneration after melphalan 
8-2-1 Epidermal growth factor (EGF) 
Epidermal growth factor, a 53 amino aci ct peptide first isolated 
from male mouse submaxi 11 ary glands (Cohen, 1962; Carpenter and 
Cohen, 1979), stimulated DNA synthesis and cell proliferation in 
adult murine intestine (Scheving et al, 1979, 1980; Al-Nafussi and 
Wright, 1982a; Chabot et al, 1983), and development of 
gastrointestinal enzyme activities in suckling mice (Malo and Menard, 
1982). In animals, EGF protected gastric mucosa from aspirin-induced 
ulceration, by increasing DNA synthesis (Konturek et al, 1981), and 
also inhibited gastric acid secretion (Gregory, 1975). In vivo and in 
vitro, EGF stimulated growth of a wide variety of epidermal cells, 
including transformed lines,and of many mesodermal cells including 
mouse and human fibroblasts and vascular endothelial cells 
(Gospodarowicz et al, 1978; Carpenter and Cohen, 1979). It seemed 
likely that EGF would protect murine intestine from melphalan-induced 
damage. 
Biosynthetic human EGF (hEGF), urogastrone, was used. Human and 
mouse EGF (mEGF) are highly homologous, have identical biological 
effects and cross-react in many antibody systems (Cohen and 
Carpenter, 1975; Gregory, 1975; Carpenter and Cohen, 1979). Because 
of circadian variation in mouse gastrointestinal activity, 
administration of melphalan and EGF and assays were all performed at 
the same time of day in each experiment (Scheving et al, 1979, 1980; 
Al-Nafussi and Wright, 1982b). The biological activity of the hEGF 
was confirmed, following Cohen {1962) and Moore et al (1981). 
Subcutaneous administration of hEGF, 4mg/kg daily for 10 days to 9 
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newborn cba mice resu 1 ted in eye 1 id opening on days 8-1 O, comp a red 
with days 14-17 for 11 litter mates treated with saline. 
8-2-2 Effect of EGF on melphalan gastrointestinal toxicity at 4 and 
7 days 
Groups of 3 mice were treated with melphalan 15 or 20mg/kg ip, 
and controls were treated with saline ip. These melphalan doses were 
chosen so that jejunum microcolony survival would be 30-70%. Two 
hours before melphalan (or saline) treatment, hEGF lOOug/kg or water 
was administered i p and continued 8 hourly for 4 days (total 12 
doses). Jejunum microcolonies and 14c-xylose uptake were determined 
4 and 7 days later (Figure 8-5). 
The melphalan-treated mice all lost weight, the loss tending to 
be greater with hEGF. Uptake of 14c-xyl ose showed no si gni fi cant 
differences from controls, nor any effect of hEGF treatment. Severe 
gastrointestinal damage would markedly reduce 14c-xyl ose uptake. No 
14c was detectable in blood 3 days after oral 14c-xylose, allowing 
serial measurements. Treatment with hEGF further reduced jejunal 
crypt survival after melphalan 15mg/kg ip, from 97% to 71% (p<0.02) 
on day 4, and from 90% to 73% (p < 0.05) on day 7. Treatment with 
hEGF alone (saline instead of melphalan) had no effect on jejunum 
microcolonies. 
In another experiment, two groups of 3 mice had been treated 
with melphalan 25mg/kg ip on day O. Two hours before melphalan 
administration, mouse EGF lOOug/kg or water was given ip, and 
continued twice daily for 9 doses. A further 3 control mice v1ere 
untreated. Jejunum mi crocol oni es assayed on day 4 shmted no effect 
of rnEGF, su rv·i val being 4. 6 _::_ 1.1% after me l pha l an and 6. 3 + 1.4% 
after rnelphalan \tith mEGF. The higher rnelphalan dose v1as used 
) 
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because an effect to increase survival was sought. Thus neither hEGF 
nor mEGF reduced melphalan jejunum toxicity, and indeed starting hEGF 
2 hours before melphalan might even have promoted it. Since the 
regimen of EGF administration might be important, a number of 
different ones were explored. 
8-2-3 Effect of hEGF administered in 6 different regimens on 
melphalan gastrointestinal toxicity at 4 days 
Groups of 3 mice were treated with melphalan 17.Smg/kg ip on day 
0, with hEGF ip in one of the 6 regimens shown in Figure 8-6. When 
hEGF was given on day O it preceded melphalan by 2 hours, except in 
group 6 where hEGF was commenced 6 hours after melphalano On day 4, 
14c-xylose uptake and gut microcolonies were assessed (Figure 8-6)0 
Microcolony survival in the ileum and colon was determined in an 
analogous way to that in the jejunum. 
Only administration of hEGF lOOug/kg ip 8 hourly beginning 24 
hours before melphalan (group 5) increased jejunum crypt survival 
(p .(O.Ol)but the effect was small. No significant effects of hEGF 
were seen on ileum and colon microcolonies, nor on 14c-xylose uptake. 
FIGURE 8-5 220 
Effect of hEGF on weight, 14c-xylose uptake and jejunum microcolony 
survival after treating cba mice with melphalan 
melphalan, 15mg/kg ip (M15) or 20mg/kg ip (M20), saline ip (C) 
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8-2-4 Effect of late administration of ·hEGF on melphalan 
gastrointestinal toxicity 
· It was possible that hEGF ·might only have an effect once 
histological damage was extensive, from day 4 onwards. Groups of 
mice treated with melphalan 15mg/kg ip on day O were treated with 
hEGF lOOug/kg ip or water ip 8 hourly, beginning 6 hours or 4 days 
after melphalan. Uptake of 14c-xy1ose was measured on days 4, 8 and 
13, and mi crocol ony survival on days 8 and 13 (i='i gure 8-7). 
Human EGF begun 6 hours after melphalan treatment had no effect 
on jejunum or ileum microcolony survival at 8 or 13 days, but ileum 
microcolony survival was not affected by melphalan 15mg/kg ip (Figure 
8-7a). Colon crypt survival was not affected by melphalan, alone or 
with hEGF (data not shown). The low value for 14c-xylose uptake in 
control mice on day 8 is unexplained, but none of the treated groups 
differed significantly from the day 4 control value or from each 
other. Delaying hEGF treatment until 4 days after melphalan had no 
significant effect on gastrointestinal recovery (Figure 8-7b). 
8-2-5 Effect of oral hEGF on melphalan gastrointestinal toxicity 
Although oral EGF had no trophic effect on intact intestinal 
epithelium (anon, 1985), topical application might affect damaged 
epithelium. Melphalan 20mg/kg ip was given to 2 groups of 5 mice on 
day O. One group received hEGF lOOug/kg by oropharyngeal tube under 
1 i ght ether anaesthesia twice daily (9 doses), and the other group 
anaesthesia only, beginning immediately before melphalan 
admi ni strati on. On day 4, no effect of hEGF was detected on the 
gastrointestinal toxicity of melphalan (Figure 8-8). 
deli very of hEGF was not more effective than parenteral. 
Topical 
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FIGURE 8-7 Effect of delaying hEGF treatment on gastrointestinal toxicity of melphalan in cba mice 
melphalan 15 mg/kg ( M15), untreated control (C) 
hEGF lOOug/kg ip 8 hourly (shaded) begun (a) 6hr after melphalan or (b) on day 4 







Effect of oral hEGF on gastrointestinal toxicity of melphalan 
melphalan 20mg/kg ip (M20), untreated control (C) 
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8-2-6 Discµssion and conclusions 
This investigation failed to find a consistent and significant 
protective or restorative effect of hEGF on mouse gastrointestinal 
damage from high-dose melphalan. The only significant results were 
increased jejunum crypt survival after melphalan 17 .5mg/kg ip by hEGF 
lOOug/kg ip 8 hourly begun 24 hours before melphalan, and decreased 
jejunum crypt survival after melphalan 15mg/kg ip by the same dose of 
hEGF begun 2 hours before melphalan. The doses and regimens of EGF 
employed included doses and times of administration shown to affect 
DNA synthesis and cell proliferation in murine intestine (Scheving et 
al, 1979, 19,80; Al-Nafussi and Wright, 1982a,b; Chabot et al, 1983). 
However, the extent of stimulation of gastrointestinal proliferation 
by EGF depended on the part of the intestine and its phase· in the 
circadian cycle (Scheving et al, 1979, 1980L and on feeding (Chabot 
et al, 1983). Indeed, EGF failed to increase DNA synthesis and cell 
proliferation in the jejunum of fed mice, although EGF increased DNA 
synthesis in jejunum, ileum and colon of fasted mice (Scheving et al, 
1980; Al-Nafussi and Wright, 1982a; Chabot et al, 1983). 
Melphalan-treated mice tend not to eat and might be more like fasted 
mice, who have lower serum levels of endogenous EGF {Chabot et al, 
1983). However, melphalan damage might stimulate endogenous EGF 
release so that no effect would occur after exogenous EGF. Even if 
EGF had protected the gastrointestinal tract from melphalan damage 
and promoted epithelial recovery, there would still be concern that 
EGF might also promote tumour cell proliferation. 
226 
8-3 Summary 
Although vasoactive intestinal peptide (VIP) decreased jejunum 
blood flow without affecting tumour blood flow, VIP did not decrease 
jejunum 14c-melphalan uptake nor microcolony survival after 
melphalan. 
In the regimens of administration used, epidermal growth factor 
(EGF) failed to protect the murine gastrointestinal tract or enhance 
recovery from epithelial damage by melphalan. The only significant 
effects of EGF were an increase in jejunum crypt survival after 
melphalan 17.5mg/kg ip by hEGF lOOug/kg ip 8 hourly begun 24 hours 
before melphalan, but a decrease after melphalan 15mg/kg ip when the 
hEGF was begun 2 hours previously. 
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CHAPTER 9 DISCUSSION 
9-1 Tumour blood flow, melphalan uptake and cytotoxicity 
9-1-1 Introduction 
Uptake of cytotoxic agents by tumour eel ls depends on . many 
factors, including the area under the blood concentration versus time 
curve (AUC), whether delivery of the cytotoxic agent is limited by 
blood flow or permeability, and on cellular membrane transport. Only 
for tumours where blood flow limits uptake could it be possible to 
increase uptake of a cytotoxic agent by increasing perfusion. The 
experiments reported here considered the effects of a vasoact i ve 
agent which increased tumour blood flow, angiotensin II, on in vivo 
uptake and cytotoxicity of melphalan. Comparisons could be made with 
verapamil, which had no effect on tumour blood flow but increased 
both the AUC for melphalan in mice and cellular melphalan 
accumulation. Blood flow did not seem to limit melphalan uptake and 
cytotoxi city. Differences emerged in the vascular supply of 
subcutaneous murine fibrosarcomas and human melanoma HX46 xenografts. 
9-1-2 Tumour blood flow and response to vasoactive agents 
The relative distribution of blood flow to tumours and normal 
tissues in mice measured with 86Rb (section 3-1) was similar to that 
in other studies using unanaesthetised mice (Zanelli et al, 1975; 
Robinson et al, 1982; Stewart and Begg, 1983; Bomber et al, 1986). 
Uptake by both muri ne fi brosarcomas and human melanoma HX46 
xenografts exceeded that of normal skin and muscle. Normal tissue 
86Rb uptake was remarkably similar in control mice from different 




Of the vasodil ators, only acid alcohol increased tumour blood 
flow; verapamil, flunarizine, epoprostenol and phentolamine all 
failed to increase 86Rb uptake by the murine fibrosarcomas (Chapter 
4). This was perhaps predictable because vasodilators tend to cause 
systemic hypotension and decrease tumour perfusion (Chan et al, 1984; 
Suzuki et al, 1984). However verapami 1 and fl unari zi ne had both 
increased blood flow by a factor of 1.5 in mammary carcinomas in 
unanaesthetised rats, measured with microspheres, using doses which 
did not significantly reduce systemic blood pressure (Kaelin et al, 
1982, 1984). It is unlikely that an increase in tumour blood flow 
with verapamil was missed because although verapamil increased 
cardiac output in rats, it differentially reduced vascular resistance 
in the tumours which would alter 86Rb distribution. Verapamil did 
not increase 86Rb uptake by RMS sarcomas in mice (Bomber, personal 
communication), and it was possible that changes in 86Rb uptake were 
1 ess than changes in mi crosphere di stri but ion for given changes in 
blood flow, particularly if 86Rb uptake was not entirely flow-limited 
(Sheehan and Renkin, 1972; Foster and Frydman, 1978). However, both 
decreases and increases in tumour 86Rb were detected in other 
experiments. Furthermore, nisoldipine, another calcium antagonist, 
decreased blood flow in 3 rat tumours, measured by 133xe-xenon 
clearance (Knapp et al, 1985). Species differences in cardiovascular 
effects, differences in tumour vasculature and implantation site, and 
possibly an excessive (hypotensive) dose of verapamil are more likely 
explanations. It is probably worth studying further the effects of 
verapamil on tumour blood flow in larger animals, where blood 
pressure can be monitored. 
The vasoconstrictors, methoxamine and adrenaline both reduced 
_) 
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tumour 86Rb uptake, a lower dose of adrenaline having no effect. 
Propranolol was studied extensively (section 4-5) because it 
increased 86Rb uptake by sarcomas in balb/c mice (Bomber et al, 
1986), but no such effect was found despite using the same doses and 
time intervals. The findings in unanaesthetised mice agreed with 
those in anaesthetised rats where propanol al had no effect on 86Rb 
uptake by the tumours, while decreasing cardiac output and absolute 
blood flow (Debreczeni et al, 1980). 
Infusion of angiotensin II increased 86Rb uptake by FS13 
fibrosarcomas, over a relatively narrow range of dose-rates (section 
4-9). Angiotensin II had increased perfusion of the- relatively less 
reactive tumour vascul ature by increasing systemic vascular 
resistance (Jirtle et al, 1978b; Suzuki et al, 1981, 1984), but at 
higher doses this effect was lost because of progressive reduction ·in 
cardiac output and fl ow to the host tissue (Ji rtl e et al, 1978b; 
Tvete et al, 1981a). The increase in 86Rb uptake by the murine 
fibrosarcomas was small compared with the 5-fold increase in absolute 
flow in subcutaneous hepatomas in anaesthetised rats (Suzuki et al, 
1981), and an increase in tumour vascular volume (Hori et al, 1985} 
could not be demonstrated with 59Fe-labelled red cells (section 5-6). 
This perhaps reflects differences in the tumours, host animals, 
methods of measurement or effects of anaesthesia. The failure of 
both angiotensin II and the acid alcohol :saline 1:20 solvent to 
increase FDCO to human melanoma HX46 xenografts (sections 3-3-1, 4-9) 
suggested differences in their blood supply from that of the 
fibrosarcomas. These were either intrinsic or the result of 
implantation technique or of total body irradiation, which might 
alter the tumour vascular bed (Clifton and Jirtle, 1975). If the 
) 
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latter applied, the xenografts vJOuld be a poor model for human 
tumours, except after irradiation. 
It proved difficult to increase relative tumour blood flm-1, 
using vasoactive agents. The effects of vasoactive agents on tumour 
perfusion seem to depend on the particular tumour, its site and 
vasculature, the host tissue vessels and host cardiovascular 
responses to the agent. The use of 86Rb was appropriate in the 
context of in.creasing drug delivery because 86Rb reflects nutritional 
blood flow and excludes shunts (Friedman, 1968). The inability to 
measure cardiac output and blood pressure in unanaesthetised mice was 
a disadvantage. Those agents which reduced tumour blood flow might 
find application with hyperthermia; heat dissipation would be slower 
from the tumour promoting selective heating, as has been demonstrated 
for isoprenaline and hydralazine (Voorhees and Babbs, 1982; Volenec 
et al, 1984), and proposed for nisoldipine (Knapp et al, 1985). 
9-1-3 Tumour blood flow and 14c-melphalan uptake 
The 14c-melphalan content at 60 minutes varied widely for the 
muri ne FS13 fi brosarcomas and the human melanoma HX46 xenografts 
(section 3-2), as was found for human melanoma HX32 and lung 
car~inoma xenografts (Selby et al, 1979; Wist et al, 1981). However 
in contrast to one minute 86Rb uptake, which decreased with increase 
in tumour weight, by 60 minutes tumour 14c-melphalan content of the 2 
fibrosarcomas in each mouse was very similar, and tended to increase 
with tumour weight. This suggests that there were poorly perfused 
regions, particularly in larger tumours, but that if 60 minutes was 
allowed for equilibration, melphalan reached all parts of the 
tumours, as was illustrated by auto~adiography (Figure 3-17), 
i 
14c-melphalan uptake not being limited by perfusion. Some blood was 
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trapped in tumour blood vessels, but since the vascular space of the 
fibrosarcomas was 1.4% of the tumour volume (section 5-6) this would 
have little effect on tumour 14c-melphalan. 
Delivery of most cytotoxic agents (MW (2,000) is thought to be 
perfusion-limited, with rapid diffusion through highly permeable 
tumour vessels (Song and Levitt, 1971; Nugent and Jain, 1984). 
However, for substances not rapidly cleared from the blood, delivery 
was not limited by perfusion so long as flow exceeded a certain 
minimum. Thus distribution of 14c-misonidazole was limited by flow 
only in very poorly perfused parts of subcutaneous sarcomas (Blasberg 
et al, 1985), methotrexate distribution was independent of blood flow 
in the relatively well-perfused dog lymphosarcoma (Straw et al, 
1974), and labelled albumin reached even ·poorly perfused regions of 
rat fibrosarcomas (Peterson et al, 1984). 
Although 86Rb uptake by the fibrosarcomas was increased by the 
melphalan acid alcohol solvent at 20 minutes (section 3-3-2), tumour 
14c-melphalan uptake was unaffected at 20 minutes, 1 and 4 hours, 
when solvent concentrations of 1:100 and 1:50 were compared with 1:20 
' tended to 
(section 3 ... 3-3). The higher solvent concentration aa 1 :5/\decrease, 
both tumour 86Rb and 14c-melphalan uptake at 20 minutes but no effect 
on 14c-melphalan uptake was detectable by 1 and 4 hours. The solvent 
also had no effect on tumour platinum uptake at 1 hour (section 6-3). 
Ethanol causes vasodilatation, especially of cutaneous vessels, 
probably by a central vasomotor effect (Gilman et al, 1980), yet 
there was no increase i"ri FDCO to the skin nor change in FDCO to 
other organs with aa 1:20 (Figures 3-21, 3-22), suggesting greater 
vasodilatation in the tumour than host tissues. However, once blood 
pressure fell, as probably occurred when the solvent concentration 
was increased from 1:10 to 1:5, the increase in tumour blood flow was 
lost. The increase in renal FDCO at aa 
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1:5 probably results 
from autoregulation of renal flow, in the presence of a fall in 
cardiac output. In contrast, the HX46 xenograft vasculature showed 
no response to the acid alcohol solvent (Figure 3-22). 
The increased FDCO to the fibrosarcomas with acid alcohol was 
not accompanied by increases in 14c-melphalan uptake, nor increases 
in growth delay (sections 3-3-4, 5-4), suggesting that uptake was not 
limited by blood flow. Although ethanol enhanced the cytotoxicity of 
b 1 eomyci n combined with moderate hyperthermi a in Lewis 1 ung 
carcinomas (Tak iyama et a 1, 1984), no exp 1 anat ion vias off erect, and 
the effects of ethanol on chemotherapy alone are unknown. 
9-1-4 Tumour blood flov1, 14c-melphalan uptake and cytotoxicity 
effect of angiotensin II 
Angiotensin II infusion increased the FDCO to fibrosarcomas, and 
also increased 14c-melphalan uptake at 30 minutes, but not 
significantly at 60 minutes (sections 4-9, 5-2). Angiotensin II had 
a non-significant tendency to increase blood 14c-melphalan levels. 
In the two experiments where blood 14c-melphalan was significantly 
increased in the angiotensin II-treated mice at 60 minutes, tumour 
14c-melphalan was also significantly increased (Figure 5-3, Table 
5-1). Angiotensin II had no effect on growth delay by melphalan of 
the fibrosarcomas (section 5-4). Even though increased relative 
tumour blood flow increased the early (30 minutes) uptake of 
14c-melphalan by the fibrosarcomas, there was no enhancement of 
cytotoxicity. For the HX46 xenografts, angiotensin II had no effects 
on 86Rb uptake, 14c-melphalan content (nor blood 14c-melphalan 
content) at 30 minutes, nor on melphalan growth delay (sections 4-9, 
5-2, 5-4). In the absence of a significantly increased AUC for 
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melphalan, increasing tumour blood flow with angiotensin II had only 
a shortlived effect on tumour 14c-melphalan uptake, and no lasting 
effect on cytotoxicity. 
The possibility that the duration of angiotensin II infusion 
might be too short for effects on me 1 pha 1 an uptake and cytotoxi city 
was considered in section 5-3. Blood 14c-melphalan levels fell 
rapidly after iv administration (Figures 5-1, 6-3) and increased 
blood flow would be expected to have maximum effects in the first 
10-15 minutes. The increase in tumour 14c-melphalan was actually 
delayed, and was evident at 30 minutes but not 5 minutes, suggesting 
some limitation to melphalan delivery, but the difference was lost 
after 60 minutes equilibration (Figure 5-2). Cisplatin is cleared 
from the blood and bound to tissues more quickly than melphalan 
(Siddik et al, 1984; Sternson et al, 1984) and its distribution would 
reflect blood flow at the time of administration rather more than 
subsequent equilibration. Indeed tumour platinum was significantly 
increased 60 minutes after administration with angiotensin II 
(section 5-5). The increase in tumour blood flow occurred rather 
later, 20 minutes, after acid alcohol, and this may explain why 
tumour platinum was not increased by aa 1:20 (section 6-3). 
Angiotensin II has been reported to enhance the cytotoxicity of 
adriamycin and mitomycin C in animal and human tumours (Suzuki et al, 
1981; Koyama et al, 1983; Wakui and Suzuki, 1983), although all 3 
studies could be criticised (see section 1-3-5), in contrast to 
results with melphalan in murine fibrosarcomas. Uptake of cytotoxic 
agents by tumours after angiotensin II has not been reported. 




Although verapamil lOmg/kg ip had no effect on the FDCO to 
murine fibrosarcomas (section 4-2), both the AUC and tumour uptake of 
14c-melphalan at 60 minutes were increased (sections 6-1, 6-2). 
Verapamil 2.5mg/kg iv (having the same effects on temperature as 
15mg/kg ip) and 2.5mg/kg ip had no effects on either pharmacokinetics 
or tumour uptake of melphalan, even though the iv dose reduced tumour 
relative blood flow. As was discussed in section 6-1 verapamil might 
enhance melphalan absorption after ip administration, or delay renal 
elimination by reducing renal blood f1ow, thereby increasing the AUC 
in mice. In the HX46 xenografts verapamil failed to increase tumour 
14G-melphalan at 60 minutes, but no pharmacokinetic effect was 
evident in that experiment. In both the fi brosarcomas and HX46 
xenografts, verapamil lOmg/kg ip (but not 2.5mg/kg ip) enhanced the 
growth delay by melphalan (section 6-4). 
The marked increase in AUG for melphalan with verapamil was 
accompanied by greater tumour 14G-melphalan uptake and enhanced 
cytotoxicity. However a contribution from enhanced cellular 
melphalan uptake by verapamil (section 7-3) was likely, for 
enhancement of growth delay and of cellular melphalan uptake v,1ere 
both greater for FS12 than FS13 fibrosarcomas (Figures 6-11, 6-12, 
7-13). The absence of a fall in tumour 14c-melphalan content despite 
the fall in 86Rb uptake, in the absence of an effect on the AUG, 
after verapamil 2.5mg/kg iv (Figure 6-6) could be explained by the 
absence of limitation by blood flow of 60 minute 14G-melphalan uptake 
or by enhancernent of cellular melphalan uptake. An increase in 
uptake of parent melphalan with an increased AUC was also reported 
) 
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for intramuscular sarcomas in mice treated with whole body 
hyperthermia (Honess et al, 1985), but did not entirely account for 
the prolongation in growth delay. It is not known whether verapamil 
affects melphalan pharmacokinetics in humans. Since verapamil 
increased hepatic, splanchnic and renal blood flow on acute (but not 
chronic) administration in man (Meredith et al, 1985), decreased 
renal elimination of melphalan is unlikely, and little net change in 
melphalan pharmacokinetics in man would be expected. 
The other effects of verapamil on tumour vasculature, increased 
red cell deformability in hypoxia and inhibition of platelet 
aggregation and of metastasis (Van Nueten and Vanhoutte, 1981; Kaelin 
et al, 1982; Honn et al, 1985) would not be expected to enhance 
tumour growth delay. The lOmg/kg ip dose of verapamil appeared to be 
less than that which would cause growth delay by calmodulin 
inhibition (see section 9-2-2), for verapamil alone had no effect on 
growth of the fibrosarcomas and HX46 xenografts (section 6-4). 
9-1-6 Correlation of tumour blood flow, melphalan uptake and 
cytotoxi city 
Enhancement of relative tumour blood flow by angiotensin II or 
by acid alcohol solvent was not associated with enhanced melphalan 
cytotoxicity (section 9-1·-4). Despite the early increase in tumour 
14c-melphalan after angiotensin II, there was no significant increase 
in AUC for melphalan nor lasting effect on tumour 14c-melphalan. In 
contrast, verapamil, which had no effect on relative tumour blood 
flow, increased both tumour 14c-melphalan uptake and cytotoxicity, 
probably because of the increased AUC for melphalan with a 
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contribution from increased cellular melphalan uptake (section 
9-1-5). For fibrosarcomas and HX46 xenografts in mice, uptake and 
cytotoxicity of melphalan varied with the AUC and not with tumour 
blood fl ow. This appears contrary to the conclusions that 
differences in blood supply might account for the greater sensitivity 
and 14c-melphalan uptake of smaller nodal metastases compared with 
primary HX32 xenografts (Selby et al, 1979) and for the lack of 
correlation of melphalan sensitivity and uptake in 4 different human 
lung carcinoma xenografts (Wist et al, 1981), all in cba mice. Blood 
flow was not measured in either study, but the dependence of 
melphalan uptake on perfusion might vary with the tumour, its age and 
its site. Indeed, Wist et al {1981) found different changes in 
tumour 14c-melphalan uptake with weight for the 4 xenografts. 
No reports compare tumour blood fl ow with both uptake and 
cytotoxicity of a chemotherapeutic agent. The relationship of blood 
flow to cytotoxicity has been studied mainly using angiotensin II 
(sections 1-3-5, 9-1-4). However Pallavicini and Hill (1979) 
reported no correlation of tumour blood flow with response to 
cyclophosphamide in 2 murine tumours •. There may be tumours or parts 
of tumours where blood supply is so impaired or intermittent that 
mani pul ati ons of blood fl ow would increase chemotherapy uptake and 
cytotoxicity. This may be true for human solid tumours where blood 
flow may be as low as 1/30 that of surrounding normal tissue (Shibata 
and Maclean, 1966). Although the absence of response of the human 
melanoma HX46 xenografts to the acid alcohol solvent and angiotensin 
II raises doubts over their effectiveness in other tumours, 
particularly in humans, HX46 may not be representative because of 
implantation in an irradiated host (Clifton and Jirtle, 1975). 
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Changes in tumour melphalan uptake at 60 minutes correlated with 
effects on growth delay, suggesting that 60 minute 14c-melphalan 
content was relevant. As others found, tumour melphalan levels at 
30-60 minutes were 1-2 times blood levels (Furner and Brown, 1980; 
Honess et al, 1985). Melphalan determined as 14c includes melphalan, 
hydrolysis products and melphalan covalently bound to proteins and ,. 
macromolecules including DNA. Hydrolysis, about 30%/hour in plasma 
at 37°c (section 7-1-4), and binding in blood, about 10% in the first 
hour (Ahmed et al, 1982a),. mean. that free parent melphalan levels 
fall even faster than blood 14c levels. Thus melphalan distribution 
would be affected predominantly by factors operating during the first 
1-2 hours. The amount of melphalan bound to DNA, and potentially 
capable of a cytotoxic effect, was not determined. However tumour 
14c-melphalan levels appeared to correlate with parent melphalan by 
HPLC and with 14c-melphalan bound to cellular macromolecules (Brown 
et al, 1980; Furner and Brown, 1980). It is likely that increased 
tumour uptake of 14c-melphalan is necessary for increased nuclear 
binding in a tumour, the lack of correlation between melphalan uptake 
and cytotoxicity in unrelated tumours being due to other cellular 
processes which affect sensitivity, such as melphalan detoxification 
and DNA repair {Vistica, 1983; Connors, 1934; Fox, 1984). 
1. For further discussion, please see Appendix I. 
9-2 Cellular uptake of melphalan enhancement by verapamil 
9-2-1 Cellular melphalan uptake effects of verapamil 
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Verapamil had a marked effect on accumulation of melphalan by 
mononuclear murine bone marrow cells (section 7-1). In noncytotoxic 
concentrations, verapamil increased steady state 14c-melphalan levels 
by a factor of 1.5, in a reversible, dose-related way, dependent on 
temperature, but not on medium calcium concentration. Verapamil had 
no detectable effect on influx of melphalan, but inhibited efflux. 
The excess melphalan accumulated was parent drug. Another calcium 
antagonist, flunarizine also increased melphalan accumulation by 
mononuclear murine bone marrow cells (section 7-2). Similar effects 
occurred for fibrosarcoma cells, verapamil increasing steady state 
melphalan levels and reducing efflux (section 7-3). 
In contrast, verapamil had no effect on 14c-melphalan uptake by 
the mononuclear cell fraction of human bone marrow (section 7-4) nor 
by human promyelocytic leukaemia HL60 cells (section 7-5), and had no 
effect on efflux from the HL60 cells. Steady state cell:medium 
concentration gradients for 14c-melphalan were 3 times greater for 
the human marrow and HL60 cells, than for murine marrov..r and 
fibrosarcoma cells. 
Melphalan uptake, through at least tvrn amino acid transport 
systems, has been well characterised in several murine and human cell 
lines (see section 1-4-3), and shown to be represented by uptake of 
14c-melphalan (Begleiter et al, 1979; Goldenberg et al, 1979; Redwood 
and Colvin, 1980; Vistica, 1983). The L system has been identified 
in human lymphocytes and the mononuclear cell fraction of human bone 
marrow (Begleiter et al, 1980; Dufour et al, 1985), but not in the 
clonogenic cells of murine bone marrow suggesting either it was 
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lacking or had altered affinity for amino acids (Vistica, 1980; 
Vistica et al, 1983). Removal of red cells by ammonium chloride 
lysis (Vistica et al, 1979, 1983; Vistica, 1980) reduced the 
proportion of me l pha 1 an transported by the L system in P388 ce 11 s 
compared with cells prepared using Lymphoprep (Dufour et al, 1985) 
and may have contributed to the reduced L system activity. However, 
the lower steady state melphalan accumulation in the mononuclear cell 
fraction of bone marrow of murine compared with human origin 
indicates a marked difference in melphalan transport even when 
Lymphoprep was used. 
Verapamil increased the proportion and absolute amount of free 
melphalan accumulated by the mononuclear murine bone marrow cells 
(section 7-1-4). Melphalan hydrolysis was unaffected by verapamil 
and occurred at a similar rate, half life about 2 hours, in cells, 
PBS medium and plasma. Although melphalan covalently bound to 
cellular macromolecules was not measured, it was less than 20% at 30 
minutes, because 80% of the 14c-melphalan loaded over 30 minutes at 
37°c left the cells, mostly in the subsequent 5-10 minutes (section 
7-1-6). In the fibrosarcoma cells, 64% of the 14c-melphalan was 
exchangeable after 30 minutes (section 7-3). These results compare 
with 70-80% exchangeable melphalan in murine tumour cell lines after 
10-20 mi nut es loading (Golden berg et a 1, 1979; Redwood and Colvin, 
1980; Begleiter et al, 1982) and 12% irreversibly bound in L1210 
cells by 30 minutes (Martin et al, 1982). 
9-2-2 Cellular melphalan uptake: correlation with cytotoxicity 
Verapamil enhanced the cytotoxicity of melphalan by a factor of 
2 in murine haemopoietic progenitor cells (CFU-GM), but had no effect 




of 14c-melphalan was measured in the mononuclear cell fraction of 
bone marrow which includes stem cells (CFU-S) and conmitted 
progenitor cells (CFU-GM, making up about 0.5% cells in mice, and 
0.15% in humans, section 6-6), as well as differentiating and mature 
cells. The similar enhancement by verapamil of melphalan 
cytotoxicity to progenitor cells, and of 14c-melphalan accumulation 
by the mononuclear cell fraction of murine bone marrow, argues for an 
effect of verapamil not only in the CFU-GM fraction but a 1 so in the 
majority of the marrow eel 1 s. This is perhaps supported by the 
report that various amino acids had similar effects on cytotoxi city 
(CFU-GM) and on cellular 14c-melphalan uptake in human marrow 
mononuclear cells (Dufour et al, 1985). In tumour cell lines, the 
cloning efficiency is much higher, 30% for HL60 cells (section 6-6) 
and 90-100% for Ll210 cells (Vistica, 1983), and cytotoxicity can 
then be directly related to cellular uptake. It is considerably more 
difficult to perform cellular uptake studies in cell suspensions 
prepared from animal or human tissues than in homogeneous cell lines 
taken from culture, and a clean enough cell suspension could not be 
obtained from HX46 xenografts. 
The greater sensitivity to mel phalan of human bone marrow and 
HL60 cells may be explained by their 3-fold greater accumulation of 
melphalan. These findings, as well as the absence of an effect of 
verapamil on mel phal an accumulation and cytotoxi city in the human 
marrow, compared with marked enhancement in mu ri ne marrow, pro vi de 
independent evidence for a difference in melphalan transport in human 
and murine marrow cells (Vistica, 1980; Vistica et al, 1983). 
Furthermore changes in melphalan uptake correlated with cytotoxicity 




uptake and cytotoxicity were increased more in FS12. 
Calmodulin inhibitors, which include the relatively weak 
verapamil, inhibited growth of animal and human tumour cell lines in 
vitro and in vivo (Hickie et al, 1983; Ito and Hidaka, 1983; MacNeil 
et al, 1984), at concentrations greater than those modifying drug 
sensitivity, probably through inhibition of calmodulin-mediated 
processes in proliferation (Veigl et al, 1984). However at 10 ug/ml 
in vitro, and lOmg/kg ip in mice, verapamil had no significant 
cytotoxic effect (sections 6-4, 6-6). 
9-2-3 Cellular transport of mel pha l an and other cytotoxic 
agents : effects of verapamil 
Verapamil increased the sensitivity of tumour cells resistant to 
anthracyclines, vinca alkaloids and etoposide and reduced efflux of 
these drugs (see section 1-4-5). Cells with pleiotropic drug 
resistance were cross-resistant to melphalan (ling et al, 1983; Curt 
et al, 1984), and adriamycin and vincristine reduced melphalan 
accumulation in Ll210 cells (Martin et al, 1982), raising the 
possibility of a component of drug transport shared by melphalan and 
other drugs, which changes with the development of resistance and 
which might be affected by verapamil. 
It is possible that verapamil affects melphalan transport in 
mu ri ne bone marrow eel 1 s through an effect on the ce 11 membrane, 
independent of calcium channel blockade. The absence of an effect of 
verapamil on melphalan influx argues against an effect on the amino 
acid transport systems (section 7-1-7). However, verapamil inhibited 
efflux of melphalan from murine marrow and fibrosarcoma cells 
(sections 7-1-6, 7-3), as was found for vinca alkaloids, 
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anthracyclines and etoposide in tumour cell lines (Tsuruo et al, 
1981, 1982a, 1983a; Yalowich and Ross, 1985). The reduced capacity 
for melphalan uptake, attributed to the absence of L system transport 
(V·istica, 1980), may make murine bone marrow more susceptible to 
verapamil, a greater concentration gradient being possible when the 
rate of efflux is reduced. The murine fibrosarcoma cells may have a 
similarly altered L system, or share other membrane characteristics 
with the murine marrow cells, accounting for their enhanced melphalan 
transport with verapamil. Flunarizine had similar effects to 
verapamil on melphalan accumulation by murine bone marrow, and the 
effect may be common to calcium antagonists, although independent of 
medium calcium concentration. 
The greater steady state melphalan accumulation and lack of 
effect of verapami l in human bone marrow and HL60 cells may be a 
property of cells of human origin. Unfortunately attempts to measure 
melphalan uptake in human HX46 xenograft cells and human 5637 cells 
failed. However absence of L system transport was recently reported 
in cells of 4 human tumours taken directly from patients (Dufour et 
al, 1985), so this is not a property only of murine cells. 
The recently reported effects of verapamil on etoposi de 
transport in Ll210 cells (Yalowich and Ross, 1985) closely parallel 
the findings for melphalan transport in murine bone marrow (section 
7-1). Etoposide efflux was inhibited; etoposide accumulation, 
cytotoxi city (and DNA binding) were increased; further uptake 
occurred on addition of verapamil to cells already equilibrated with 
etoposide. The effect was reversible, independent of calcium, absent 
at o0c and occurred in cells not resistant to etoposide (Yalowich and 
Ross, 1985). This is strong support for a similar effect of 
) 
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verapamil on transport of etoposide and melphalan. 
Much greater changes in cellular accumulation and sensitivity 
occurred with calcium/calmodulin antagonists for vinca alkaloids and 
anthracyclines in leukaemia and tumour cell lines with resistance 
induced in vitro (Tsuruo et al, 1981, 1982b, 1983a,c; Slater et al, 
1982; Ramu et al, 1984a) than in cloned human tumour cells or 
leukaemic cells which became resistant in vivo (Dana and Hoodruff, 
1984; Goodman, 1984; Pradhan et al, 1984; Rogan et al, 1984; Stark, 
1984). The role of verapamil in clinical human tumour sensitivity 
will depend on whether resistance in vivo resembles PDR and whether 
drug transport limits sensitivity in individual tumours. 
Although verapamil had no effect on me 1 pha 1 an resistance of 2 
human tumour cell lines (Harker et al, 1984; Rogan et al, 1984) the 
combination of verapamil with melphalan has not otherwise been 
studied. The effects of verapamil on melphalan transport in cells 
without induced resistance to melphalan, absence of L system 
transport in some human tumours (Dufour et al, 1985) and association 
of resistance with changes in melphalan transport in some tumour 
cells (Redwood and Colvin, 1980; Vistica, 1983; Connors, 1984; Curt 
et al, 1984; Goldenberg and Begleiter, 1984) make it likely that 
verapamil could enhance sensitivity to melphalan in some human 
tumours. 
9-2-4 Relationship of in vivo tumour melphalan uptake to cellular 
uptake : effects of verapamil 
In vivo melphalan uptake occurs in the presence of amino acids. 
Physiological concentrations of L-leucine and L-glutamine reduced 
melphalan uptake and cytotoxicity in murine haemopoietic progenitor 
cells and Ll210 leuka~mia cells, in vivo and in vitro (Vistica et al, 
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1979; Vistica, 1983), and amino acids stimulated melphalan efflux in 
many cell lines (Begleiter et al, 1980). Cells would the ref ore 
accumulate less melphalan in vivo than in amino acid-free media. It 
is difficult to assess what proportion of the increase in melphalan 
uptake and cytotoxi city in the fi brosarcomas with verapamil was due 
to enhanced cellular melphalan accumulation. However the greater 
enhancement of melphalan uptake and of cytotoxicity for FS12 compared 
with FS13 suggests that the contribution from melphalan transport in 
vivo was significant, both tumours subjected to the same 
pharmacokinetic effect of verapamil. 
The concentrations of verapamil which affected 14c-melphalan 
efflux and accumulation, 1-lOug/ml (Chapter 7) have clinical 
relevance. Therapeutic levels of verapamil are 0.1-0.3ug/ml in rats 
and humans (Kaelin et al, 1982; McMahon and Sheaffer, 1982) but in 
human ovarian carcinoma 0.2-lug/ml or more verapamil is being used 
with adriamycin (Rogan et al, 1984). This may need review for 
verapamil had a dose-limiting toxicity of first degree heart block at 
average blood levels of 0.29ug/ml, infused with vinblastine (Benson 
et al, 1985). Reversal of resistance to anthracyclines, vincristine 
and other drugs was achieved with O .25-3ug/ml verapamil, although 
higher doses up to lOug/ml tended to be used in cultured cell lines 
and human tumour clonogenic assays (Tsuruo et al, 1981, 1982b, 
1983a,c, 1985b; Dana and Woodruff, 1984; Goodman, 1984; Harker et al, 
1984; Pradhan et al, 1984; Rogan et al, 1984; Stark, 1984). The cell 
uptake studies usually used lug/ml melphalan, similar to blood levels 
in humans in the first hour after conventional iv doses (Tattersall 
et al, 1978; Alberts et al, 1979), and a little less than blood 
levels in mice at 60 minutes (sections 3-3-3, 5-2, 6-2). 
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9-3 Normal tissue toxicity of melphalan 
9-3-1 Effects of angiotensin II and verapamil 
An enhanced therapeutic index for melphalan can only be achieved 
if an incre-0se in normal tissue toxicity can be avoided when 
antitumour effect is increased, or if toxicity itself can be reduced. 
For alkylating agents, both tumour cytotoxicity and toxicity vary 
with the AUC, over a considerable range of drug concentrations and 
times of exposure (De Vita, 1982). The effects of angiotensin II and 
verapamil on toxicity tended to follow their effects on cytotoxicity, 
so that neither agent altered the therapeutic index of melphalan in 
mice. 
Verapamil enhanced marrow toxicity in the mice both through the 
increased AUC and enhanced cellular uptake, and increased 
gastrointestinal toxicity (sections 6-5, 6-6). Jejunum 14c-melphalan 
content tended to be increased after verapamil (section 6-2), 
probably due more to the increased AUC than to the increase in FDCO 
to the jejunum. Delayed melphalan absorption after ip administration 
might have accounted for the increase in jejunum 14c-melphalan in the 
irradiated mice with HX46 xenografts who failed to show an increased 
AUC with verapamil (section 6-2). Angiotens in II had no effect on 
melphalan gastrointestinal toxicity, although like verapamil it 
increased FDCO to the jejunum (sections 4-9, 5-7). 
In human bone marrow, verapamil had no effect on cellular 
melphalan uptake and cytotoxicity in vitro. The two studies of 
verapamil in human bone marrow found enhanced cytotoxi city for 
etoposide but not for vincristine and adriamycin (Fine et al, 1984; 
Yalowich et al, 1985), and cellular uptake was not studied. The 




toxicity of melphalan (and other agents) in humans are not known. If 
verapami 1 did increase melphalan blood levels, combined 
administration of melphalan with verapamil, or other calcium 
antagonists, should be cautioned. If verapamil had no 
pharmacokinetic effect and if melphalan transport of a human tumour 
vrns modified by verapamil ( see section 9-2-3), at noncardi odepressant 
concentrations, the therapeutic index could be enhanced. Verapamil 
could be safely explored in isolated limb perfusions with melphalan 
for malignant melanoma, where spillover into the systemic circulation 
is minimal (Hafstrom et al, 1984; Minor et al, 1985). 
9-3-2 Effects of vasoactive intestinal peptide and epidermal growth 
factor on gastrointestinal toxicity 
Vasoacti ve intestinal peptide reduced FDCO to the jejunum, but 
had no effect on the gastrointestinal damage by melphalan (section 
8-1). There was no change in 14c-melphalan content of fibrosarcomas 
nor jejunum after VIP although blood levels were increased. Jejunum 
blood flow was 3-4 times tumour blood flow (Figure 8-2) even after 
VIP, and melphalan uptake and toxicity did not appear to be limited 
by fl ow. 
The jejunum microcolony assay measures the survival of stem 
cells in the murine intestinal epithelium (Withers and Elkind, 1970), 
the epithelium of each crypt being derived from a single progenitor 
cell in the fundus (Ponder et al, 1985). There is a circadian rhythm 
both in proliferation of the gastrointestinal epithelium (Scheving et 
al, 1979, 1980; Al-Nafussi and Wright, 1982b) and in melphalan 
toxicity (Lesnaya and Lobova, 1972), and all experiments on 




range of dose schedules EGF failed to protect murine gastrointestinal 
epithelium from melphalan damage, and did not hasten recovery (see 
section 8-2-6). 
It was not possible to reduce melphalan gastrointestinal 
toxicity in mice either by modification of jejunum blood flow or 




Melphalan is an effective antitumour agent but response is 
limited by inherent or acquired resistance. Although greater 
responses were achieved using very high doses, administered with 
autol ogous bone marrow rescue and priming, further dose esca 1 ati on 
was limited by toxicity. The aim of this investigation was to 
increase delivery of melphalan to tumours, without increasing the 
dose and without increasing toxicity to bone marrow and 
gastrointestinal tract. Two main approaches were employed 
manipulation of tumour blood flow and enhancement of cellular 
melphalan uptake. In addition, new ways of reducing gastrointestinal 
toxicity were sought. 
The subcutaneous mu ri ne fi brosarcomas and human melanoma HX46 
xenografts studied had blood flows intermediate between those of 
liver and skin, determined from the fractional distribution of 86Rb. 
Only angiotensin II infusion (vasoconstrictor) and the melphalan acid 
alcohol solvent (vasodilator) increased blood flow to the murine 
fi brosarcomas. Neither agent affected 86Rb uptake by the HX46 
xenografts suggesting a difference in their blood supply which, if 
due to prior irradiation, would make them a poor model for tumours in 
humans. Increases in blood flow in the fibrosarcomas were not 
associated with sustained increases in tumour 14c-melphalan uptake, 
nor with any potentiat·ion of melphalan cytotoxicity. Melphalan 
delivery was not limited by blood flow. However, angiotensin II and 
ethanol might increase tumour uptake of cytotoxic agents cl eared very 
rapidly from the blood and might have a greater effect on tumours 
with much lower blood flows such as some human solid tumours. 
Melphalan is administered clinically in a similar ethanol-based 
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solvent and it would be important to optimise the dose of ethanol if 
the solvent were found to alter melphalan uptake in human tumours. 
Both angiotensin II, and ethanol could be further studied in isolated 
limb perfusions in humans. 
In contrast verapamil had no effect on tumour blood flow, but 
both increased the AUC for melphalan in mice and increased cellular 
l4c-melphalan uptake in murine fibrosarcomas and bone marrow. The 
result was a more sustained increase in 14c-melphalan content of the 
fi brosarcomas, and enhanced cytotoxi city in both the Fi brosarcomas 
and the HX46 xenografts. However there was no therapeutic gain in 
the mice because the bone marrow and gastrointestinal toxicity of 
melphalan were also increased by verapamil. Increases in 
cytotoxicity were correlated with increases in the AUC for melphalan, 
and with increases in tumour melphalan uptake, but not with increases 
in blood flow, for the fibrosarcomas and HX46 xenografts. 
Verapamil increased steady state melphalan accumulation, and 
cytotoxicity, in murine bone marrow and fibrosarcoma cells in a 
reversible, dose-related way independent of medium calcium 
concentration but dependent on temperature, probably by inhibition of 
melphalan efflux. The higher steady state melphalan levels and lack 
of effect of verapamil in human bone marrow confirmed a difference in 
melphalan transport between human and murine marrow. This could be 
exploited clinically for it is likely that cellular melphalan uptake 
by some human tumours could be increased by verapamil, so that if, as 
seems likely, verapamil did not increase the AUC for melphalan in 
humans the therapeutic index would be increased. If however 
verapamil did affect melphalan pharmacokinetics in man, combined 
administration needs caution. Cellular melphalan uptake by human 
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tumours should be studied and the effects of verapamil on uptake and 
cytotoxicity determined. Other calcium/calmodulin antagonists may be 
found with more potent effects on melphalan transport and less 
cardiovascular side effects than verapamil and fl unari zi ne. The 
results also suggest that a component of melphalan transport, 
probably efflux, is shared by other drugs, including vinca alkaloids, 
anthracyclines and etoposide, and is affected by calcium/calmodulin 
antagonists. Verapamil (and analogues) may have an important role in 
cancer chemotherapy through effects on chemosensitivity, tumour 
metastasis and perhaps blood flow. 
Two new approaches to reduce the gastrointestinal toxicity of 
melphalan failed. Reduction of jejunum blood flow using vasoactive 
intestinal peptide had no effect on either jejunum 14c-melphalan 
content or toxicity, probably because blood flow was not limiting. 
Epidermal growth factor neither protected the gastrointestinal 
epithelium nor promoted its recovery from melphalan damage. 
,) 
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Epidermal growth factor (hEGF) has no effect on murine 
intestine epithelial damage and regeneration after melphalan 
B.A. Robinson1 • 2 , R.D. Clutterbuck1, J.L. Millar1 & T.J. McElwain2 
1 Department of Medicine Laboratories, Institute of Cancer Research; and 2 Department of Medicine, Royal 
Marsden Hospital, Sutton, Surrey, UK. 
Summary The effect of epidermal growth factor (hEGF) on intestinal epithelial damage by melphalan was 
explored in CBA mice. Human EGF was administered in doses of lOOµgkg- 1 or lOOOµgkg- 1 using a variety 
of schedules. Mucosa! damage was assessed 4, 8 and 13 days later, by [14C]-xylose uptake and by 
microcolony survival of jejunum, ileum and colon. The only regimen to show enhanced jejuna! crypt survival 
was administration of hEGF, lOOµgkg-1, i.p., 8 hourly, beginning 24h before melphalan treatment. Oral 
administration of hEGF had no effect on melphalan induced damage nor on subsequent recovery of intestinal 
mucosa. Activity of hEGF in mice was confirmed by demonstration of precocious eyelid opening in newborn 
mice. No consistent protective or restorative effect of hEGF on melphalan-induced intestinal epithelial 
damage could be demonstrated with the doses and schedules used. 
Epidermal growth factor (EGF) is a 53 amino acid 
peptide, mo!. wt 6045, initially isolated from the 
submaxillary glands of adult male mice (Cohen, 
1962; Cohen & Taylor, 1974; Carpenter & Cohen, 
1979). Mouse EGF (mEGF) stimulated precocious 
eyelid opening and incisor eruption in newborn 
mice due to promotion of epidermal growth and 
increased keratinization (Cohen, 1962; Cohen & 
Elliott, 1963; Carpenter & Cohen, 1979). A 
polypeptide from human urine, urogastrone, which 
inhibits gastric acid secretion and promotes gastric 
mucosa! healing, is probably the human equivalent 
(hEGF) of mouse EGF (Gregory, 1975). The two 
polypeptides are highly homologous, have identical 
biological effects and cross-react in many antibody 
systems (Cohen & Carpenter, 1975; Gregory, 1975; 
Carpenter & Cohe!!, 1979). Epidermal growth 
factor stimulates growth of a wide variety of 
epidermal cells in vivo and in vitro, including 
transformed lines, and of many mesodermal cells 
including mouse and human fibroblasts and 
vascular endothelial cells (Gospodarowicz et al., 
1978; Cohen & Taylor, 1974; Carpenter & Cohen, 
1979). 
In man, hEGF occurs in submandibular glands 
and Brunners glands (Elder et al., 1978) and in 
much lower concentrations in the thyroid gland, 
jejunum and kidney (Hirata & Orth, 1979). 
Epidermal growth factor inhibits gastric acid 
secretion in man, dogs and rats (Gregory, 1975; 
Bower et al., 1975; Koffman et al., 1982), while 
non-anti-secretory doses protect the gastric mucosa 
of cats and rats from aspirin-induced ulceration, by 
increasing DNA synthesis (Konturek et al., 1981). 
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Rat small intestinal villi have EGF receptors 
(Forgue-Lafitte et al., 1980), and mEGF stimulates 
DNA synthesis and cell proliferation in adult 
murine intestine (Scheving et al., 1979, 1980; Al-
Nafussi & Wright, 1982a; Chabot et al., 1983), and 
the development of gastrointestinal enzyme 
activities in suckling mice (Malo & Menard, 1982). 
Treatment with melphalan in mouse and man 
is limited by bone marrow depression, which may 
be circumvented by autologous marrow 
transplantation, and by gastrointestinal mucosa! 
toxicity (Millar et al., 1978; McE!wain et al., 1979). 
Because EGF is trophic for the mouse gastro-
intestinal tract and protects the gastric mucosa 
from ulceration, EGF might protect the gastro-
intestinal tract from melphalan damage or enhance 
its recovery. We have explored this possibility in 
mice and present herewith our preliminary results. 
Materials and methods 
Adult male and female CBA/ca mice, at least 12 
weeks old weighing 20-30 gm, were maintained at 
22°C with food and water ad libitum. Melphalan 
and hEGF administration and assays were all 
performed at the same times throughout this study 
to eliminate effects from circadian variation in 
mouse gastrointestinal tract proliferation (Scheving 
et al., 1979, 1980; Al-Nafussi &Wright, 1982b). 
Human EGF, urogastrone, was highly purified 
biosynthetic material supplied by ICI Pharma-
ceuticals Division (Macclesfield, UK) and G.D. 
Searle (High Wycombe, UK). This was dissolved in 
sterile water to final concentrations of 10 or 
100 µg ml - i, and kept frozen until used. The 
biological activity of hEGF was confirmed, 
© The Macmillan Press Ltd., 1985 
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following Cohen (1962) and Moore et al. (1981). 
S.c. administration of hEGF 4mgkg- 1 daily for 10 
days to 9 newborn CBA mice resulted in eyelid 
opening on days 8-10, compared with days 14--17 
for 11 litter mates treated with saline. Melphalan 
(Alkeran, Burrough's Wellcome) was dissolved in 
2% acid alcohol (5 M HCI: absolute ethanol 1:50) 
and diluted in saline immediately prior to i.p. 
administration. The doses of 15-20mgkg- 1 i.p. 
were chosen to result in 30-70% survival of 
jejunum crypts. Control mice received water or 
saline, lOmlkg- 1 i.p. 
Four days after melphalan treatment, and then 
every 3-5 days until sacrifice, [1 4C]-xylose uptake 
was measured. Mice were anaesthetised with ether, 
0.5 µCi [14C]-xylose (Amersham International) 
administered by oropharyngeal tube and tail vein 
blood obtained 30 min later. A Packard Oxidiser 
306 (United Technologies Packard) was used to 
estimate 14C; 14C02 was trapped in 8-lOml of 
Carbosorb (Packard) and added to 13 ml of 
Permafluor V scintillant (Packard). Samples were 
counted in a /J-counter and uptake of [14C]-xylose 
calculated as a percentage of the administered dose 
per ml of blood. No 14C was detectable 3 days 
after [1 4 C]-xylose administration. 
On days 4, 7 or 8, and 13 after melphalan 
treatment groups of mice were killed, the intestine 
excised and surviving cryptogenic cells assessed 
using a modification of the method of Withers & 
Elkind (1970), described by Millar et al. (1978). 
Two or three segments of jejunum and one each of 
ileum and colon were taken from each mouse. The 
number of regenerating crypts per circumference of 
transverse 4--5 µm formalin-fixed sections stained 
with haematoxylin and eosin, were expressed as a 
percentage of the number of crypts per circum-
ference in normal mice. 
Results are presented as the mean ( ± s.e.) for 3-6 
mice, or of the ratio for percentages, and compared 
using the t-test for small samples. 
Results 
M elphalan, hEGf and gut damage at 4 and 7 days 
Groups of 3 mice were treated with melphalan, 15 
or 20 mg kg- 1 , or saline, i.p. Two hours before 
melphalan or saline treatment hEGF (100 µg kg- 1) 
or water was administered i.p. and continued 8 
hourly for 4 days (total 12 doses). Jejunum 
microcolonies and [1 4 C]-xylose uptake were 
determined on days 4 and 7 (Figure 1). 
The melphalan-treated mice all lost weight, and 
the loss tended to be greater with hEGF. Uptake of 
[14C]-xylose showed no significant differences from 
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Figure 1 (a) Weight (day 4), (b) [14C]-xylose uptake 
and (c) jejunum microcolonies 4 and 7 days after 
treatment of mice with melphalan 15mgkg- 1 i.p. 
(MI5) or 20mgkg- 1 i.p. (M20) or saline (C), with 
(shaded) or without hEGF 100 µgkg- 1 i.p., 8 hourly, 
12 doses. 
Treatment with hEGF further reduced jejuna! crypt 
survival after melphalan 15mgkg- 1 i.p. from 97% 
to 71% (P<0.02) on day 4, and from 90% to 73% 
(P<0.05) on day 7. Treatment with hEGF alone 
had no effect in either assay. This suggested that 
commencing hEGF 2h before melphalan might be 
detrimental and other regimens were therefore 
explored. 
Six different regimens of hEGF administration 
Groups of 3 mice received melphalan (17.5mgkg- 1 ; 
i.p.) on day 0, with hEGF i.p. in one of 6 regimens 
shown on Table I. When hEGF was given on day 
0, it preceded melphalan by 2 h, except in group 6 
where hEGF was commenced 6 h after melphalan. 
On day 4, [1 4 C]-xylose uptake and gut 
microcolonies were assessed (Table I). 
Only administration of hEGF (lOOµgkg-1; i.p.; 
8 hourly) beginning 24 h before melphalan (regimen 
5) increased jejuna! crypt survival (P<0.01). No 
significant effects of hEGF were seen on ileum and 
) 
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colon microcolonies nor [14C]-xylose uptake after 
any of the 6 regimens (data not shown). 
Delay in administration of hEGF until 4 days after 
melphalan 
It was possible that EGF might be effective only 
once histological damage was extensive, i.e. from 
day 4 onwards. Therefore groups of mice treated 
with melphalan (15mgkg- 1 , i.p.) on day O were 
treated with hEGF lOOµgkg- 1 i.p. or water i.p. 8 
hourly for 8-10 days, beginning either 6 h or 4 days 
after melphalan. Uptake of [14C]-xylose was 
measured on days 4, 8 and 13 and surviving 
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Day(s) of Jejunum 
No. doses hEGF microcolonies 
hEGF/day treatment % control 
Nil Nil 100.0± 5.7 
Nil Nil 38.5± 3.5 
1 -2 39.9± 3.4 
1 -1 36.1± 2.4 
1 1-->4 35.5± 5.5 
3 -1-->0 46.1 ± 12.4 
3 -1-->4 55.3 ± 3.2" 
3 0-->4 45.4±20.4 
Human EGF begun 6 h after melphalan 
treatment had no effect on survival of jejunal crypts 
or ileum crypts at 8 or 13 days. However, ileum 
crypt survival was not reduced by melphalan 
(15mgkg- 1 , i.p.) (Figure 2a). Colon crypt survival 
was not affected by melphalan 15 mgkg- 1 i.p. or 
by hEGF (data not shown). The low value of [14C]-
xylose uptake in control mice on day 8 is 
unexplained, but none of the treated groups 
differed significantly from the day 4 control value 
or from each other. Delaying hEGF treatment until 
4 days after melphalan had no significant effect on 
gastrointestinal recovery (Figure 2b ). All the treated 
mice lost weight, with a nadir at 4-5 days, recovery 
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Figure 2 Jejunum and ileum microcolonies and [14C]-xylose uptake after treatment of mice with melphalan 
15mgkg- 1 i.p. (Ml5) with (shaded, .6.) or without (e) hEGF lOOµgkg- 1 i.p., 8 hourly, begun either 6h after 
melphalan (a) or on day 4 (b), compared with untreated controls (C, •J. 
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Oral hEGF and melphalan gut damage 
Melphalan (20mgkg- 1, i.p.) was given to 2 groups 
of 5 mice on day 0. One group received hEGF 
(lOOµg kg- 1) by oropharyngeal tube under light 
ether anaesthesia twice daily (9 doses), and the 
other group anaesthesia only, beginning 
immediately before melphalan administration. On 
day 4, there was no difference in gastrointestinal 
toxicity between the group treated with topical 
hEGF and controls treated only with melphalan 
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Figure 3 (a) Weight, (b) [ 14C]-xylose uptake, (c) 
jejunum and (d) ileum microcolonies (day 4) after 
treatment of mice with melphalan 20mgkg- 1 i.p. 
(M20) with (shaded) or without oral hEGF lOOkgkg- 1 
twice daily, compared with controls (C). 
Discussion 
This study failed to show a consistent and 
significant protective or restorative effect of hEGF 
on mouse gastrointestinal damage from high dose 
melphalan. The only significant findings were an 
increase in jejunum crypt survival after melphalan 
(17.5mgkg- 1, i.p.) by hEGF (lOOµgkg-1, i.p. 8 
hourly) begun 24 h before melphalan and a decrease 
in jejunum crypt survival after melphalan 
15mgkg-1 i.p. by the same dose of hEGF begun 
2 h before melphalan. 
The jejunum is the segment of mouse intestine 
most affected by melphalan with damage most 
extensive at 4 days when gastrointestinal toxicity is 
usually assessed (Millar et al., 1978). However, the 
jejunum may be the segment least affected by 
exogenous EGF. Synthesis of DNA and cell 
proliferation in mouse intestine follows a circadian 
rhythm (Scheving et al., 1979, 1980; Al-Naffusi & 
Wright, 1982b), which may be related to the 
circadian periodicity of EGF in the male mouse 
submaxillary gland controlled by the sympathetic 
nervous system in response to the dark-light cycle 
or to feeding (Krieger et al., 1976). The extent of 
stimulation of gastrointestinal proliferation by EGF 
depends on the part of the intestine, its phase in the 
cycle (Scheving et al., 1979, 1980) and on feeding 
(Chabot et al., 1983). 
In fasted mice, mEGF (25 µg per mouse) 
increased DNA synthesis in the jejunum, ileum and 
colon (Chabot et al., 1983), but not in the jejunum 
of fed mice (Scheving et al., 1979; Chabot et al., 
1983). Cell production, by vincristine metaphase 
arrest, was also not increased in the jejunum of fed 
mice after mEGF, lOµgkg- 1, 8 hourly for 6 doses 
(Al-Nafussi & Wright, 1982a). Melphalan-treated 
mice tend not to eat and might resemble fasted 
mice, who have lower serum levels of endogenous 
EGF (Chabot et al., 1983). However, melphalan 
damage might promote endogenous EGF release 
and stimulation so that exogenous EGF is 
ineffective. 
The dosage, mode of administration and timing 
of hEGF should have been adequate to detect an 
effect if hEGF has the same biological effects as 
mEGF in mice. Thus lOOµgkg- 1, up to 8 hourly 
for up to 10 days, and lOOOµgkg- 1 (25µg per 25g 
mouse) i.p., span the doses and times of 
administration of mEGF which affect DNA 
synthesis and cell proliferation in murine intestine 
(Scheving et al., 1979, 1980; Al-Naffusi & Wright, 
1982a, b; Chabot et al., 1983). Precocious eyelid 
opening in newborn mice requires daily doses of 1-
4mgkg-1 mEGF, although 0.3mgkg- 1 has a 
detectable effect (Cohen, 1962; Moore et al., 1981); 
hEGF has a similar potency (Gregory, 1975). The 
close homology between mEGF and hEGF makes 
it unlikely that failure. to show a protective effect in 
murine intestine is due to the use of hEGF. Indeed, 
mEGF, 100 µg kg- 1 i.p. twice daily for 4 days 
failed to protect murine jejunum from melphalan 
(unpublished observations). 
The conclusion from this study is that hEGF, in 
the doses and regimens employed, did not protect 
the mouse gastrointestinal tract and particularly the 
jejunum, from melphalan damage, nor did it 
enhance epithelial recovery. No optimal timing of 
hEGF administration with respect to melphalan 
emerged. However, different scheduling of hEGF 
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and mode of administration of hEGF might be 
successful. It remains an attractive possibility to 
protect normal tissue with a growth factor to 
enable administration of melphalan with less 
toxicity or in higher doses. There must be caution, 
however, in view of the stimulatory effects of EGF 
on transformed as well as normal cells. 
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APPENDIX I 
The majority of experiments employed 14c-melphalan as a measure of 
melphalan uptake, as in most recent studies in man and mouse (Alberts et 
al, 1979; Selby et al, 1979; Brown et al, 1980; Furner and Brown, 1980). 
Melphalan analysis by HPLC would have enabled separate deterrninat'ion of 
parent melphalan and melphalan hydrolysed ·or bound to tissues, but the 
technique only became available late in the study. In order to 
standardise the extent of melphalan hydrolysis, 14c-melphalan was 
determined at either 30 or 60 minutes in most in vivo and in vitro 
experiments. Hydrolysed melphalan does not become concentrated in cells 
by the two amino acid transport systems, and in vivo, 14c-melphalan 
uptake is regarded a valid representation of melphalan uptake (Goldenberg 
et al, 1977; Vistica, 1983). Inside cells, melphalan hydrolysis and 
macromolecular binding will continue (Redwood and Colvin, 1980; Begleiter 
et al, 1982), but HPLC confirmed that the increase in cellular melphalan 
with verapamil was indeed parent me]phatan (section 7-1-4). 
Hydrolysis and macromolecular binding mean that the proportion of 
14c-melphalan attributed to parent melphalan in vivo decreases with time 
since administration, depending on the tissue and species studied (Brown 
et al, 1980; Furner and Brown, 1980; Ahmed et al, 1982b). During the 
first 2 hours,' although 14c-melphalan may overestimate parent melphalan 
in muririe tissues by up to 10-fold, 14c-melphalan appeared to reflect 
changes in both parent melphalan and that bound to cellular 
macromolecules (Brown et al, 1980; Furner and Brown, 1980). However, as 
already alluded to, even parent melphalah levels may not reflect 
melphalan which is cytotoxic; new techniques including development of 
monoclonal antibodies to DNA-bound melphalan may help elucidate this. 
